Induction of differential stress resistance and uses thereof

ABSTRACT

This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.

RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application Ser.No. 60/908,636, filed Mar. 28, 2007, and U.S. Provisional ApplicationSer. No. 60/942,561, filed Jun. 7, 2007, the contents of which areincorporated herein by reference in their entirety.

FUNDING

The present invention was made, at least in part, with the financialsupport of NIH/NIA grants AG20642 and AG025135. The government hascertain rights in the invention.

FIELD OF THE INVENTION

The present invention, in general, relates to methods for treatingcancer. In particular, the present invention provides methods forenhancing the effectiveness of chemotherapy by inducing differentialstress resistance in normal cells and cancer cells via short-termstarvation, cell growth inhibitors, or reduced caloric or glucoseintake.

BACKGROUND OF THE INVENTION

Until recently, the treatment of cancer has been largely focused on thedevelopment of therapeutic agents or techniques that kill cancer cells.For example, most chemotherapeutic drugs work by impairing mitosis (celldivision), effectively targeting fast-dividing cells. As these drugscause damage to cells they are termed cytotoxic. Some drugs work bycausing cells to undergo apoptosis (so-called “cell suicide”).Unfortunately, scientists have yet to be able to locate specificfeatures of malignant and immune cells that would make them uniquelytargetable (barring some recent examples, such as the Philadelphiachromosome as targeted by imatinib). This means that other fast dividingcells such as those responsible for hair growth and for replacement ofthe intestinal epithelium (lining) are also affected.

Because chemotherapy affects cell division, both normal and cancerouscells are susceptible to the cytotoxic effects of chemotherapeuticagents. Success of conventional chemotherapeutic regiment is based onthe principle that tumors with high growth fractions (such as acutemyelogenous leukemia and the lymphomas, including Hodgkin's disease) aremore sensitive to chemotherapy because a larger proportion of thetargeted cells are undergoing cell division at any given time. Thisstrategy often results in undesirable side-effects such as hair loss andnormal tissue/organ damage. It also has severe limitations on the dosageof chemotherapeutic agents that can be administered to a patient, thus,limiting the effective range of chemotherapy.

SUMMARY OF THE INVENTION

The present invention provides a novel approach to cancer therapy byproviding a method to differentially enhance the resistance of normalcells to chemotherapeutic agents, thereby, improving the effectivenessof chemotherapeutic agents in killing cancerous cells. By making normalcells more resistant to chemotherapeutic agents, a patient's tolerancefor cytotoxicity is improved, which, in turn, also improves theeffectiveness of chemotherapy.

More specifically, in one aspect, the invention features methods ofinducing differential stress resistance in a subject with cancer. Onemethod comprises starving the subject for 24-60 (e.g., 48) hours andadministering to the subject a chemotherapy agent. The method mayfurther comprise administering to the subject a cell growth inhibitor.

Another method of the invention comprises administering a cell growthinhibitor to the subject and administering to the subject a chemotherapyagent. For example, by using a cell growth inhibitor, the serumconcentration of IGF-I in the subject may be reduced by 75-90%.

Another method of the invention comprises reducing the caloric intake orthe glucose intake by the subject and administering to the subject achemotherapy agent. For example, the caloric intake may be reduced by10-100%, and the blood glucose concentration in the subject may bereduced by 20-50%.

In another aspect, the invention features methods of contacting a cancercell with a chemotherapy agent and methods of increasing resistance of anon-cancer cell to a chemotherapy agent. One method comprises starvingthe cell for 24-60 (e.g., 48) hours and contacting the cell with achemotherapy agent. The method may further comprise contacting the cellwith a cell growth inhibitor.

Another method of the invention comprises contacting the cell with acell growth inhibitor and contacting the cell with a chemotherapy agent.

Another method of the invention comprises cultivating the cell in amedium with reduced serum, IGF-I, or glucose concentration andcontacting the cancer cell with a chemotherapy agent. For example, theserum concentration in the medium may be reduced by 10-90%, the IGF-Iconcentration in the medium may be reduced by 10-100%, and the glucoseconcentration in the medium may be reduced by 20-50%.

A chemotherapy agent may be a DNA alkylating agent, oxidant, ortopoisomerase inhibitor. Examples of chemotherapy agents include, butare not limited to, methyl methanesulfonate, cyclophosphamide,etoposide, doxorubicin, and menadione. Examples of cancer include, butare not limited to, glioma, neuroblastoma, pheochromocytoma, andprostate cancer.

A cell growth inhibitor inhibits, e.g., IGF-I, IGF-IR, GH, Akt, Ras,Tor, or Erk. Examples of cell growth inhibitors include, but are notlimited to, IGFBPs, IGF-R blocking antibodies, and small moleculeinhibitors such as octreotide.

The above-mentioned and other features of this invention and the mannerof obtaining and using them will become more apparent, and will be bestunderstood, by reference to the following description, taken inconjunction with the accompanying drawings. These drawings depict onlytypical embodiments of the invention and do not therefore limit itsscope.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. A) DSR of short-term starvation (STS) against acute H₂O₂ ormenadione treatments. Survival of wild type (DBY746), sch9/aktΔ,RAS2^(val19), sch9/aktΔras2Δ and sch9/aktΔRAS^(val19) after a 48-hourstarvation and exposure to H₂O₂ (400 mM, 60 min) and to menadione (1 mM,30 min). The cultures were diluted in K-phosphate buffer to an initialOD₆₀₀ 1 for both treatments. Serial dilutions were spotted onto YPDplates and incubated at 30° C. for 2-3 days. This experiment wasrepeated at least 3 times with similar results. A representativeexperiment is shown. B, C) DSR against chronic CP and MMS treatments inmixed cultures. sch9/aktΔ and sch9/aktΔRAS2^(val19) were mixed andincubated for 2 hours shaking at 30° C. The initial sch9/aktΔ:sch9/aktΔRAS2^(val19) ratio as measured by growth on selective media was 25:1.Mixed cultures were treated with either CP (0.1 M) or MMS (0.01%).Viability was measured by quantifying colony-forming units (CFUs) every24 hours by plating onto appropriate selective media. This experimentwas repeated at least 2 times with similar results. A representativeexperiment is shown. D) DSR against chronic CP treatment. Wild type(DBY746), sch9/aktΔ, RAS2^(val19), sch9/aktΔ and sch9/aktΔRAS2^(val19)stains were individually grown and treated with CP (0.1 M). Viabilitywas measured by the same method as in the mixed culture experiment.

FIG. 2. DSR against a chemotherapeutic drug (CP) in primary rat mixedglial cells and rat glioma cell lines. A) Glucose restriction inducedDSR. Cells were incubated in either low glucose (0.5 g/L) (STS) ornormal glucose (1.0 g/L), supplemented with 1% serum for 24 hours.Viability was determined by the ability to reduce MTT following CPtreatment (dose response range: 6-12 mg/ml) (n=9). B) Serum restrictioninduced DSR. Cells were incubated in medium with either 1% (STS) or 10%FBS for 24 hours. Cytotoxicity was determined by measuring the relativelevel of LDH released following CP treatment (15 mg/ml) (n=12). C) Lackof IGF-I induced DSR. Cells were incubated in medium with 1% serum andrhIGF-I (100 ng/ml) for 48 hours. Cytotoxicity was determined bymeasuring the relative level of LDH released following CP treatment (12mg/ml) (n=21). D) aIR3 induced DSR. Cells were incubated in DMEM/F12with 1% serum and neutralizing anti-IGF-IR monoclonal antibody aIR3 (1μg/ml) for 24 hours. Cytotoxicity was determined by measuring therelative level of LDH released following CP treatment (15 mg/ml) (n=12).All data presented as mean ±SD. P-values were calculated by theStudent's t-test (* p<0.05, ** p<0.01).

FIG. 3. A) Differential stress resistance in A/J mice after STS andoctreotide treatment. All mice received an i.v. injection of 80 mg/Kgetoposide (Eto) on day 7. The different groups were treated as follows:Gr. 1 (35 mice): pre-treatment with a 1 mg/Kg/day octreotide (OCT) for 4days+48-hour STS (day 4-6)+treatment with 80 mg/Kg Eto on day7+post-treatment with 1 mg/Kg/day octreotide (OCT) on days 8-11. Gr. 2(16 mice): 48-hour STS on days 4-6+treatment with 80 mg/Kg Eto on day 7.Gr. 3 (17 mice): pre-treatment with 1 mg/Kg/day octreotide (OCT) for 4days+treatment with 80 mg/Kg Eto on day 7+post-treatment with 1mg/Kg/day octreotide (OCT) on days 8-11. Gr. 4 (23 mice): treatment with80 mg/Kg Eto on day 7. B) Percentage weight loss (a measure of toxicity)after STS and etoposide treatment. C) Differential stress resistance inCD1 mice after STS. All mice (5 mice/group) received an i.v. injectionof 110 mg/Kg etoposide (Eto), after a 60-hour starvation. The toxicity,evaluated by percentage of survival, is shown. P values were calculatedby Peto's log rank test: (P<0.0001). D) Percentage weight loss (ameasure of toxicity) after STS and etoposide treatment. ** day at whichall mice died of toxicity.

FIG. 4. Survival of neuroblastoma (NXS2)-bearing mice after chemotherapytreatment. All mice were inoculated i.v. with 200,000 NXS2 cells/mouseon day 4. The different groups were treated as follows: A) Gr. 1:Control (8 mice)=i.v. inoculation with NSX2 tumor cells on day 4. Gr. 2:OCT (8 mice)=pre-treatment with 1 mg/Kg/day octreotide (OCT) for 4 daysbefore and after tumor inoculum. Gr. 3: OCT/STS/OCT (8mice)=pre-treatment with 1 mg/Kg/day OCT before tumor cellinoculum+48-hour STS on days 4-6+post-treatment with 1 mg/Kg/day OCT ondays 8-11. Gr. 4: OCT/STS/Eto/OCT (8 mice)=pre-treatment with 1mg/Kg/day OCT for 4 days before tumor cell inoculum+48-hour STS on day4-6+i.v. injection of 80 mg/Kg etoposide (Eto) on day 7+post-treatmentwith 1 mg/Kg/day OCT on days 8-11. Gr. 5: STS (8 mice)=48-hour STS ondays 4-6. Gr. 6: STS/Eto (7 mice)=48-hour STS on days 4-6+i.v. injectionof 80 mg/Kg etoposide (Eto) on day 7. B) Gr. 7: Eto (6 mice)=i.v.injection of 80 mg/Kg etoposide (Eto) on day 7. Gr. 8:OCT/Eto/OCT=pre-treatment with 1 mg/Kg/day OCT for 4 days before tumorcell inoculum+i.v. injection of 80 mg/Kg etoposide (Eto) on day7+post-treatment with 1 mg/Kg/day OCT on days 8-11. Statistics: P Gr. 4vs Gr. 1<0.0001, P Gr. 4 vs Gr. 3<0.0001, P Gr. 6 vs Gr. 1=0.14, P Gr. 8vs Gr. 1=0.38, P Gr. 7 vs Gr. 1=0.99, P Gr. 4 vs Gr. 6=0.01, P Gr. 8 vsGr. 5=0.66. Survival of mice was monitored daily. P values werecalculated by Peto's log rank test.

FIG. 5. A) OCT/STS/OCT treated mice and B) control mice shown afteretoposide treatment.

FIG. 6. A, B) Differential stress resistance (DSR) against chroniccyclophosphamide and methyl methanesulfonate treatments in mixed yeastcultures. sch9/aktΔ and sch9/aktΔ RAS2^(val19) cells were inoculated inSDC medium at OD=0.1 and incubated at 30° C. with shaking. 24 hourslater (OD˜10), sch9/aktΔ and sch9/aktΔ RAS2^(val19) were mixed andincubated for 2 hours at 30° C. with shaking. The initialsch9/akt:sch9/aktΔ RAS2^(val19) ratio, measured by growth on selectivemedia, was 25:1. Mixed cultures were then treated with either CP (0.1 M)or MMS (0.01%). Viability was measured every 24 hours by plating ontoappropriate selective media that allows the distinction of the 2strains. Data from 3 independent experiments are shown as mean ±SD.

FIG. 7. A) Resistance to high-dose chemotherapy in A/J mice after STSand/or octreotide treatment. Mice were treated as follows: Gr. 1 (35mice): pre-treatment with 1 mg/kg/day octreotide for 4 days+48-hour STS(day 4-6)+treatment with 80 mg/kg Eto on day 7+post-treatment with 1mg/kg/day octreotide on days 8-11. Gr. 2 (16 mice): 48-hour STS on days4-6+treatment with 80 mg/kg Eto on day 7. Gr. 3 (17 mice): pre-treatmentwith 1 mg/kg/day octreotide for 4 days+treatment with 80 mg/kg Eto onday 7+post-treatment with 1 mg/kg/day octreotide on days 8-11. Gr. 4 (23mice): treatment with 80 mg/kg Eto on day 7. B) Percent weight loss ofA/J mice (a measure of toxicity) after STS and Eto treatment. C)Resistance to high-dose chemotherapy in CD1 mice after STS. All mice (5mice/group) received an i.v. injection of 110 mg/kg etoposide (Eto),after a 60-hour starvation. The toxicity, evaluated by percent survival,is shown. P values were calculated by Pete's log rank test: (P<0.0001).D) Percent weight loss of CD1 mice (a measure of toxicity) after STS andEto treatment. ** day at which all mice died of toxicity. E) Resistanceto high-dose chemotherapy in athymic (Nude-nu) mice after STS. All micereceived an i.v. injection of 100 mg/kg Eto, after a 48-hour starvation.The toxicity, evaluated by percent survival, is shown. F) Percent weightloss (a measure of toxicity) of athymic (Nude-nu) after STS andetoposide treatment. G) Resistance to high-dose chemotherapy in LIDmice. All mice received an i.p. injection of 500 mg/kg Cyclophosphomideand were single caged throughout the experiment. The toxicity, evaluatedby percent survival, is shown p<0.002). H) Percent weight loss (ameasure of toxicity) of LID mice after Cyclophosphamide treatment. I)Survival fraction of STS treated and untreated mice after etoposideinjection. Mice from 3 different genetic backgrounds (A/J, CD1 and Nude)were injected with etoposide with or without STS pre-treatment. Alltreatments with STS have been combined and compared with all treatmentswithout STS and shown as percent survival after etoposide injection.Also, the percent survival of each treatment after etoposide injectionis compared and shown.

FIG. 8. Survival of neuroblastoma (NXS2)-bearing mice. All mice wereinoculated i.v. with 200,000 NXS2 cells/mouse on day 4. The differentgroups were treated as follows: A) Gr. 1: Control (16 mice)=i.v.inoculation with NSX2 tumor cells on day 4. Gr. 2: Oct (8mice)=pre-treatment with 1 mg/kg/day octreotide for 4 days before andafter tumor injection on day 4. Gr. 3: Oct/STS/Oct (8mice)=pre-treatment with 1 mg/kg/day Oct before tumor cell injection onday 4+48-hour STS on days 4-6+post-treatment with 1 mg/kg/day Oct ondays 8-11. Gr. 4: Oct/STS/Eto/Oct (8 mice)=pre-treatment with 1mg/kg/day Oct for 4 days before tumor cell injection+48-hour STS on day4-6+i.v. injection of 80 mg/kg etoposide (Eto) on day 7+post-treatmentwith 1 mg/kg/day Oct on days 8-11. Gr. 5: Oct/Eto/Oct (8mice)=pre-treatment with 1 mg/kg/day Oct for 4 days before tumor cellinjection+i.v. injection of 80 mg/Kg etoposide (Eto) on day7+post-treatment with 1 mg/kg/day Oct on days 8-11. Gr. 6: STS (8mice)=i.v. inoculation with NSX2 tumor cells on day 4+48-hour STS ondays 4-6. Gr. 7: STS/Eto (16 mice)=i.v. inoculation with NSX2 tumorcells on day 4+48-hour STS on days 4-6+i.v. injection of 80 mg/kgetoposide (Eto) on day 7. Gr. 8: Eto (6 mice, *2 deaths caused by theinjection procedure)=i.v. inoculation with NSX2 tumor cells on day4+i.v. injection of 80 mg/kg etoposide (Eto) on day 7. B) Effect ofoctreotide on etoposide cytotoxicity in NXS2 neuroblastoma cells. NXS2cells treated with different concentrations of etoposide (1-3 microM) inthe presence or absence of octreotide (10 and 50 microM) for 72 hourswere harvested by scraping, washed with complete medium, and incubatedwith trypan blue for 1 minute at 37° C. Viability was determined bycounting the cells with a contrast phase microscope. The proportion ofdead (or living) cells was calculated by dividing the number of dead (orliving) cells by the total number of cells per field. C) The DSR model:oncogenes prevent cells from entering into a protective maintenance modein response to starvation and low IGF-1 signaling. One of the hallmarksof cancer cells is the ability to grow or remain in a growth moderegardless of external regulatory signals including IGF-1R, Ras, Akt andmTor.

FIG. 9. A) Oct/STS/Eto/Oct group and B) control group shown after Etotreatment (day 7).

FIG. 10. A, B) Survival of STS-treated yeast cells deficient in Sch9and/or Ras2 (sch9A, and sch9Δras2Δ), and cells overexpressing Sch9 orexpressing constitutively active RAS2^(val19) (SCH9. RAS2^(val19),sch9ΔRAS2^(val19), and tor1ΔRAS2^(val19)) after treatment with H₂O₂ ormenadione. 24 hours after the initial inoculation (OD=0.1) in SDCmedium, cultures were washed, resuspended and incubated in water for 48hours with shaking. At day 3, cells were treated with either H₂O₂ for 30min, or menadione for 60 min. Serial dilutions (up to 1,000-fold) of thetreated cultures were spotted onto YPD plates and incubated for 2-3 daysat 30° C. This experiment was repeated at least 3 times with similarresults. A representative experiment is shown. C) DSR against chronic CPtreatment. Wild type (DBY746), RAS2^(val19), sch9Δ and sch9ΔRAS2^(val19)strains were inoculated at OD=0.1, grown separately in glucose media,and treated with CP (0.1 M) 24 hours after initial inoculation.Viability was measured as colony forming units (CFU) at 24 and 48 hours.

FIG. 11. A) In vitro STS effect on differential stress response (DSR) tocyclophosphamide treatments. Primary rat glial cells and the C6 ratglioma cells were grown to 70% confluency and then incubated in eitherlow glucose (0.5 g/L) (STS) or normal glucose (1.0 g/L), supplementedwith 1% serum for 24 hours followed by cyclophosphamide (12 mg/ml)treatment. Cytotoxicity was measured by LDH release. Data represented asmean ±SD. p-values were calculated using Student's t-test (** p<0.005).B) Phosphorylation of Erk1/2 in response to starvation conditions in 5cancer cell lines. Rat glioma and human neuroblastoma cell lines (FIG.11A) were starved by preincubation in glucose- and serum-free media for17 hours (STS), or were kept in glucose- and serum-free media for 16hours followed by a 1 hour treatment with serum (1% FBS). Western blotsshow Erk1/2 phosphorylation.

FIG. 12. 24 hr treatment with IGF-I sensitizes cortical neurons but notin PC12 cells to oxidative toxicity. Primary rat cortical neurons orPC12 cells incubated in 1% serum and 4 g/L glucose were treated for 24hr with vehicle, 100 μM of paraquat, 100 ng/ml of IGF-I followed by 100μM of paraquat, or 100 ng/ml of IGF-1 alone and were then subjected toMTT reduction activity assay to assess cell viability. Data from 4independent experiments are normalized to control and expressed as themean ±S.E.M.

FIG. 13. Comparison of the long-term survival of mice from the Eto groupthat survived the initial toxicity and mice from the Oct/STS/Eto/Octgroup. Statistical evaluation was done using Kaplan-Meier curves andlog-rank test.

FIG. 14. A mouse from the (A) control group and (B) liver-IGF-1 deleted(LID) group shown after cyclophosphamide treatment.

FIG. 15. Similar pathways regulate longevity and resistance to stress inyeast and mice.

FIG. 16. The IGF-I, Ras and Akt pathways, whose down-regulation regulateresistance to damage and aging in different model systems (FIG. 15),play central roles in mitosis and cancer.

FIG. 17. A, B) Survival of STS-treated yeast cells deficient in Sch9/Aktand/or Ras2 (sch9/aktΔ, and sch9/aktΔ ras2Δ), and cells overexpressingSch9/Akt or expressing constitutive active RAS2^(val19) (Sch9/Akt,RAS2^(val19), sch9/aktΔ RAS2^(val19), and tor1Δ RAS2^(val19)) aftertreatment with H₂O₂ or menadione. 24 hours after the initial inoculation(OD=0.1) in SDC medium, cultures were washed, resuspended and incubatedin water for 48 hours with shaking. At day 3, cells were treated witheither H₂O₂ for 30 min, or menadione for 60 mm. Serial dilution (up to1,000-fold) of the treated cultures were spotted onto YPD plates andincubated for 2-3 days at 30° C. This experiment was repeated at least 3times with similar results. A representative experiment is shown. C)Differential stress resistance (DSR) against chronic cyclophosphamideand methyl methanesulfonate (MMS) treatments in mixed yeast cultures.sch9/aktΔ and sch9/aktΔ RAS2^(val19) cells were inoculated in SDC mediumat OD=0.1 and incubated at 30° C. with shaking. 24 hours later (OD˜10),sch9/aktΔ and sch9/aktΔ RAS2^(val19) were mixed and incubated for 2hours at 30° C. with shaking. The initial sch9/aktΔ:sch9/aktΔRAS2^(val19) ratio, measured by growth on selective media, was 25:1.Mixed cultures were then treated with either CP (0.1 M) or MMS (0.01%).Viability was measured every 24 hours by plating onto appropriateselective media that allows the distinction of the 2 strains. Data from3 independent experiments are shown as mean ±SD. D) DSR against chronicCP treatment. Wild type (DBY746), RAS2^(val19), sch9/aktΔ andsch9/aktΔRAS2^(val19) strains were inoculated at OD=0.1, grownseparately in glucose media, and treated with CP (0.1 M) 24 hours afterinitial inoculation. Viability was measured as colony forming units(CFU) at 24 and 48 hours.

FIG. 18. Rates of survival and metastases in the LID-TRAMP model. Micewere analyzed at the time of death. Survival curves for the two strainsare shown. There was no significant difference in the survival ratebetween male LID-TRAMP and L/L-TRAMP mice. The hazard ratio of maleLID-TRAMP mice to male L/L-TRAMP mice was 0.736. There was no differencein rate of metastasis; however, IGF-I levels were 10% of TRAMP in theLID-TRAMP model.

FIG. 19. Levels of GH-IGF axis analytes in the LID TRAMP cohort. Shownare the endogenous elevations of IGF-I and IGFBP-3 in the TRAMP modeland the dramatic reductions in IGF-I in the LID model.

FIG. 20. A/J mice, weighing 18-20 g, were starved for 48 hours (STS),and followed by a single intravenous injection of high dose doxorubicin(16 mg/kg). The toxicity, evaluated by (A) percent survival and (B)daily weight measurements, are shown.

FIG. 21. Resistance to high-dose chemotherapy in LID mice. All micereceived an i.v. injection of 100 mg/kg etoposide and were single cagedthroughout the experiment. The toxicity, evaluated by (A) percentsurvival and (B) daily weight measurements, are shown. p-value wascalculated by log rank test (p=0.06, n=10).

FIG. 22. Resistance to multiple treatments with doxorubicin. Doxorubicinwas intravenously administered at 20 mg/kg on Day 0 and 28 mg/kg on Day22 (n=5). The toxicity, evaluated by (A) percent survival and (B) dailyweight measurements, are shown. p-value was calculated by log rank test(p<0.05).

FIG. 23. Inhibiting ERK1/2 protects neurons against oxidative stress.Cortical neurons from E18 rat embryos were cultured onto 96-well plates(A) or glass coverslips in 6-well plates (B). On 10-14 DIV, the neuronswere pre-treated with MEK1/ERK1/2 inhibitors U0126 or SL327. Oxidativestress was induced by hydrogen peroxide or menadione. Cell viability wasmeasured with MTT survival assay (A) or live/dead assay (B). C) % deathwas calculated from the number of dead (red) and live (green) cells.

DETAILED DESCRIPTION OF THE INVENTION

In the present invention, it has been unexpectedly discovered that thedeletion of SCH9/AKT genes from cells and/or short-term starvation (STS)treatment has a differential cyto-protective effect on normal cells ascompared with cancer or cancer-like cells expressing constitutivelyactively Ras2^(val19) (the cyto-protective effect may be up to 10,000times more effective). Further, reduction of IGF-I/IGF-IR signaling orSTS protected primary glial cells but not 6 different rat and humanglioma and neuroblastoma cancer cell lines against chemotherapy. LiverIGF-I deficient (LID) mice were also protected against high dosechemotherapy confirming the in vitro results and providing a candidatedrug target to replace starvation. STS in combination with thesomatostatin analogue octreotide provided complete protection to micebut did not protect injected cancer cells against high dosechemotherapy. The present invention thus provides evidence for theefficacy of short-term starvation and/or lowering IGF-IR signaling inthe protection of normal but not cancer cells against chemotherapy,radiotherapy or any other toxic treatment or environment.

One method of the invention involves starving a subject with cancer for24-60 (e.g., 30-55, 35-50, 40-45, and 48) hours and administering to thesubject a chemotherapy agent, thereby inducing differential stressresistance in the subject.

By “starving” is meant subjecting a cell or subject to reduced or nonutrients.

As used herein, a “subject” refers to a human or animal, including allmammals such as primates (particularly higher primates), sheep, dog,rodents (e.g., mouse or rat), guinea pig, goat, pig, cat, rabbit, andcow. In a preferred embodiment, the subject is a human. In anotherembodiment, the subject is an experimental animal or animal suitable asa disease model.

As used herein, “cancer” refers to a disease or disorder characterizedby uncontrolled division of cells and the ability of these cells tospread, either by direct growth into adjacent tissue through invasion,or by implantation into distant sites by metastasis. Exemplary cancersinclude, but are not limited to, primary cancer, metastatic cancer,carcinoma, lymphoma, leukemia, sarcoma, mesothelioma, glioma, germinoma,choriocarcinoma, prostate cancer, lung cancer, breast cancer, colorectalcancer, gastrointestinal cancer, bladder cancer, pancreatic cancer,endometrial cancer, ovarian cancer, melanoma, brain cancer, testicularcancer, kidney cancer, skin cancer, thyroid cancer, head and neckcancer, liver cancer, esophageal cancer, gastric cancer, intestinalcancer, colon cancer, rectal cancer, myeloma, neuroblastoma,pheochromocytoma, and retinoblastoma. Preferably, the cancer is glioma,neuroblastoma, pheochromocytoma, or prostate cancer.

Chemotherapy agents are antineopl astic drugs used to treat cancer,including alkylating agents, anti-metabolites, plant alkaloids andterpenoids, topoisomerase inhibitors, anti-tumour antibiotics,monoclonal antibodies, oxidants, hormones, and the like. Preferablechemotherapy agents are methyl methanesulfonate, cyclophosphamide,etoposide, doxorubicin, and menadione. Other chemotherapy agents areknown in the art, some of which are described below.

By short-term starvation, differential stress resistance (DSR) isinduced in a subject with cancer, i.e., while the resistance of cancercells to a chemotherapy agent is reduced or unchanged, the resistance ofnon-cancer cells (e.g., normal cells) to the chemotherapy agent isconcomitantly increased.

DSR may also be induced by administering a cell growth inhibitor to asubject with cancer. A “cell growth inhibitor” inhibits the growth of acell. For example, such inhibitors (e.g., IGFBPs, IGF-R blockingantibodies, and small molecule inhibitors such as octreotide) mayinhibit IGF-I, IGF-IR, GH, Akt, Ras, Tor, or Erk by inhibiting geneexpression or protein activity. In some embodiments, the serumconcentration of IGF-I in the subject may be reduced by 75-90% (e.g.,80-85%), as compared to normal conditions. Other cell growth inhibitorsare known in the art, some of which are described below.

Another method of inducing DSR in a subject with cancer is via reducingthe caloric or glucose intake by the subject. In some embodiments, DSRmay be achieved by reducing the caloric intake by 10-100% (e.g., 20-90%,30-80%, 40-70%, 50-60%) or by reducing the blood glucose concentrationin the subject by 20-50% (e.g., 25-45%, 30-40%, and 45%), as compared tonormal conditions.

The methods of the invention may be combined to maximize DSR. Forexample, DSR may be induced in a subject with cancer by a combination ofshort-term starvation and administration of a cell growth inhibitor.

The methods described above can be used to improve the effectiveness ofcancer treatment. A subject to be treated may be identified in thejudgment of the subject or a health care professional, and can besubjective (e.g., opinion) or objective (e.g., measurable by a test ordiagnostic method). To treat a subject with cancer, DSR is induced inthe subject prior to the administration of an effective amount of achemotherapy agent by short-term starvation, administration of aneffective amount of a cell growth inhibitor, glucose, etc.

The term “treatment” is defined as administration of a substance to asubject with the purpose to cure, alleviate, relieve, remedy, prevent,or ameliorate a disorder, symptoms of the disorder, a disease statesecondary to the disorder, or predisposition toward the disorder.

An “effective amount” is an amount of a compound that is capable ofproducing a medically desirable result in a treated subject. Themedically desirable result may be objective (i.e., measurable by sometest or marker) or subjective (i.e., subject gives an indication of orfeels an effect).

A compound to be administered can be incorporated into pharmaceuticalcompositions. Such compositions typically include the compounds andpharmaceutically acceptable carriers. “Pharmaceutically acceptablecarriers” include solvents, dispersion media, coatings, antibacterialand antifungal agents, isotonic and absorption delaying agents, and thelike, compatible with pharmaceutical administration.

A pharmaceutical composition is formulated to be compatible with itsintended route of administration. See, e.g., U.S. Pat. No. 6,756,196.Examples of routes of administration include parenteral, e.g.,intravenous, intradermal, subcutaneous, oral (e.g., inhalation),transdermal (topical), transmucosal, and rectal administration.Solutions or suspensions used for parenteral, intradermal, orsubcutaneous application can include the following components: a sterilediluent such as water for injection, saline solution, fixed oils,polyethylene glycols, glycerine, propylene glycol or other syntheticsolvents; antibacterial agents such as benzyl alcohol or methylparabens; antioxidants such as ascorbic acid or sodium bisulfite;chelating agents such as ethylenediaminetetraacetic acid; buffers suchas acetates, citrates or phosphates; and agents for the adjustment oftonicity such as sodium chloride or dextrose. pH can be adjusted withacids or bases, such as hydrochloric acid or sodium hydroxide. Theparenteral preparation can be enclosed in ampoules, disposable syringes,or multiple dose vials made of glass or plastic.

It is advantageous to formulate oral or parenteral compositions indosage unit form for ease of administration and uniformity of dosage.“Dosage unit form,” as used herein, refers to physically discrete unitssuited as unitary dosages for the subject to be treated, each unitcontaining a predetermined quantity of an active compound calculated toproduce the desired therapeutic effect in association with the requiredpharmaceutical carrier.

The dosage required for treating a subject depends on the choice of theroute of administration, the nature of the formulation, the nature ofthe subject's illness, the subject's size, weight, surface area, age,and sex, other drugs being administered, and the judgment of theattending physician. Suitable dosages are in the range of 0.01-100.0mg/kg. Wide variations in the needed dosage are to be expected in viewof the variety of compounds available and the different efficiencies ofvarious routes of administration. For example, oral administration wouldbe expected to require higher dosages than administration by intravenousinjection. Variations in these dosage levels can be adjusted usingstandard empirical routines for optimization as is well understood inthe art. Encapsulation of the compound in a suitable delivery vehicle(e.g., polymeric microparticles or implantable devices) may increase theefficiency of delivery, particularly for oral delivery.

Methods similar to those described above may be used to contact a cancercell with a chemotherapy agent (e.g., to reduce resistance of the cancercell to the chemotherapy agent) and to increase resistance of anon-cancer cell to the chemotherapy agent. Such method may involve, forexample, starving the cell for 24-60 (e.g., 30-55, 35-50, 40-45, and 48)hours, and optionally, contacting the cell with a cell growth inhibitor;contacting the cell with a cell growth inhibitor; or cultivating thecell in a medium with reduced concentration of serum (e.g., by 10-90%,20-80%, 30-70%, 40-60%, and 50%), IGF-I (e.g., by 10-100%, 20-90%,30-80%, 40-70%, and 50-60%), or glucose (e.g., by 20-50%, 25-45%,30-40%, and 45%), as compared to normal conditions.

These methods can be used to identify candidate protocols, cell growthinhibitors, and chemotherapy agents for in vivo applications. Forexample, a protocol, cell growth inhibitor, or chemotherapy agent may betested using the methods described above. If the protocol, cell growthinhibitor, or chemotherapy agent leads to reduced or unchangedresistance of a cancer cell to a chemotherapy agent and increasedresistance of a non-cancer cell to a chemotherapy agent under the sameconditions, the protocol, cell growth inhibitor, or chemotherapy agentis identified to be a candidate for in vivo application of DSRinduction.

The following examples are intended to illustrate, but not to limit, thescope of the invention. While such examples are typical of those thatmight be used, other procedures known to those skilled in the art mayalternatively be utilized. Indeed, those of ordinary skill in the artcan readily envision and produce further embodiments, based on theteachings herein, without undue experimentation.

EXAMPLE 1 A Starvation Response-Based Differential Stress resistancemethod to enhance cancer Treatment Material and Methods Cell Lines

Primary mixed glial cells were obtained from the cerebral cortex of 1 to3 day old Sprague Dawley rat pups (Charles River) as described before.Cells cultured for 10-14 days in DMEM/F12 medium with 10% fetal bovineserum (FBS) were used in assays. C6, A10-85, 9L and RG2 rat glioma celllines and LN229 human glioma cell line and SH-SY5Y human neuroblastomacell line were maintained in DMEM/F12 medium with 10% FBS at 37° C.under 5% CO₂.

STS Treatments

Cells were seeded into 96-well microtiter plates at 20,000-30,000cells/well and incubated for 2 days. Cells were washed with phosphatebuffered saline (PBS) prior to treatments as indicated in the text. Alltreatments were performed at 37° C. under 5% CO₂.

Glucose restriction was done by incubating cells in glucose free DMEM(Invitrogen) supplemented with either low glucose (0.5 gL) or normalglucose (1.0 gL) for 24 hours. Serum restriction was done by incubatingcells in DMEMIF12 with either 10% or 1% FBS for 24 hours. IGF-Itreatment was carried out by incubating cells for 48 hours in DMEM/F12with 1% FBS and rhIGF-I (100 n g/ml, ProSpec-Tany TechnoGene, Rehovot,Israel), which is shown to be within the IGF-I level range for middleage humans. To antagonize IGF-I receptor activity, cells were incubatedwith neutralizing monoclonal anti-IGF-IR antibody (aIR3, 1 pg/ml;Calbiochem) in DMEM/F12 1% FBS for 24 hours.

In Vitro Chemotherapeutic Treatment

A widely used chemotherapeutic drug (cyclophosphamide, CP, Sigma) wasused for in vitro studies. CP was prepared in DMEM/F12 with 1% FBS at 40mg/ml and was filter sterilized. The stock solution was stored at 4° C.for no longer than 2 weeks.

Following STS treatments, cells were incubated with varyingconcentrations of cyclophosphamide (6-15 mg/ml) for 10 hours in DMEM/F12with 1% FBS. Cytotoxicity was measured by either LDH release using theCytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Promega) or theability to reduce methylthiazolyldiphenyltetrazolium bromide (MTT). %LDH release was determined with reference to the maximum and backgroundLDH release of control cells. MTT assay results were presented aspercentage of MTT reduction level of control cells.

Yeast Strains and Growth Conditions

Experiments were carried out in wild type DBY746 MTα, leu2-3,112,his3D1, trp1-289, ura3-52, GAL+, and isogenic strains lacking eitherSch9 (Fabrizio et al., 2001) or both Sch9 and Ras2 (Fabrizio et al.,2001). Wild type (DBY746) and sch9A strains expressing hyperactiveRas2^(val19) constructed by transformation with a centromericplasmidcontaining Ras2^(val19) (pRS406-Ras2^(val19), CEN URA3). Yeast cultureswere grown in liquid synthetic dextrose complete medium (SDC) with 2%glucose, supplemented with amino acids, adenine, as well as a four-foldexcess of tryptophan, leucine, histidine, uracil. Strains harboring thecentromeric plasmid containing Ras2^(val19) were always grown in theabsence of uracil to maintain selection.

Yeast Viability

Overnight cultures were diluted to OD₆₀₀ 0.1 into SDC medium. After 24hours (day I), the appropriate strains were mixed 1:1 based on OD₆₀₀ andincubated for 2 hours. The mixed cultures were then treated with eithercyclophosphamide (CP, 0.1 M) or methylmethionine sulphonium chloride(MMS, 0.01%, Sigma) in medium or water (STS). For treatment SDC, MMS wasintroduced directly into the mixed culture to a final concentration of0.01%. However, due to the high concentration of CP (0.1 M) used, CP wasdissolved directly into the medium. To do so, mixed cultures werecentrifuged for 5 minutes at 2,500 rpm and the media was collected, inwhich CP was dissolved to a concentration of 0.1 M. The mixed culturewas then resuspended in the CP-containing medium. For treatments inwater (STS), mixed cultures were centrifuged for 5 minutes at 2,500 rpmand the media was replaced with either distilled/sterile water ordrug-dissolved water. Viability was measured by quantifyingcolony-forming units (CFUs) every 24 hours by plating onto appropriateselective media. Viability of individual strains was measured using thesame method as for the mixed cultures.

DSR Assays in Yeast

Stress resistance against MMS, menadione (Sigma), and H₂0₂ (Sigma) wasmeasured by spotting serial dilutions of control and treated cells.Briefly, overnight cultures were diluted in 1 ml of liquid SDC mediumwith 2% glucose to an initial OD₆₀₀ 0.1 and incubated overnight shakingat 30° C. 24 hours later, aliquots of cells were washed and resuspendedin water for 48 hours (STS). Following STS, cultures were diluted toOD₆₀₀ 1 in K-phosphate buffer and treated with menadione (1 mM; pH7.4)or H₂O₂ (400 mM, pH6.0) for 60 and 30 minutes, respectively. Then,serial dilutions were spotted onto YPD plates and incubated at 30° C.for 2-3 days.

In Vivo Therapeutic Studies in Mice

The murine NX3IT28 cell line was generated by hybridization of theGD2-negative C1300 murine neuroblastoma cell line (A/J background) withmurine dorsal root ganglional cells from C57BL16J mice, as previouslydescribed. The NXS2 subline was then created by the selection of NX3IT28cells with high GD2 expression.

Six-to-seven-week-old female NJ mice, weighing 15-18 g were purchasedfrom Harlan Laboratories (Harlan Italy, S. Pietro al Natisone, Italy)and housed in sterile enclosures under specific virus and antigen-freeconditions. All procedures involving mice and their care were reviewedand approved by licensing and ethical committee of the National CancerResearch Institute, Genoa, Italy, and by the Italian Ministry of Health.

N J mice were pretreated with 1 mg/kg/day doses of human octreotide(OCT, ProSpec-Tany TechnoGene, Rehovot, Israel) for 4 days given slowlythrough the tail vein in a volume of 100 μl and then injectedintravenously with murine neuroblastoma NXS2 cell line (200,000/mouse),as previously described. After tumor cell inoculum, some groups ofanimals were starved for 48 hours and then i.v. treated with 80 mg/kg ofEtoposide Teva (Teva Pharma B.V., Mijdrecht, Holland), administered as asingle dose. Additional daily doses of OCT were administered for 4 daysafter chemotherapy. Control groups of mice without diet starvation andOCT treatment were also investigated.

Octreotide pre-treatment: 4 days, 1 mg/kg/day

NXS2: 200,000/mouse on day 4

STS: from day 4 to day 6 (after tumor cell inoculum)

Etoposide: 80 mg/kg on day 7

Octreotide post-treatment: days 8-11

To determine toxicity and efficacy, mice were monitored routinely forweight loss and general behavior. The animals were killed by cervicaldislocation after being anesthetized with xilezine (Xilor 2%, Bio98 Srl,Milan, Italy) when they showed signs of poor health, such as adbominaldilatation, dehydration, or paraplegia. Survival time was used as themain criterion for determining the efficacy of each treatment.

The statistical significance of differential survival betweenexperimental groups of animals was determined by Kaplan-Meier curves andlog-rank eeto test by the use of StatDirect statistical software(Camcode, Ashwell, UK).

In some experiments, four-week-old female CD1 mice (Harlan), weighing18-20 g were used to evaluate stress resistance after 60 hours ofstarvation. These animals, i.v. injected with 110 mg/kg etoposide, weremonitored routinely for weight loss and general behavior. Survival timewas used as the main criterion for determining the differential stressresistance after short-term starvation.

Experimental

The inventor's diligent studies in S. cerevisiae and those of others inworms, flies, and mice have uncovered a strong association between lifespan extension and resistance to multiple stresses. This resistance isobserved in long-lived yeast cells lacking the orthologs of the humanRas (RAS2) and Akt (SCH9/AKT) proto-oncogenes and in long-lived wormsand mice with reduced activity of homologs of the IGF-I receptor(IGF-IR), which functions upstream of Ras and Akt in mammalian cells,also implicated in many human cancers. This resistance is also observedin model systems in which the calorie intake is reduced by 30 to 100%.Based on the unexpected discovery of the role of Ras2 and Sch9/Akt inthe negative regulation of stress resistance together with theassociation between mutations that activate IGF-IR, Ras or Akt and manyhuman cancers, it was believed that normal but not cancer cells wouldrespond to starvation or down-regulation of growth hormone GH/IGF-Isignaling by entering a chemotherapy resistance mode. It was also notedthat one of the major phenotypic characteristics of malignant cells isthe hyperactivation of pathways including the IGF-IR, Ras and Aktpathways and the ability to grow or remain in a growth mode even in theabsence of growth factors.

To test whether constitutively active oncogenes or oncogene homologswould prevent the switch to a protective maintenance mode in response tostarvation, it was first determined whether acute starvation would be aseffective in increasing stress resistance as long-term calorierestriction (CR).

DSR studies in S. cerevisiae were performed. A short-term starvationparadigm was selected as well as the deletion of the SCH9/AKT and/orRAS2 genes, each of which mimics in part calorie restriction. It wasbelieved that the combination of these genetic manipulations withstarvation would maximize DSR. The combination of STS (switch fromglucose medium to water for 24-48 hours) with the deletion of SCH9/AKTor both SCH9/AKT and RAS2 homolog causes a 1,000- to 10,000-fold DSR inresponse to a 30- to 60-minute treatment with hydrogen peroxide ormenadione compared to cells expressing the constitutively activeRAS2^(val19) or cells lacking SCH9/AKT (sch9/akfA) but expressingRAS2^(val19) (sch9/aktΔ RAS2^(val19)) (FIG. 1A). STS of wild type cellsalso caused DSR relative to RAS2^(val19) expressing cells but thedifferential effect for wild type cells was lower in response to H₂O₂treatment and was not observed after treatment with the hydrogenperoxide and superoxide generating agent menadione (FIG. 1A). Thetypical increase of resistance to hydrogen peroxide after STS comparedto incubation in medium was between 10- and 100-fold for wild typecells. The objective for this experiment was to model in a simple systemthe effect of the combination of short-term starvation and a geneticapproach on differential stress resistance between normal and cancercells. The results showed that the expression of the oncogene-likeRAS2^(val19) prevented the 1,000- to 10,000-fold protection caused bythe combination of STS and inhibition of Sch9/Akt activity.

To test whether DSR would also occur after treatment of yeast withchemotherapy drugs, the effect of STS and SCH9/AKT mutations on thetoxicity caused by alkylating agents methyl methanesulfonate (MMS) andcyclophosphamide (CP, a widely used chemotherapy drug) was studied. As amodel for the effect of STS and/or IGF-I inhibition on advanced stagecancer in which cancer cells were mixed with normal cells, mutantslacking SCH9/AKT with mutants lacking SCH9/AKT but also expressingRAS2^(val19) were mixed in the same flask at a 25:1 ratio. They werethen exposed to chronic treatment with CP or MMS. The viability of thetwo populations could be assessed by the ability of each population togrow on plates containing different selective media. Of theapproximately 10 million sch9/aktΔRAS2^(val19) cells mixed with 250million sch9/aktΔ, none of the sch9/aktΔRAS2^(val19) cells survived a48-hour treatment with 0.01% MMS (FIG. 1B). By contrast, the greatmajority of sch9/aktΔ survived this treatment (FIG. 1B). Similar resultswere obtained with mixed sch9/aktΔRAS2^(val19)/sch9/aktΔ culturestreated with cyclophosphamide (CP) (FIG. 1C). A similar experiment inwhich each cell type was treated with CP separately was also performed,and a similar differential stress resistance between cells expressingRAS2^(val19) and cells lacking SCH9/AKT was observed (FIG. 1D). Notably,a 48-hour treatment with CP was toxic to both RAS2^(val19) and wild typecells (FIG. 1D) suggesting that the lack of SCH9/AKT causes a majorincrease in protection relative to RAS2^(val19) expressing cells butalso wild type cells. These results confirm that DSR obtained byaltering gene expression is effective in protecting normal cells but notcancer-like cells against chemotherapy.

To test the efficacy of the starvation-based DSR method on mammaliancells, primary rat mixed glial cells (astrocytes+5-10% microglia) orthree different rat glioma tumor cell lines in medium containing eithernormal (1 g/L) or low (0.5 g/L) glucose (1 g/L. glucose is within thenormal human blood glucose range. A 0.5 g/L glucose concentration can bereached during starvation) were incubated and then treated with thechemotherapy drug CP. Whereas 80% of glial cells were resistant to 12mg/ml CP in the presence of 0.5 g/L glucose, only 20% of the cellssurvived this treatment in 1 g/L glucose (FIG. 2A). The differentialstress resistance between the two concentrations of glucose (0.5 and 1g/L) was observed starting at 6 mg/ml CP but became much more pronouncedat 12 mg/ml CP (FIG. 2A). By contrast, the lower glucose concentrationdid not affect the resistance of either C6, A10-85, or RG2 glioma cellsto the same doses of CP (FIG. 2A). The lower glucose concentrationactually increased the toxicity of CP to RG2 glioma cells at 6 and 8mg/ml doses (FIG. 2A).

A similar DSR effect was obtained with a different form of starvationachieved by reducing the serum concentration. Treatment with 15 mg/ml CPwas toxic to primary glial cells in 10% serum but the switch to 1% serumcaused a major reduction in toxicity (FIG. 2B). Instead, the sameconcentration of CP was as toxic to C6 glioma cells in 10% serum as itwas in 1% serum (FIG. 2B).

In S. cerevisiae experiments it was shown that the deletion ofSCH9/AKTprotects whereas the constitutive activation of Ras2(RAS2^(val19)) sensitizes the yeast cells to chemotherapy drugs. Sincemammalian Ras and Akt function downstream of the IGF-I receptor, andconsidering the role of the IGF-I pathway in regulating stressresistance, the effect of IGF-I and of an antibody against IGF-IR on DSRwas also tested. Treatment with 100 ng/ml IGF-I (in the low IGF-I levelrange for normal human adults) caused a 4-fold increase in the toxicityof cyclophosphamide to primary mixed glia but only caused a minorincrease in the toxicity of CP to C6 glioma cells (FIG. 2C).Furthermore, pre-incubation with an IGF-IR antagonist antibody protectedprimary glia but only provided a small protection of two of the threeglioma lines tested against CP toxicity (FIG. 2D). These results innormal glia and in glioma cell lines are consistent with those in yeastcells and showed that short-term starvation and/or drugs thatdown-regulate GH/IGF-I/Ras/Akt signaling can protect normal cells muchmore effectively than cancer cells against chemotherapy.

In an in vivo test, mice were treated with high doses of chemotherapy incombination with STS and/or a GH/IGF-I lowering therapy. For thispurpose etoposide, a widely used chemotherapy drug which damages DNA bymultiple mechanisms and displays a generalized toxicity profile rangingfrom myelosuppression to liver and neurologic damage, was selected.Unusually high doses of etoposide (80-110 mg/Kg) were administered aftera GH/IGF-I lowering treatment, period of starvation or both. In humans,a third of this concentration of etoposide (30-45 mg/Kg) is consideredto be a high dose and therefore in the upper allowable range.

To reduce GH/IGF-I A/J mice were pre-treated for four days with thegrowth hormone release inhibitor somatostatin analogue octreotide. Thispre-treatment was followed by etoposide administration. A sub-group ofmice were also starved for 48 hours before treatment with etoposide. Themice pre-treated with octreotide received this treatment for 4additional days after chemotherapy. Whereas 80 mg/Kg etoposide killed43% of control (Eto, n=23, 2 experiments) and 29% of octreotidepre-treated mice (OCT/Eto, n=17), in two separate experiments none ofthe mice treated with octreotide and also pre-starved for 48 hours diedafter 80 mg/kg etoposide treatment (OCT/STS/Eto/OCT, n=35) and only oneof the mice that were only starved (STS/Eto, n=16) died after etoposidetreatment (FIG. 3A). Remarkably, STS/octreotide pre-treated mice, whichlost 25% of the weight during the 48 hours of starvation, regained allthe weight in the four days after etoposide treatment (FIG. 3B) whereasin the same period the control mice lost approximately 20% of the weight(FIG. 3B). Non-STS pre-treated mice also showed reduced mobility andruffled hair.

The effect of STS alone on the protection of mice of another geneticbackground (CD1) was also tested. To determine whether an extended STSstrategy can be effective against a higher concentration of chemotherapydrugs 110 mg/Kg etoposide was administered and also the starvationperiod was increased to 60 hours. Based on the experiments withoxidative stress, it was determined that this period is the maximum STSthat provides protection. Longer starvation periods can weaken theanimals and have the opposite effect. This concentration of etoposidekilled all the control mice (Eto 110) but none of the STS pre-treatedmice (STS/Eto 110, n=5) (FIG. 3C). As for the A/J mice, CD1 STSpre-treated mice, which lost 40% of the weight during the 60 hours ofstarvation, regained all the weight in the week after the etoposidetreatment and showed no sign of toxicity (FIG. 3D). In summary, out of56 mice from two genetic backgrounds that were starved before etoposidetreatment, only one mouse from the STS only group and none of the micefrom the STS/octreotide pre-treated group died. By contrast, out of the45 mice treated with etoposide alone or etoposide and octreotide, 20died of toxicity.

These results are consistent with the yeast and glia/glioma data showingincreased resistance to chemotherapy toxicity in response to starvation.In mice, octreotide alone was not sufficient to protect againstetoposide toxicity and virtually all the protection was due instead toSTS. Notably, octreotide treatment was sufficient to protect miceagainst the superoxide generator paraquat.

To determine whether the differential stress resistance observed inyeast and mammalian cells would also occur in mice, the survival of miceinjected with cancer cells was followed. A particularly aggressive tumorline (NXS2) was selected, which models a common childhood cancer:neuroblastoma. The NXS2 neuroblastoma line induces consistent andreproducible metastases in a pattern which resembles the situationobserved in neuroblastoma patients at advanced stages of disease.Experimental metastases in the liver, kidneys, adrenal gland, andovaries were observed after 25-30 days of the inoculation with 200,000NXS2 cells (Table 1) as previously described. Although the tumordevelopment and survival of STS/etoposide treated mice was notsignificantly different from that of controls (Gr. 6 vs Gr: 1 p=0.14),half of the pre-starved mice were alive at a point when thenon-etoposide treated mice were all dead (FIG. 4A, Table 1) suggestingthat STS only partially protects cancer cells against etoposide. Thus,several or many chemotherapy cycles in combination with STS may berequired for the effective killing of all the metastasized cancer cells.

TABLE 1 Median Survival Adrenal Hemorrhagic survival Range Groups LiverKidneys Ovaries gland ascites (days) (days) Gr. 1 Control 16/16 14/1613/16  3/16 16/16 32 32-38 Gr. 2 OCT 8/8 8/8 8/8 2/8 8/8 33 31-37 Gr. 3OCT/STS/OCT 8/8 5/8 6/8 1/8 8/8 31 27-33 Gr. 4 OCT/STS/Eto/OCT  5/8* 5/8*  5/8*  0/8*  6/8*  56* 46-90 Gr. 5 STS 8/8 5/8 7/8 1/8 8/8 3026-35 Gr. 6 STS/Eto 14/14  7/14  5/14  0/14 14/14 44 35-60 Gr. 7 Eto 1/3*  1/3*  1/3*  0/3*  1/3*  90* 87-90 Gr. 8 OCT/Eto/OCT  0/3**  0/3** 0/3**  0/3**  0/3**  90** 90-90

Remarkably, none of the octreotide/STS/etoposide injected with NXS2cells died until day 46, and at day 90, 25% of these mice were stillalive (FIG. 4, Table 1) (Gr. 4 vs Gr. 1 p=0.0001). Mice in theNXS2/etoposide and octreotide/NXS2/etoposide groups also did not developtumors until day 80 (Table 1) but, as described above, 50-65% of themwere killed by the initial dose of etoposide (FIGS. 3A and 4B). The 25%cancer-free rate at 90 days of the octreotide/STS/NXS2/etoposide-treatedmice (FIG. 4A) together with the major postponement of metastasis anddeath in the remaining 75% of these mice (Table 1) suggest that thistreatment is a highly effective strategy to kill cancer cells whileprotecting the organism. Considering that the STS/etoposide/NXS2-treatedgroup did not survive as long as the group that also included octreotide(survival of Gr. 6 vs. Gr. 4 p=0.01), these results indicate thatoctreotide contributes to killing NXS2 cells, possibly by inducingapoptosis as shown by others. In fact, somatostatin receptors areexpressed in neuroblastoma cells but also in breast and colon cancercells. Thus, octreotide may play a dual role in enhancing protection ofnormal cells while enhancing the death of cancer cells. However, in theabsence of short-term starvation) octreotide alone did not protect miceagainst NXS2-dependent death (FIG. 4), suggesting that it is thesynergism between etoposide and octreotide that is effective in killingcancer cells. The 90-day cancer free survival of the 3octreotideletoposide-treated mice (Table 1) that were not killed by theinitial dose of etoposide (FIG. 4B) is consistent with such an effectiverole of the combination of high doses of chemotherapy and octreotide incuring metastatic cancer.

The conserved DSR response between normal cells (yeast and mammaliancells) and cancer-like or cancer cells demonstrates that it is possibleto protect the organism much more effectively than under normal feedingconditions while maintaining the toxicity of chemotherapy to tumorcells. The basis for this is the existence of a “maintenance mode”entered in response to starvation for the purpose of investing theremaining energy resources in protecting every cell and tissue. Inyeast, worms and mice starvation or the genetic manipulation ofstarvation response pathways causes a major increase in protectionagainst multiple stresses including heat shock and oxidative damage. Inmammals, starvation causes a reduction in IGF-I levels which isassociated with increased stress resistance. IGF-I is only one of thefactors involved in the starvation response, but are among the majornegative regulators of the entry into a stress resistant mode. Althoughthe role of calorie restriction or reduced activity of theGH/IGF-I/RAS/AKT axis in the stress resistance of primates is unknown,studies in monkeys and humans suggest that calorie restriction can haveeffects similar to those observed in simple eukaryotes and mice.

One of the most surprising discovery of this invention is the ability ofmice that have been starved for 48 hours to gain back the 25-40% weightlost during starvation even in the presence of doses of etoposide thatcause a 20-30% weight loss and kill over 40% of the control mice. Thishigh resistance to a drug that damages the DNA of dividing cells and isparticularly toxic to blood cells would be consistent with the entry ofmost or all of the normally dividing cells into a highly protective cellcycle arrested mode in response to the 48 hour starvation. Sinceetoposide is known to be rapidly excreted (up to 90% within 48 hours inhumans), such “protective mode” may only need to last for a few days.

Chemotherapy treatment has relied mainly on one or a combination ofseveral DNA damaging agents such as etoposide, cyclophosphamide, anddoxorubicin. Although these agents are supposedly much more toxic tocancer cells than to normal cells, the in vitro studies show thatcyclophoshamide, for example, can be as or more toxic to primary glialcells as it is to glioma cells. This implies that the combination ofmultiple chemotherapy drugs causes massive damage to normal cells,especially at high doses. Thus, it is particularly important to applystrategies such as the one presented here and aimed at reducing oreliminating the side effects of normal doses of chemotherapy or limitingthe toxicity of very high doses of chemotherapy that are effectiveagainst metastatic cancers.

Notably, the differential stress resistance of mammalian cells to thealkylating agents cyclophosphamide by the starvation-response methodswas less than 10-fold whereas starved yeast lacking SCH9/AKT reached a1,000-10,000-fold higher resistance to menadione, hydrogen peroxide,MMS, and cyclophosphamide compared to cancer-like RAS2^(val19)expressing yeast cells (FIGS. 1 and 2). Furthermore, the 10,000-folddifferential toxicity in yeast was obtained after only 30 minutes withhydrogen peroxide compared to the several days required for thedifferential toxicity of MMS or cyclophosphamide. Although toxicmolecules such as hydrogen peroxide or menadione are probably notsuitable for human treatments, these results suggest that the selectionof novel chemotherapy drugs in combination with DSR can result in agreatly more effective cancer treatment and may lead to treatments thatcan be carried out in minutes to hours. The ability to reach a10,000-fold differential toxicity between cancer cells and normal humancells would most likely lead to the cure of many cancers including thoseat advanced metastatic stages. Considering the remarkable resultsobtained with the aggressive NXS2 neuroblastoma line that was injectedin mice it is reasonable to expect novel drugs and conditions that canyield results close to the 10,000-fold DSR.

REFERENCES

-   1. Holzenberger, M. et al. IGF-I receptor regulates lifespan and    resistance to oxidative stress in mice. Nature 421, 182-7 (2003).-   2. Lithgow, G. J., White, T. M., Melov, S. & Johnson, T. E.    Thermotolerance and extended life-span conferred by single-gene    mutations and induced by thermal stress. Proc. Natl. Acad. Sci. USA    92, 7540-4 (1995).-   3. Longo, V. & Finch, C. E. Evolutionary medicine: from dwarf model    systems to healthy centenarians? Science 299, 1342-1346 (2003).-   4. Migliaccio, E. et al. The p66shc adaptor protein controls    oxidative stress response and life span in mammals. Nature 402,    309-13 (1999).-   5. Fabrizio, P., Pozza, F., Pletcher, S. D., Gendron, C. M. &    Longo, V. D. Regulation of longevity and stress resistance by Sch9    in yeast. Science 292, 288-90. (2001).-   6. Longo, V. D. & Finch, C. E. Evolutionary Medicine: from Dwarf    Model Systems to Healthy Centenarians? Science 299, 1342-1346    (2003).-   7. Fabrizio, P. et al. SOD2 Functions Downstream of Sch9 to Extend    Longevity in Yeast. Genetics 163, 35-46 (2003).-   8. Pollak M. N., Schernhammer, E. S. & Hankinson, S. E. Insulin-like    growth factors and neoplasia. Nat Rev Cancer 4, 505-18 (2004).-   9. Lass, A, Sohal, B. H., Weindruch, R., Forster, M. J. &    Sohal, R. S. Caloric restriction prevents age-associated accrual of    oxidative damage to mouse skeletal muscle mitochondria. Free Radic    Biol Med 25, 1089-97 (1998).-   10. Harper, J. M. et al. Stress resistance and aging: influence of    genes and nutrition. Mech Ageing Dev 127, 687-94 (2006).-   11. Bruce-Keller, A. J., Umberger, G., McFall, R. & Mattson, M. P.    Food restriction reduces brain damage and improves behavioral    outcome following excitotoxic and metabolic insults. Ann Neuro 145,    8-15 (1999).-   12. Fabrizio, P. et al. Sir2 blocks extreme life-span extension [see    comment]. Cell 123, 655-67 (2005).-   13. Kaeberlein, M. et al. Regulation of yeast replicative life span    by TOR and Sch9 in response to nutrients [see comment]. Science 310,    1193-6 (2005).-   14. Lin, S. J., Defossez, P. A. & Guarente, L. Requirement of NAD    and SIR2 for lifespan extension by calorie restriction in    Saccharomyces cerevisiae. Science 289, 2126-8. (2000).-   15. Poole, C. J. et al. Epirubicin and cyclophosphamide,    methotrexate, and fluorouracil as adjuvant therapy for early breast    cancer. N Engl J Med 355, 185 1-62 (2006).-   16. Brown-Borg, H. M., Rakoczy, S. G., Romanick M. A. &    Kennedy, M. A. Effects of growth hormone and insulin-like growth    factor I on hepatocyte antioxidative enzymes. Exp Biol Med 227,    94-104 (2002).-   17. Marietta, J. et al. Effect of training on the GHIIGF-I axis    during exercise in middle-aged men: relationship to glucose    homeostasis. Am J Physiol Endocrinol Metab 283, E929-36 (2002).-   18. Grunberg, S. M. Cyclophosphamide and etoposide for non-small    cell and small cell lung cancer. Drugs 58 Suppl3, 11-5 (1999).-   19. Mistry, A. R. et al. DNA topoisomerase II in therapy-related    acute promyelocytic leukemia. N Engl J Med 352, 1529-38 (2005).-   20. Vinolas, N., Graus, F., Mellado, B., Caralt, L. & Estape, J.    Phase I1 trial of cisplatinum and etoposide in brain metastases of    solid tumors. J Neurooncol 35, 145-8 (1997).-   21. Kroger, N. et al. Busulfan, cyclophosphamide and etoposide as    high-dose conditioning therapy in patients with malignant lymphoma    and prior dose-limiting radiation therapy. Bone Marrow Transplant    21, 1171-5 (1998).-   22. Gronbaek, H. et al. Inhibitory effects of octreotide on renal    and glomerular growth in early experimental diabetes in mice. J    Endocrinol 172, 637-43 (2002).-   23. Tang, C., Liu, C., Zhou, X. & Wang, C. Enhanced inhibitive    effects of combination of rofecoxib and octreotide on the growth of    human gastric cancer. Int J Cancer 112, 470-4 (2004).-   24. Lode, H. N. et al. Targeted interleukin-2 therapy for    spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer    Inst 89, 1586-94 (1997).-   25. Briganti, V. et al. Imaging of somatostatin receptors by    indium-11 1-pentetreotide correlates with quantitative determination    of somatostatin receptor type 2 gene expression in neuroblastoma    tumors. Clin Cancer Res 3, 2385-91 (1997).-   26. Smitha, M. C., Maggi, M. & Orlando, C. Somatostatin receptors in    non-endocrine tumours. Dig Liver Dis 36 Suppl 1, S78-85 (2004).-   27. Longo, V. D. & Kennedy, B. K. Sirtuins in aging and age-related    disease. Cell 126, 257-68 (2006).-   28. Norrelund, H., Nair, K. S., Jorgensen, J. O.,    Christiansen, J. S. & Moller, N. The protein-retaining effects of    growth hormone during fasting involve inhibition of muscle-protein    breakdown. Diabetes 50, 96-104 (2001).-   29. Leiser, S. F., Salmon, A. B. & Miller, R. A. Correlated    resistance to glucose deprivation and cytotoxic agents in fibroblast    cell lines from long-lived pituitary dwarf mice. Mech Ageing Dev    127, 821-9 (2006).

30. Walford, R. L., Mock, D., Verdery, R. & MacCallum, T. Calorierestriction in biosphere 2: alterations in physiologic, hematologic,hormonal, and biochemical parameters in humans restricted for a 2-yearperiod. J Gerontol A Biol Sci Med Sci 57, B211-24 (2002).

-   31. Roth, G. S., Ingram, D. K. & Lane, M. A. Caloric restriction in    primates and relevance to humans. Ann N Y Acad Sci 928, 305-15    (2001).-   32. McCarthy, K. D. & de Vellis, J. Preparation of separate    astroglial and oligodendroglial cell cultures from rat cerebral    tissue. J Cell Biol 85, 890-902 (1980).-   33. Greene, L. A. et al. Neuronal properties of hybrid neuroblastoma    X sympathetic ganglion cells. Proc Natl Acad Sci USA 72, 4923-7    (1975).

EXAMPLE II Starvation and IGF-I Reduction Protect Normal But not CancerCells Against High Dose Chemotherapy

The inventor's studies in S. cerevisiae and those of others in worms,flies, and mice have uncovered a strong association between life spanextension and resistance to multiple stresses. This resistance isobserved in long-lived yeast cells lacking the orthologs of the humanRas (RAS2) and Akt (SCH9/AKT) proto-oncogenes and in long-lived wormsand mice with reduced activity of homologs of the IGF-I receptor(IGFIR), which functions upstream of Ras and Akt in mammalian cells, andis also implicated in many human cancers. This resistance is alsoobserved in model systems in which the calorie intake is reduced by atleast 30%.

To test whether constitutively active oncogenes or oncogene homologs canprevent the switch to a protective maintenance mode in response tostarvation, it was first determined whether acute starvation would be aseffective in increasing stress resistance as it has been shown forlong-term calorie restriction (CR). Such long-term CR strategy would notbe appropriate for human chemotherapy treatments since it requiresseveral months to be effective.

DSR studies were first performed in S. cerevisiae. A short-termstarvation paradigm as well as the deletion of the SCH9/AKT and/or RAS2genes were selected, each of which mimics in part calorie restrictionand was shown in previous studies to cause high resistance to oxidativestress. It was believed that the combination of these geneticmanipulations with starvation would maximize DSR. The combination of STS(switch from glucose medium to water at day 1 [OD=9-10] and incubationin water for 24-48 hours) with the deletion of SCH9/AKT or both SCH9/AKTand RAS2 increased resistance to a 30- to 60-minute treatment withhydrogen peroxide or menadione a 1,000- to 10,000-fold compared to cellsexpressing the constitutively active oncogene homolog RAS2^(val19) orcells lacking SCH9/AKT (sch9/aktΔ) but expressing RAS2^(val19)(sch9/aktΔRAS2^(val19)) (FIG. 10A). The rationale for this experimentwas to model in a simple system the effect of the combination ofshort-term starvation and a genetic approach on the differentialprotection of normal and cancer cells. The results show that theexpression of the oncogene-like RAS2^(val19) prevents the1,000-10,000-fold protection caused by the combination of STS andinhibition of Sch9/Akt activity.

The effect of another oncogene homolog (SCH9/AKT) on resistance tooxidants was tested. As with RAS2^(val19), overexpression of SCH9/AKTsensitized yeast cells to both H₂O₂ and menadione was also tested (FIG.10B). Similarly to the effect of the deletion of RAS2 and SCH9/AKT, thedeletion of the homolog of TOR, another gene implicated in cancer,slightly increased the resistance to oxidants. Whereas the expression ofRAS2^(val1) completely reversed the protective effect of the deletion ofsch9/akt, it only had a minor effect on the reversal of the protectiveeffect of the tor1Δ (FIG. 10B). This is an important difference becauseit suggests that it may be risky to achieve DSR by inhibitingintracellular targets since inhibition of certain targets may alsoprotect cancer cells.

To test whether DSR would also occur after treatment of yeast withchemotherapy drugs, the effect of SCH9/AKT mutations on the toxicitycaused by alkylating agents methyl methanesulfonate and cyclophosphamide(CP, a widely used chemotherapy drug) was studied. As a model for theeffect of STS and/or IGF-I inhibition on metastatic cancer, mutantslacking SCH9/AKT were mixed in the same flask with mutants lackingSCH9/AKT but also expressing RAS2^(val19) at a 25:1 ratio and themixture was exposed to chronic treatment with CP or MMS. The monitoringof the viability of the two mixed populations was possible since eachpopulation can be distinguished by growth on plates containing differentselective media. Of the approximately 10 million sch9/aktΔRAS2^(val19)cells mixed with 250 million sch9/aktΔ, less than 5% of thesch9/aktΔRAS2^(val19) cells survived a 48-hour treatment with 0.01% MMS(FIG. 6A). By contrast, the great majority of sch9/aktΔ survived thistreatment (FIG. 6A). The combination of these mutations with STS wasalso effective against a yeast model for cancer cells and killed all theRAS2^(val19)-expressing cells by 24 hours. Similar results were obtainedwith mixed sch9/aktΔRAS2^(al19)/sch9/aktΔ cultures and cyclophosphamidetreatment (FIG. 6B). An experiment in which each cell type was treatedwith CP separately was also performed, and a similar differential stressresistance between cells expressing RAS2^(val19) and cells lackingSCH9/AKT was observed (FIG. 10C). These results confirm that mutationsin the Ras and Sch9/Akt and starvation are effective in protectingnormal cells but not yeast cells that model cancer cells (RAS2^(val19))against chemotherapy.

To test the efficacy of the starvation-based DSR method on mammaliancells, primary rat mixed glial cells (astrocytes+5-10% microglia) orthree different rat and one human glioma and one human neuroblastomacell lines were incubated in medium containing 1% serum and eithernormal (1 g/L) or low (0.5 g/L) glucose and then treated with thechemotherapy drug CP (1 g/L glucose is within the normal human bloodglucose range whereas a 0.5 g/L glucose concentration can be reached inhumans during starvation). The 1% serum concentration minimizes thecontribution of glucose from serum, which is approximately 1 g/L toavoid major differences in proliferation. Glia and glioma cells wereallowed to reach a 100% confluency. Whereas 80% of glial cells wereresistant to 12 mg/ml CP in the presence of 0.5 g/L glucose, only 20% ofthe cells survived this treatment in 1 g/L glucose (FIG. 2A). Thedifferential stress resistance between the two concentrations of glucose(0.5 and 1 g/L) was observed starting at 6 mg/ml CP but became much morepronounced at 12 mg/ml CP (FIG. 2A). By contrast, the lower glucoseconcentration did not affect the resistance of cancer cell linesincluding C6, A10-85, RG2 rat glioma, LN229 human glioma or humanSH-SY5Y neuroblastoma cells to 12-14 mg/ml CP (FIG. 2A). The lowerglucose concentration actually increased the toxicity of CP to RG2glioma cells at 6 and 8 mg/ml doses (FIG. 2A). To determine whether theDSR is affected by the high cell density, this experiment was repeatedwith cells that were only 70% confluent and similar results wereobtained (FIG. 11).

To determine whether the Ras/Erk pathway may be implicated in theunresponsiveness of the glioma and neuroblastoma cells above tostarvation the phosphorylation of Erk, which functions downstream ofRas, was measured in 10% serum or serum starved cells. Thephosphorylation data indicate that 2 of the 5 lines maintain a highlevel of Erk activity even after a 16-hour starvation (FIG. 11B), inagreement with the 30% frequency of Ras mutations in human cancers. Thereduction of Erk phosphorylation but inability to increase protection tocyclophosphamide in the other 3 lines (FIG. 2A) is consistent with ananti-resistance role of other common mutations in pro-growth pathwayssuch as the PTEN/PI3K/AKT pathway. Thus, it is believed that theconstitutive activation of any pro-growth pathway by a mutation wouldmake cancer cells unresponsive or much less responsive to thestarvation- or IGF-I reduction-dependent protection.

The experiments discussed above were performed in medium containing 1%glucose and different concentrations of glucose. The effect of reducingthe level of serum from the standard 10% to 1% on the toxicity ofhigh-dose cyclophosphamide was also tested. Treatment with 15 mg/ml CPwas toxic to primary glial cells in 10% serum but the switch to 1% serumcaused a reduction in toxicity (FIG. 2B). By contrast, the sameconcentration of CP was as toxic to C6 glioma cells in 10% serum as itwas in 1% serum (FIG. 2B).

In the S. cerevisiae experiments, it was showed that the deletion ofSCH9/AKT protects whereas the constitutive activation of Ras2(RAS2^(val19)) sensitizes the yeast cells to chemotherapy drugs. Sincemammalian Ras and Akt are major signal transduction proteins downstreamof the IGF-I receptor, and considering the role of the IGF-I pathway inregulating stress resistance, the effect of IGF-I and of an antibodyagainst IGF-IR on DSR was also tested. It was reasoned that primarycells would respond to the IGF-1-inhibiting treatment by increasingstress resistance whereas cancer cells, which often express oncogenesthat cause constitutive Ras and Akt activation, would not. Treatmentwith 100 ng/ml IGF-I (in the low IGF-I range for human adults) caused a3-fold increase in the toxicity of cyclophosphamide to primary mixedglia but did not increase the toxicity of CP to C6 glioma cells (FIG.2C). Furthermore, pre-incubation with an anti-IGF-IR antibody (aIR3)protected primary glia but not three glioma cell lines tested against CPtoxicity (FIG. 2D). A similar sensitizing role of IGF-I was observedwith primary rat cortical neurons but not the rat pheochromocytoma tumorPC12 cell line treated with oxidants (FIG. 12). These results in normalglia and in rat and human glioma and neuroblastoma cell lines areconsistent with those in yeast cells and support the belief thatshort-term starvation and/or drugs that down-regulate IGF-IR/Ras/Aktsignaling can protect normal cells much more effectively than cancercells against chemotherapy. Notably, this differential stress resistanceshould apply to the great majority of pro-growth oncogenic mutations andnot only to cancer cells with mutations in the Ras, Akt or Tor pathways.In fact, it worked with all the six cancer cell lines tested (FIG. 2),independently of the type of oncogenic mutations.

In an in vivo test, mice were treated with high dose chemotherapy incombination with STS and/or GH/IGF-I lowering strategies. For thispurpose, etoposide, a widely used chemotherapy drug which damages DNA bymultiple mechanisms and displays a generalized toxicity profile rangingfrom myelosuppression to liver and neurologic damage, was selected.Unusually high doses of etoposide (80-110 mg/kg) after a period ofstarvation, GH/IGF-I lowering treatment or both were administered. Inhumans, a third of this concentration of etoposide (30-45 mg/kg) isconsidered to be a high dose and therefore in the maximum allowablerange.

To reduce GH/IGF-I mice were pre-treated for four days with thesomatostatin analogue octreotide. This pre-treatment was followed byetoposide administration. A sub-group of mice were also starved for 48hours (STS) before treatment with etoposide. The mice pre-treated withoctreotide received this treatment for 4 additional days afterchemotherapy. Whereas 80 mg/kg etoposide killed 43% of control (Eto,n=23, 2 experiments) and 29% of octreotide pre-treated mice (OCT/Eto,n=17), none of the mice treated with octreotide and also pre-starved for48 hours died after 80 mg/kg etoposide treatment (Oct/STS/Eto/Oct, n=35)and only one of the mice that were only starved (STS/Eto, n=16) diedafter etoposide treatment (FIG. 7A). Remarkably, STS-octreotidepre-treated mice, which lost 20% of the weight during the 48 hours ofstarvation, regained all the weight in the four days after chemotherapy(FIG. 7B) whereas in the same period the control mice lost approximately20% of the weight (FIG. 7B). Control mice treated with etoposide showedsigns of toxicity including reduced mobility, ruffled hair and hunchedback posture (FIG. 9B) whereas Oct/STS/Oct pre-treated mice showed novisible signs of stress or pain following etoposide treatment (FIG. 9A).

The effect of STS alone on the protection of mice of another geneticbackground (CD1) was also tested. To determine whether an extended STSstrategy can be effective against a higher concentration of chemotherapydrugs 110 mg/kg etoposide was administered and the starvation period wasalso increased to 60 hours. Based on the experiments with oxidativestress, it was determined that this period is the maximum STS thatprovides protection. Longer starvation periods can weaken the animalsand have the opposite effect. This concentration of etoposide killed allthe control mice (Eto 110) but none of the STS pre-treated mice (STS/Eto110, n=5) (FIG. 7C). As with the A/J mice, pre-starved CD1 mice lost 40%of the weight during the 60 hours of starvation but regained all theweight in the week after the etoposide treatment and showed no visiblesign of toxicity (FIG. 7D).

The effect of the STS-based method was similar in athymic (Nude-nu)mice, which are widely used in cancer research because they allow thestudy of human tumors in the mouse model. Whereas 100 mg/kg etoposidekilled 56% of the nude mice and all the mice co-treated with octreotide,none of the STS/Eto/Oct or STS/Eto treated mice (48-hour starvation)died (FIG. 7E). As observed with the other two genetic backgrounds, thepre-starved mice gained weight during the period in which theEto-treated mice lost weight (FIG. 7F).

In summary, out of 70 mice from three genetic backgrounds that werestarved before etoposide treatment, only one mouse in the STS only groupand none of the mice in the STS/Oct group died (FIG. 7I). By contrast,out of the 63 mice treated with etoposide alone or etoposide andoctreotide, 34 died of toxicity. These results are consistent with theyeast and glia/glioma data showing increased resistance to chemotherapytoxicity in response to starvation or low IGF-I. In mice, octreotidealone was not sufficient to protect against etoposide toxicity andvirtually all the protection was due instead to STS. The discrepancybetween the effect of IGF-I in vitro and octreotide in vivo may be dueto the relatively modest effect of octreotide on the reduction ofcirculating IGF-I level.

To determine whether a much more severe reduction in IGF-I level thanthat achieved with octreotide can increase resistance to chemotherapy invivo as was shown in vitro, the resistance against a high dose ofcyclophosphamide of male and female LID mice, in which the liver IGF-Igene was conditionally deleted, resulting in a 75-90% reduced serumIGF-I concentration was studied. The LID mice treated with 500 mg/kgcyclophosphamide showed a remarkable improvement in resistance, with 30%mortality vs the 70% mortality for control mice (FIG. 7G, P<0.002).Furthermore, the LID mice lost an average of 10% of weight vs the 20%weight loss in control mice (FIG. 7H). The 70% surviving LID mice alsodid not show any signs of toxicity (FIG. 13B). Together with the invitro results with IGF-I and anti-IGF-IR antibodies and the establishedrole of starvation on the reduction of IGF-I levels, these data suggestthat the inhibition of IGF-IR signaling mediates part of the effects ofSTS on resistance to chemotherapy in vivo. Notably, IGF-IR antibodieshave been used successfully in a number of studies to reduce the growthor increase the death of cancer cells and are currently being evaluatedin clinical trials.

To determine whether the differential stress resistance observed inyeast and mammalian cells would also occur in mice, the survival of miceinjected with cancer cells was followed. A particularly aggressive tumorline (NXS2) that models neuroblastoma (NB), the most common extracranial solid tumor, and the first cause of lethality in pre-school agechildren, was selected. Advanced NB patients, who representapproximately 50% of the cases, show metastatic dissemination atdiagnosis, and have a long-term survival rate of only 20% in spite ofaggressive chemotherapy with autologous hematopoietic stem cell support.

The NXS2 neuroblastoma line in mice induces consistent and reproduciblemetastases in a pattern which resembles the clinical scenario observedin neuroblastoma patients at advanced stages of disease. Experimentalmetastases in the liver, kidneys, adrenal gland, and ovaries wereobserved after 25-30 days of the inoculation with 200,000 NXS2 cells(Table 2) as previously described.

TABLE 2 Frequency of metastases and survival in NXS2 injected mice (STS,Oct, Etoposide treatments) (Groups 1-8 represent the mice shown in FIG.8A). N° Hemor- Median Survival N° toxicity Adrenal rhagic survival RangeGroups mice deaths Liver Kidneys Ovaries gland ascites (days) (days) Gr.1 16  0/16 16/16 14/16 13/8   3/16 16/16 32 32-38 Control Gr. 2 OCT 80/8 8/8 8/8 8/8 2/8 8/8 33 31-37 Gr. 3 8 0/8 8/8 5/8 6/8 1/8 8/8 3127-33 OCT/STS/OCT Gr. 4 8 0/8 8/8 8/8 6/8 0/8 6/8 56  46-130OCT/STS/Eto/OCT Gr. 5 8 5/8  2/3*  2/3*  0/3*  0/3*  2/3* 130* 120-180OCT/Eto/OCT Gr. 6 STS 8 0/8 8/8 5/8 7/8 1/8 8/8 30 26-35 Gr. 7 16  1/1615/15  9/15  9/15  0/15 14/15 44 35-60 STS/Eto Gr. 8 Eto 6 3/6 3/3 3/30/3 0/3 3/3 130   87-140A/J mice were i.v. inoculated with 200,000 NXS2 cells/mouse and treatedas described in Experimental Procedures. All mice were followed untildeath and necropsies were performed. Only 3 mice from group 7 and 8survived the initial etoposide treatment. The deaths caused by etoposidetoxicity in the early days that occurred in groups 6, 7, 8 were notconsidered in the calculation of median survival. *1 mouse alive at 180days.

The tumor development and survival of STS/Eto treated mice wassignificantly different from that of controls (Gr. 7 vs. Gr. 1 p<0.0001)(FIG. 8, Table 2) suggesting that STS alone provides strong protectionto the mouse but only partially protection of cancer cells againstetoposide. Based on these results, the use of STS alone would requireseveral or many chemotherapy cycles to obtain toxicity to cancer cellscomparable to that caused by high dose chemotherapy alone.

By contrast, none of the Oct/STS/Eto/Oct injected with NXS2 cells dieduntil day 46, at a point when all the controls had died of cancer (FIG.8, Table 2) (Gr. 4 vs. Gr. 1 p<0.0001). One mouse from this groupsurvived until day 130. The survival of Oct/NXS2/STS/Eto/Oct mice wasnot statistically significantly different from that of NXS2/Eto andOct/NXS2/Eto/Oct groups (Table 2) but, as described above, 50% of micenot protected with STS died of etoposide toxicity (FIGS. 7A and 8). Evenif the initial etoposide-dependent death is not considered, thelong-term survival of the octreotide/STS/NXS2/etoposide group was notsignificantly different from that of the NXS2/etoposide andsignificantly different but close to that of the Oct/NXS2/Eto/Oct group(FIG. 13). These results suggest that in combination with octreotide,STS protects the animal but not the cancer cells against chemotherapy.

Somatostatin analogues have been reported to promote anti-tumor activitythrough two distinct effects: direct actions, mediated by somatostatinreceptors, and indirect actions, independent of the receptors. Thesomatostatin/octreotide receptor-mediated effect includes inhibition ofcell cycle and growth factors effects, and induction of apoptosis. Incontrast, the indirect effects comprise inhibition of the release ofgrowth factors such as growth hormone and IGF-I.

To determine whether octreotide was acting directly on cancer cells, thetoxicity of etoposide to NXS2 cells cultured in vitro in the presence orabsence of octreotide was tested. Either 10 or 50 micromolar octreotidedid not sensitize NXS2 cells to etoposide treatment suggesting that itis not increasing the survival of the NXS2 injected mice by directlysensitizing the cells to etoposide (FIG. 8B). Because of the manystudies showing an anti-tumor growth and survival effect of lower GH andIGF-I or inhibition of the IGF-I and GH receptors, these results suggestthat octreotide is improving long-term survival of STS treated mice byits well established role in decreasing GH and IGF-I levels, althoughother effects cannot be ruled out. Notably octreotide and othersomatostatin analogues have been shown to have therapeutic effects in anumber of cancer. In the absence of short-term starvation, octreotidealone did not protect mice against NXS2-dependent death (FIG. 8),suggesting that it is the synergism between etoposide and octreotidethat is effective in killing tumor cells. These results also suggestthat octreotide pre-treatment before the injection of NXS2 cells doesnot affect the tumor growth.

The data above indicate that short-term starvation and/or reduction ofIGF-I/IGF-IR signalling protects normal cells and mice but not a varietyof cancer cells treated with chemotherapy drugs. While not wanting to bebound by the theory, it is believed that the basis for this is theexistence of a “maintenance mode” which cells enter in response tostarvation for the purpose of investing the remaining energy resourcesin protection of cells and tissues. In yeast, worms, and mice starvationor the genetic manipulation of starvation response pathways causes amajor increase in protection against multiple stresses including heatshock and oxidative damage. In mammals, starvation causes a reduction inIGF-I levels which is associated with increased stress resistance. IGF-Iis only one of the factors involved in the starvation response, but isamong the major negative regulators of the entry into a stress resistantmode. In this study, it was showed that LID mice which have a dramaticreduction in circulating IGF-I are protected against chemotherapytoxicity, although the protection is not as effective as that providedby short-term starvation. Notably, in preclinical studies IGF-I loweringand IGF-IR targeting strategies have been shown to be effective in thetreatment of multiple myelomas, prostate, breast and colon cancer inaddition to other cancers. Thus, the combination of IGF-IR targeting andhigh dose chemotherapy should be an effective strategy to kill cancercells, while preserving the health of the host.

Perhaps one of the most surprising findings of the present invention isthe ability of mice of 3 different genetic backgrounds that have beenstarved for 48 hours to gain back the 20-40% weight that were lostduring starvation even in the presence of doses of etoposide that causea 20-30% weight loss and kill over 40% of the control mice. These micealso showed no visible sign of toxicity in response to doses ofchemotherapy highly toxic to control animals. This high resistance to adrug that damages the DNA of dividing cells, particularly blood cells,would be consistent with the entry of most or all of the normallydividing cells into a high protection/cell cycle arrested mode inresponse to the 48-hour starvation. Since etoposide is rapidly excreted(up to 90% within 48 hours in humans), such “protective mode” may onlyneed to last for a few days.

Chemotherapy treatment often relies mainly on one or a combination ofseveral DNA damaging agents such as etoposide, cyclophosphamide, anddoxorubicin. Although these agents are supposedly much more toxic tocancer cells than to normal cells, the in vitro studies show thatcyclophosphamide, for example, can be as or more toxic to primary glialcells as it is to glioma cancer cells. This implies that the combinationof multiple chemotherapy drugs causes massive damage to normal cells,especially at high doses. Notably, the differential stress resistance ofmammalian cells to the alkylating agent cyclophosphamide by thestarvation-response methods was less than 10-fold whereas starved yeastlacking SCH9/AKT reached a 1,000-10,000-fold higher resistance tomenadione, hydrogen peroxide, MMS, and cyclophosphamide compared toRAS2^(val19) expressing yeast cells (FIGS. 6 and 2). Furthermore, the10,000-fold differential toxicity in yeast was obtained after only 30minutes with hydrogen peroxide compared to the several days required forthe differential toxicity of MMS or cyclophosphamide. Although toxicmolecules such as hydrogen peroxide or menadione are not suitable forhuman cancer treatments, these results suggest that the selection ofnovel chemotherapy drugs in combination with DSR can result in a morerapid and effective toxicity to cancer cells. The ability to reach a10,000-fold differential toxicity between cancer cells and normal humancells should lead to improved therapies for many cancers. Based on theresults obtained with the aggressive NXS2 neuroblastoma line that wasinjected in mice it is reasonable to attempt to identify novel drugs andconditions that can yield a much greater differential toxicity to normaland cancer cells.

The method discussed above covers the use of any drug, protein, peptide,or molecule that inhibits any component of the growth hormone releasinghormone, growth hormone, growth hormone receptor, IGF-I, IGF-I receptor,Ras, Akt axis or inhibits other growth factors or growth factorreceptors for the purpose of protecting normal human cells and humansubjects but not (or less) cancer and other cells against chemotherapy,radiotherapy, cancer treatment, or any other toxic treatment orenvironment.

REFERENCES

-   1. Holzenberger, M. et al. IGF-I receptor regulates lifespan and    resistance to oxidative stress in mice. Nature 421, 182-7 (2003).-   2. Lithgow, G. J., White, T. M., Melov, S. & Johnson, T. E.    Thermotolerance and extended life-span conferred by single-gene    mutations and induced by thermal stress. Proc. Natl. Acad. Sci. USA    92, 7540-4 (1995).-   3. Longo, V. & Finch, C. E. Evolutionary medicine: from dwarf model    systems to healthy centenarians? Science 299, 1342-6 (2003).-   4. Migliaccio, E. et al. The p66shc adaptor protein controls    oxidative stress response and life span in mammals. Nature 402,    309-13 (1999).-   5. Fabrizio, P. et al. SOD2 Functions Downstream of Sch9 to Extend    Longevity in Yeast. Genetics 163, 35-46 (2003).-   6. Fabrizio, P., Pozza, F., Pletcher, S. D., Gendron, C. M. &    Longo, V. D. Regulation of longevity and stress resistance by Sch9    in yeast. Science 292, 288-90 (2001).-   7. Pollak, M. N., Schernhammer, E. S. & Hankinson, S. E.    Insulin-like growth factors and neoplasia. Nat Rev Cancer 4, 505-18    (2004).-   8. Harper, J. M. et al. Stress resistance and aging: influence of    genes and nutrition. Mech Ageing Dev 127, 687-94 (2006).-   9. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100,    57-70 (2000).-   10. Bruce-Keller, A. J., Umberger, G., McFall, R. & Mattson, M. P.    Food restriction reduces brain damage and improves behavioral    outcome following excitotoxic and metabolic insults. Ann Neurol 45,    8-15 (1999).-   11. Fabrizio, P. et al. Sir2 blocks extreme life-span extension [see    comment]. Cell 123, 655-67 (2005).-   12. Kaeberlein, M. et al. Regulation of yeast replicative life span    by TOR and Sch9 in response to nutrients [see comment]. Science 310,    1193-6 (2005).-   13. Lin, S. J., Defossez, P. A. & Guarente, L. Requirement of NAD    and SIR2 for life-span extension by calorie restriction in    Saccharomyces cerevisiae. Science 289, 2126-8. (2000).-   14. Timms, A. R., Muriel, W. & Bridges, B. A. A UmuD, C-dependent    pathway for spontaneous G:C to C:G transversions in stationary phase    Escherichia coli mut Y. Mutat Res 435, 77-80 (1999).-   15. Poole, C. J. et al. Epirubicin and cyclophosphamide,    methotrexate, and fluorouracil as adjuvant therapy for early breast    cancer. N Engl J Med 355, 1851-62 (2006).-   16. Brown-Borg, H. M., Rakoczy, S. G., Romanick, M. A. &    Kennedy, M. A. Effects of growth hormone and insulin-like growth    factor-I on hepatocyte antioxidative enzymes. Exp Biol Med 227,    94-104. (2002).-   17. Manetta, J. et al. Effect of training on the GH/IGF-I axis    during exercise in middle-aged men: relationship to glucose    homeostasis. Am J Physiol Endocrinol Metab 283, E929-36 (2002).-   18. Grunberg, S. M. Cyclophosphamide and etoposide for non-small    cell and small cell lung cancer. Drugs 58 Suppl 3, 11-5 (1999).-   19. Mistry, A. R. et al. DNA topoisomerase II in therapy-related    acute promyelocytic leukemia. N Engl J Med 352, 1529-38 (2005).-   20. Vinolas, N., Graus, F., Mellado, B., Caralt, L. & Estape, J.    Phase II trial of cisplatinum and etoposide in brain metastases of    solid tumors. J Neurooncol 35, 145-8 (1997).-   21. Kroger, N. et al. Busulfan, cyclophosphamide and etoposide as    high-dose conditioning therapy in patients with malignant lymphoma    and prior dose-limiting radiation therapy. Bone Marrow Transplant    21, 1171-5 (1998).-   22. Gronbaek, H. et al. Inhibitory effects of octreotide on renal    and glomerular growth in early experimental diabetes in mice. J    Endocrinol 172, 637-43 (2002).-   23. Hunter, S. J. et al. Comparison of monthly intramuscular    injections of Sandostatin LAR with multiple subcutaneous injections    of octreotide in the treatment of acromegaly; effects on growth    hormone and other markers of growth hormone secretion. Clin    Endocrinol (Oxf) 50, 245-51 (1999).-   24. Yakar, S. et al. Normal growth and development in the absence of    hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96,    7324-9 (1999).-   25. Ngo, T. H., Barnard, R. J., Tymchuk, C. N., Cohen, P. &    Aronson, W. J. Effect of diet and exercise on serum insulin, IGF-I,    and IGFBP-1 levels and growth of LNCaP cells in vitro (United    States). Cancer Causes Control 13, 929-35 (2002).-   26. Maccario, M. et al. Effects of 36-hour fasting on GH/IGF-I axis    and metabolic parameters in patients with simple obesity. Comparison    with normal subjects and hypopituitary patients with severe GH    deficiency. Int J Obes Relat Metab Disord 25, 1233-9 (2001).-   27. De Bernardi, B. et al. Disseminated neuroblastoma in children    older than one year at diagnosis: comparable results with three    consecutive high-dose protocols adopted by the Italian Co-Operative    Group for Neuroblastoma. J Clin Oncol 21, 1592-601 (2003).-   28. Matthay, K. K. et al. Treatment of high-risk neuroblastoma with    intensive chemotherapy, radiotherapy, autologous bone marrow    transplantation, and 13-cis-retinoic acid. Children's Cancer Group.    N Engl J Med 341, 1165-73 (1999).-   29. Lode, H. N. et al. Targeted interleukin-2 therapy for    spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer    Inst 89, 1586-94 (1997).-   30. Zalatnai, A. & Schally, A. V. Treatment of    N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian    golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160    microcapsules. Cancer Res 49, 1810-5 (1989).-   31. Susini, C. & Buscail, L. Rationale for the use of somatostatin    analogs as antitumor agents. Ann Oncol 17, 1733-42 (2006).-   32. Hejna, M., Schmidinger, M. & Raderer, M. The clinical role of    somatostatin analogues as antineoplastic agents: much ado about    nothing? Ann Oncol 13, 653-68 (2002).-   33. McPherson, A., Jr. The growth and preliminary investigation of    protein nucleic acid crystals for x-ray diffraction analysis. Met.    Biochem. Anal. 23, 249-345 (1976).

EXAMPLE III Materials and Methods

Yeast strains and Growth Conditions. All the experiments were performedusing yeast of DBY746 background. Knockout strains were prepared withstandard PCR-mediated gene disruption protocol. Strains used in thisstudy:

Strain Genotype DBY746 MATa, leu2-3, 112, his3Δ1, trp1-289, ura3-52,GAL⁺ sch9/aktΔ DBY746 sch9::URA3 ras2Δ DBY746 ras2::LEU2 tor1Δ DBY746tor1::HIS3 RAS2^(val19) DBY746 RAS2^(val19) (CEN, URA3)*tor1ΔRAS2^(val19) DBY746 ras2::LEU2 RAS2^(val19) (CEN, URA3)*sch9/aktΔRAS2^(val19) DBY746 sch9::URA3 RAS2^(val19) (CEN, URA3)*SCH9/AKT DBY746 SCH9 (CEN, URA3)* *pRS416-RAS2^(val19) was constructedby inserting 1.9 kb ClaI-HindIII fragment from pMF100 into pRS416.

Yeast cells were grown in minimal medium (SC) containing 2% glucose andsupplemented with amino acids as described previously. For short termstarvation (STS) treatment, day 1 cultures (24 hours after initialOD=0.1 inoculation) were washed 3 times with sterile distilled water,resuspended in water, and incubated at 30° C. with shaking for 48 hours(day 3).

Yeast Oxidative stress assay. For oxidative stress resistance assays,day 3 cells were diluted to an OD₆₀₀ of 1 in K-phosphate buffer, pH 7.4,and treated with 0.2-1 mM menadione for 1 hour. Alternatively, cellswere diluted to an OD₆₀₀ of 1 in K-phosphate buffer, pH 6 and treatedwith 200-400 mM of hydrogen peroxide for 30 minutes. Serial dilutions ofuntreated and treated cells were spotted onto YPD plates and incubatedat 30° C. for 2-3 days.

Yeast viability assay. Overnight SDC cultures were diluted to OD₆₀₀ 0.1into fresh SDC medium. After 24 hours (day 1), the appropriate strainswere mixed 1:1 based on OD₆₀₀ (OD₆₀₀ of 10 each) and incubated for 2hours at 30° C. with shaking. The mixed cultures were then treated witheither cyclophosphamide (CP, 0.1 M) or methyl methanesulfonate (MMS,0.01%, Sigma). MMS was prepared in ddH₂0 from stock solution and wasdiluted directly into the mixed culture to a final concentration of(v/v) 0.01%. However, due to the high concentration of CP (0.1 M)required, CP crystals were dissolved directly into the medium. To do so,mixed cultures were centrifuged for 5 minutes at 2,500 rpm and the mediawas collected, in which CP crystals were dissolved to a concentration of0.1 M. The mixed culture was then resuspended in the CP-containingmedium. Viability was measured as colony-forming units (CFUs) every 24hours by plating onto appropriate selective media. Viability ofindividual strains was measured using the same method as for the mixedcultures. Relative survival shown was determined by the percentage ofthe ratio between the treated and untreated (control) cells.

Cell culture experiments. Primary mixed glial cells were obtained fromthe cerebral cortices of 1 to 3 day old Sprague Dawley rat pups (CharlesRiver) as described before. Cells cultured for 10-14 days in DMEM/F12medium (Invitrogen) with 10% fetal bovine serum (FBS) were used inassays. Primary neurons from embryonic day 18 Sprague-Dawley ratcerebral cortices were dissociated in neurobasal medium (Invitrogen)supplemented with 0.5 mM L-glutamine, 25 μM L-glutamic acid and 2% B-27and plated at 640 cells/mm² in 96-well plates which were pre-coated with10 microg/ml poly-D-lysine dissolved in Borax buffer (0.15 M, pH 8.4).Neurons were maintained at 37° C. in 5% CO₂ in neurobasal mediumsupplemented with B-27 and 0.5 mM L-glutamine for 4 days.

C6, A10-85, 9L and RG2 rat glioma cell lines and LN229 human glioma cellline, and SH-SY5Y human neuroblastoma cell line were maintained inDMEM/F12 medium with 10% PBS and the PC12 rat pheochromocytoma cell line(ATCC) was maintained in F12K medium supplemented with 15% horse serumand 2.5% fetal bovine serum at 37° C. under 5% CO₂.

STS Treatments of mammalian cells. Primary glia, glioma or neuroblastomacells were seeded into 96-well microtiter plates at 20,000-30,000cells/well and incubated for 2 days. Cells were washed with phosphatebuffered saline (PBS) prior to treatments as indicated in the text. Alltreatments were performed at 37° C. under 5% CO₂.

Glucose restriction was done by incubating cells in glucose free DMEM(Invitrogen) supplemented with either low glucose (0.5 g/L) or normalglucose (1.0 g/L) for 24 hours. Serum restriction was done by incubatingcells in DMEM/F12 with either 10% or 1% FBS for 24 hours. IGF-Itreatment was carried out by incubating cells for 48 hours in DMEM/F12with 1% FBS and rhIGF-I (100 ng/ml, ProSpec-Tany TechnoGene, Rehovot,Israel), which is shown to be within the IGF-I level range for middleage humans. To antagonize IGF-I receptor activity, cells were incubatedwith neutralizing monoclonal anti-IGF-1R antibody (αIR3, 1 microg/ml;Calbiochem) in DMEM/F12 1% FBS for 24 hours.

In vitro drug treatments. Cyclophosphamide (CP, Sigma) was used for invitro chemotherapy studies. CP was prepared in DMEM/F12 with 1% FBS at40 mg/ml and was filter sterilized. The stock solution was stored at 4°C. for no longer than 2 weeks. Following STS treatments, cells wereincubated with varying concentrations of cyclophosphamide (6-15 mg/ml)for 10 hours in DMEM/F12 with 1% FBS. Glial cells have been reported toexpress cytochrome P450 and thus capable of metabolizing the prodrugcyclophosphamide. Cytotoxicity was measured by either lactatedehydrogenase released using the CytoTox 96 Non-Radioactive CytotoxicityAssay kit (Promega) or the ability to reducemethylthiazolyldiphenyl-tetrazolium bromide (MTT). LDH released into themedium by lysed cells were measured with a 10-minute enzymatic assaythat converts a tetrazolium salt (INT) into a red formazan product. A96-well based calorimetric assay measured the amount of the red formazanformed, which is proportional to the number of dead cells. % LDH releasewas determined with reference to the maximum and background LDH releaseof control cells.

MTT is reduced in the mitochondria (metabolically active cells) bymitochondrial reductase enzymes to form insoluble purple formazancrystals, which are solubilized by the addition of a detergent. Briefly,MTT was prepared at 5 mg/ml in PBS and was diluted in DMEM/F12 1% FBSmedia to a final concentration of 0.5 mg/ml for assays. Followingexperimental treatments, media was replaced with 100 μl of MTT and wasincubated for 3-4 hours at 37° C. Formazan crystals were dissolvedovernight (16 hours) at 37° C. with 100 μl lysis buffer ((w/v) 15% SDS,(v/v) 50% dimethylformamide). MTT assay results were presented aspercentage of MTT reduction level of treated cells to control cells.Absorbance was read at 490 nm and 570 nm for LDH and MTT assaysrespectively using a microplate reader SpectraMax 250 (MolecularDevices) and SoftMax Pro 3.0 software (Molecular Devices).

NXS2 neuroblastoma cells treated with different concentrations ofetoposide (1-3 μM) in presence or absence of octreotide (10 and 50 μM)for 72 hours were harvested by scraping, washed with complete medium,and incubated with trypan blue (0.04%; Sigma; St. Louis, Mo.) for 1minute at 37° C. The cells were then placed in a Burker chamber(Tecnovetro, Monza Milan, Italy) and counted by viewing with a contrastphase microscope (Olympus Optical Co LTD, Tokyo, Japan). Trypanblue-positive cells (i.e., dead cells), trypan blue-negative cells(i.e., living cells), and total cells were counted per microscope fieldat ×100 magnification (four fields were counted for each treatment). Theproportion of dead (or living) cells was calculated by dividing thenumber of dead (or living) cells by the total number of cells per field.

Primary rat neurons and PC12 cells were treated with IGF-1 and paraquatto determine the effect of IGF-1 on oxidative stress. Cortical neuronswere treated for 24 hours in Eagle's minimal essential medium(Invitrogen) supplemented with 21 mM glucose and 1% horse serum. PC12cells were plated at 5×10⁴ cells/well onto poly-D-lysine coated 96-wellplates and were grown for 24 hours in F12K 1% HS. Both types of cellswere then treated with either 100 μM of paraquat, IGF-1 (100 ng/ml)followed 30 minutes later by paraquat (100 μM) or IGF-1 (100 ng/ml)alone in appropriate media. Survival was determined by the MTT assay andpresented as percent ratio of treated to control.

Statistical analyses were performed using GraphPad Prism 4 software(GraphPad Software).

Western blots. Cells were seeded at 2×10⁶ cells/well in a 6-well cultureplate and cultured in DMEM/F12 10% FBS for 1 day. Cells were washed withPBS twice and glucose and serum starved by incubating in glucose-freeDMEM for 16 hours, followed by 1 hour of 10% FBS treatment or 1additional hour of starvation. Western blots were performed aspreviously described with some modifications. Briefly, cells were lysedwith 100 μl of RIPA lysis buffer with phosphatase and proteaseinhibitors (50 mM Tris HCl pH8, a 50 mM NaCl, 1% NP-40, 0.5% sodiumdeoxycholate, 0.1% SDS, 1 mM orthovanadate, 10 mM NaF, proteaseinhibitors (Sigma)). Protein concentration was measured to normalizeprotein loading using the BCA protein assay. Adjusted amounts of proteinwas loaded and separated by SDS-PAGE (12%) and transferred onto PVDFmembrane (Millipore, Mass.). Membranes were dried overnight and blockedfor 1 hour with TBS-T+BSA followed by a 1-hour incubation withanti-phospho-ERK (Sigma) and signal was detected using enhancedchemiluminescence (Amersham).

In vivo therapeutic studies in mice. The murine NX3IT28 cell line wasgenerated by hybridization of the GD2-negative C1300 murineneuroblastoma cell line (A/J background) with murine dorsal rootganglional cells from C57BL/6J mice, as previously described. The NXS2subline was then created by the selection of NX3IT28 cells with high GD2expression.

Six-to-seven-week-old female A/J mice, weighing 15-18 g were purchasedfrom Harlan Laboratories (Harlan Italy, S. Pietro al Natisone, Italy)and housed in sterile enclosures under specific virus and antigen-freeconditions. All procedures involving mice and their care were reviewedand approved by licensing and ethical committee of the National cancerResearch Institute, Genoa, Italy, and by the Italian Ministry of Health.A/J mice were pretreated with 1 mg/kg/day doses of human octreotide(OCT, ProSpec-Tany TechnoGene, Rehovot, Israel) for 4 days given slowlythrough the tail vein in a volume of 100 μl and then injectedintravenously with murine neuroblastoma NXS2 cell line (200,000/mouse),as previously described. After tumor cell injection, some groups ofanimals were starved for 48 hours and then i.v. treated with 80 mg/kg ofEtoposide Teva (Teva Pharma B.V., Mijdrecht, Holland), administered as asingle dose. Additional daily doses of OCT were administered for 4 daysafter chemotherapy. Control groups of mice without diet starvation andOCT treatment were also investigated.

Octreotide pre-treatment: 4 days 1 mg/kg/day

NXS2: 200,000/mouse on day 4

STS: from day 4 to day 6 (after tumor cell injection)

Etoposide: 80 mg/kg on day 7

Octreotide post-treatment: days 8-11

To determine toxicity and efficacy, mice were monitored routinely forweight loss and general behavior. The animals were killed by cervicaldislocation after being anesthetized with xilezine (Xilor 2%, Bio98 Srl,Milan, Italy) when they showed signs of poor health, such as adbominaldilatation, dehydration, or paraplegia. Survival time was used as themain criterion for determining the efficacy of each treatment.

The statistical significance of differential survival betweenexperimental groups of animals was determined by Kaplan-Meier curves andlog-rank (Peto) test by the use of StatDirect statistical software(CamCode, Ashwell, UK).

In some experiments, four-week-old female CD1 mice (Harlan), weighing18-20 g were used to evaluate stress resistance after 60-hour dietstarvation. These animals, i.v. injected with 110 mg/kg etoposide, weremonitored routinely for weight loss and general behavior. Survival timewas used as the main criterion for determining the differential stressresistance after short-term starvation.

In other experiments, four-week old female athymic (Nude-nu) mice(Harlan), weighing 20-22 gr were used to evaluate stress resistanceafter a 48-hour starvation. These animals were i.v.—injected with 100mg/Kg etoposide and then monitored routinely for weight loss and generalbehavior. Survival time was used as the main criterion for determiningthe resistance to high-dose chemotherapy after short-term starvation.

Thirty-four to forty-two-week old LID and their control L/L⁻ mice wereused to evaluate the role of circulating liver-derived IGF-I in stressresistance. LID and L/L⁻ mice were generated using the Cre/loxP systemas described before. Briefly, albumin-cre transgenic mice were crossedwith mice homozygous for exon4 of the igf-1 gene flanked with two loxPsites (L/L), therefore generating mice deficient in producing hepaticIGF-I. L/L⁻ mice have exon4 of the igf-1 gene flanked by loxP sites andproduce normal hepatic IGF-I levels while LID mice show 75% lowercirculating IGF-I levels. All mice were individually caged throughoutthe experiment and had access to food and water ad libitum. Both LID andL/L⁻ mice were each injected 500 mg/kg of cyclophosphamide i.p. using29G insulin syringes. Cyclophosphamide was prepared in saline at 40mg/ml and warmed prior to injection. Mice were routinely monitored forweight loss and signs of pain and stress. Survival time was the maincriterion for determining the effect of low circulating IGF-I on theresistance to high-dose cyclophosphamide. The statistical significanceof differential survival between experimental groups was determined byKaplan-Meier curves and log-rank test using GraphPad Prism 4 software(San Diego, Calif.).

REFERENCES

-   1. Brachmann, C. B. et al. Designer deletion strains derived from    Saccharomyces cerevisiae S288C: a useful set of strains and plasmids    for PCR-mediated gene disruption and other applications. Yeast 14,    115-32 (1998).-   2. Morano, K. A. & Thiele, D. J. The Sch9 protein kinase regulates    Hsp90 chaperone complex signal transduction activity in vivo. Embo J    18, 5953-62 (1999).-   3. Fabrizio, P. et al. Sir2 blocks extreme life-span extension. Cell    123, 655-67 (2005).-   4. McCarthy, K. D. & de Vellis, J. Preparation of separate    astroglial and oligodendroglial cell cultures from rat cerebral    tissue. J Cell Biol 85, 890-902 (1980).-   5. Hansen, M. B., Nielsen, S. E. & Berg, K. Re-examination and    further development of a precise and rapid dye method for measuring    cell growth/cell kill. Journal of Immunological Methods 119, 203-10    (1989).-   6. Yung, H. W. & Tolkovsky, A. M. Erasure of kinase phosphorylation    in astrocytes during oxygen-glucose deprivation is controlled by ATP    levels and activation of phosphatases. J Neurochem 86, 1281-8    (2003).-   7. Greene, L. A. et al. Neuronal properties of hybrid neuroblastoma    X sympathetic ganglion cells. Proc Natl Acad Sci USA 72, 4923-7    (1975).-   8. Lode, H. N. et al. Targeted interleukin-2 therapy for spontaneous    neuroblastoma metastases to bone marrow. J Natl Cancer Inst 89,    1586-94 (1997).-   9. Yakar, S. et al. Normal growth and development in the absence of    hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96,    7324-9. (1999).-   10. Kempermann, G., Knoth, R., Gebicke-Haerter, P. J., Stolz, B. J.,    Volk, B. Cytochrome P450 in rat astrocytes in vivo and in vitro:    Intracellular localization and induction by phenyloin. J Neurosci    Res 39, 576-88 (1994).-   11. Geng, J., Strobel, H. W. Expression, induction and regulation of    the cytochrome P450 monooxygenase system in the rat glioma C6 cell    line. Brain Res 784, 276-83 (1998).

EXAMPLE IV Oncogene Homologs and the Regulation of Stress Resistance andAging in Lower Eukaryotes

The studies in S. cerevisiae and those in worms, flies, and mice haveuncovered a strong association between life span extension andresistance to multiple stresses. A remarkable resistance to multiplestresses including chemotherapy drugs and oxidants in long-lived yeastcells lacking pro-growth proteins including the orthologs of the humanRas (RAS2) and Akt (SCH9/AKT) proto-oncogenes was observed (FIG. 15).Both Ras and Akt are among the signal transduction proteins mostfrequently found in a constitutively activated form in human cancers.Stress resistance is also associated with long-lived worms and mice withreduced activity of homologs of the IGF-I receptor (IGF-IR), whichfunctions upstream of Ras and Akt in mammalian cells. This resistance isalso observed in calorie restricted model systems in which the calorieintake is reduced by 30 to 100%.

The discovery of the role of Ras2 and Sch9/Akt in the negativeregulation of stress resistance together with the association betweenmutations that activate IGF-IR, Ras or Akt and many human cancersprompted the hypothesis that normal but not cancer cells would respondto starvation or down-regulation of growth hormone (GH)/IGF-I signalingby entering a chemotherapy resistance mode. In fact, one of the majorphenotypic characteristics of malignant cells is the ability to grow orremain in a growth mode even in the absence of growth factors, in partprovided by the hyper- or constitutive activation of pathways includingthose regulated by IGF-IR, Ras and Akt.

There are many similarities between long-lived mutants in S. cerevisiae,C. elegans, Drosophila, and mice and many of the genes implicated inlife span regulation are also frequently found in mutated oncogenicforms in cancer cells. C. elegans age-1 and daf-2 mutations extend thelife-span in adult organisms by 65 to 100% by decreasing AKT-1/AKT2signaling and by activating transcription factor DAF-16. These changesare associated with the induction of superoxide dismutase (MnSOD),catalase, and HSP70. In previous work it was showed that theinactivation of the Ras/cAMP/PKA pathway in S. cerevisiae increaseslongevity as well as resistance to oxidative and thermal stress in partby activating transcription factors Msn2 and Msn4, which induce theexpression of genes encoding for several heat shock proteins, catalase(CTT1), and the DNA damage inducible gene DDR2. MnSOD also appears to beregulated in a similar manner. Previous results also suggest that theeffects of sch9/akt deletion on stress resistance and life span requirethe serine threonine kinase Rim15 and transcription factor Gis1. Inworms, SMK-1 functions downstream of DAF-16, to regulate UV andoxidative stress but not thermal stress. Thus, the yeastRas/Cyr1/PKA/Msn2/4 and Sch9/Rim15/Gis1 and the C. elegansDAF-2/AGE-1/AKT/DAF16 pathways play similar roles in regulatinglongevity and multiple stress-resistance systems. Similarly, inDrosophila, mutations in the insulin receptor/Akt/PKB pathway extendlongevity and a mutation in the G-protein coupled receptor homolog MTHcauses a 35% life span extension and increases resistance to starvationand paraquat toxicity. Life span is also extended by potentialdownstream mediators of starvation-responses such as the Indy gene.

Whereas the inactivation of these partially conserved pro-aging pathwaysincreases resistance to oxidative stress in lower eukaryotes, theconstitutive activation of analogous pathways is known to promotecancer. One object is to test whether the inactivation of the Ras andSch9/Akt pathways in S. cerevisiae by either deletion mutations orstarvation increases resistance to a range of chemotherapy drugs,including alkylating agents, topoisomerase inhibitors, and oxidants.Furthermore, another object is to test whether the overexpression of theoncogene-like RAS2 or SCH9/AKT genes can reverse the resistance ofmutated or starved yeast to chemotherapy drugs. In addition to testingthe range and mechanisms of DSR in S. cerevisiae, another object is tocharacterize the DNA damage caused by different categories ofchemotherapy drugs and study the mechanisms responsible for the effectof Ras and Sch9/Akt on the resistance to chemotherapy. The understandingof the mechanisms of DSR in yeast is important because it provides thefoundation for the development of an analogous method that can beapplied to killing cancer but not normal mammalian cells.

Oncogene Homologs and the Regulation of Stress Resistance in Mammals

The inactivation of signal transduction pathways implicated in cancerhas also been shown to increase resistance to stress and survival inmammals. The deletion of the p66^(SHC) gene, associated with Ras,increases resistance to paraquat and hydrogen peroxide and extendssurvival by 30% in mice. Mutations that cause either a deficiency in thelevel of plasma growth hormone (GH) and IGF-I or a reduction of IGF-Isignaling cause an up to 50% increase in life span. As observed inlong-lived lower eukaryotes, the activities of antioxidant enzymessuperoxide dismutases and catalase are decreased in murine hepatocytesexposed to GH or IGF-I and in transgenic mice overexpressing GH. Inrats, IGF-I attenuates cellular stress response and the expression ofstress response proteins HSP72 and hemeoxygenase. IGF-I is a polypeptideinvolved in many aspects of growth and development. IGF-I is generatedmainly in the liver and is found in the blood in a stable complex withIGF-I binding proteins. Homozygous Ames dwarf mutations in the Prop-1gene (df/df) prevent the generation of the anterior pituitary cells thatproduce growth hormone (GH), thyroid stimulating hormone, and prolactin.df/df young adult mice are approximately one third of the size ofcontrol mice but survive >50% longer than controls. This effect of dwarfmutations on life span appears to be caused by the absence of plasma GH,which stimulates the secretion of IGF-I from liver cells by activatingthe hepatic GH receptors. In fact, IGF-I is reduced dramatically in theplasma of df/df mice. The plasma GH deficiency appears to mediate theeffects of Prop-1 and Pit-1 mutations on longevity, since the mice thatcannot release GH in response to growth hormone releasing hormone alsolive longer. Furthermore, dwarf mice with high plasma GE, but a 90%lower IGF-I (GHR/BP null mice) live longer than the wild type mice.Taken together these studies suggest that the reduction in plasma IGF-Iis responsible for a major portion of the life span increase in dwarf,GH deficient, and GHR/BP null mice.

A recent study shows that deletion of the IGF-I gene exclusively in theliver (IGF-I/loxP) causes a dramatic reduction of plasma IGF-I, but doesnot result in growth and development defects suggesting that GH canaffect cellular function and the autocrine/paracrine release of IGF-I invarious tissues independently of plasma IGF-I. In fact, IGF-I mRNAexpression is normal in fat cells, muscle, kidney, heart and spleen ofIGF-I/loxP mice. Mutations that decrease the activity of the adenylylcyclase/cAMP/PKA pathway and increase life span and stress resistancewere identified. Recently, a reduction in adenylyl cyclase activity bydeletion of the 5 adenylyl cyclase (AC5) gene was shown to extend lifespan and also increase resistance to oxidative stress in mice,suggesting that the role of both the Akt and cAMP/PKA pathways in theregulation of aging and stress resistance may be conserved from yeast tomice (FIG. 15). The mammalian IGF-1 receptor activates both Akt/PKB andRas and analogously to yeast Sch9/Akt and Ras, regulates glucosemetabolism and cellular proliferation. Many studies, implicate increasedIGF-I or IGF-I signaling as a risk factor in a variety of cancers,suggesting that this pro-mitotic pathway can promote both aging but alsothe conditions necessary for cancer. Another object is to test whetherreduced glucose, serum, and/or IGF-I can protect primary mammalian cellsbut not, or less, rodent and human cancer cells against differentchemotherapy drugs.

Caloric Restriction, Dwarf Mice, and IGF-I

The chronic reduction of calories by 10-40% below ad lib intake slowsaging and extends life span in lab rodents. CR decreases age-relatedpathologies including tumors and kidney degeneration, lowers bloodglucose, IGF-I, and insulin, and elevates corticosterone (Table 3). CRalso causes a reduction in oxidative modifications of long-livedmacromolecules such as collagen and affects age-related changes in thebrain: it slows the loss of dopamine receptors and attenuates thedegeneration of spinal motoneurons in rats. Although the mechanismresponsible for the effects of CR is unknown, it may involve a decreasein the levels of circulating Insulin-like Growth Factor 1 (IGF-I). Theresults in yeast indicate that the reduction of Ras-cAMP-PKA andSch9/Akt signaling plays an important role in the effect of calorierestriction/starvation on stress resistance and aging (FIG. 17). Infact, CR mice and dwarf mice, with IGF-I signaling deficiency, shareseveral characteristics (compared to ad lib controls):

TABLE 3 Similarities between caloric restricted and dwarf mice CR Amesdwarf Body weight (young) reduced reduced Plasma glucose reduced reducedPlasma Insulin reduced reduced Body temperature reduced reduced PlasmaIGF-I reduced absent Corticosterone elevated elevated Life span extendedextended

Starvation Response in Mammals

The DSR method is based on the ability of starvation to protect normalbut not, or less, cancer cells against high dose chemotherapy. However,the use of starvation to protect cancer patients that often have alreadylost much weight would have limited applications. Therefore, it isimportant to identify factors that can mimic the effect of starvation onprotection. In the results the effect of the somatostatin analogoctreotide in DSR were tested but found to be ineffective in theprotection against the chemotherapy drug etoposide but effective in theenhancement of the toxicity to cancer cells but not normal cells afterstarvation. In other words, octreotide did not protect mice againstetoposide, but reverse the effect of starvation in the protection ofcancer cells but not normal cells. The explanation for these results iscomplex. In fact, the level of somatostatin, which inhibits the releaseof growth hormone from the pituitary, was found to be reduced by 70%after a 3-day fasting period (rats) but a 24-72-hour starvation inhibitsGH secretion, although this effect may not depend on somatostatin. Inhumans, a 48-hour starvation raises GH levels and does not increaseIGF-I level. This effect may be the result of a major increase in theIGF-I inhibitory protein IGFPB-1, which may decrease IGF-Ibioavailability and consequently prevent the feedback inhibition of GEsecretion by IGF-I. However, a longer starvation (5 days) does decreasethe level of IGF-I in humans. Thus, the decrease in the pro-growth IGF-Iby long-term starvation may contribute to the effect of starvation inthe protection against high dose chemotherapy but somatostatinadministration alone is not sufficient for protection. Another object isto study further the effect of different periods of starvation on thelevel of IGF-I and IGF-I binding proteins in mice. These studies areimportant for identifying the factors and mechanisms that mediate theeffect of starvation on resistance to chemotherapy.

Self-Sufficiency in Growth Signals and Insensitivity to Anti-GrowthSignals in Cancer Cells

Two of the major “alterations in cell physiology that dictate malignantgrowth” are: 1) self-sufficiency in growth signal, 2) insensitivity toanti-growth signals. In fact, the great majority of normal cells areunable to grow in the absence of growth factors, whereas cancer cellsexpress oncogenes that mimic the effect of growth factors. Such“independence” can be caused by changes in extracellular factors thatpromote growth, the activation of membrane receptors, or mutations thatlead to the activation of intracellular signal transduction proteins.Some of the extracellular factors overproduced by cancer cells includeTGF, PDGF and IGF-I. Among the receptors overexpressed in a number ofcarcinomas are the EGF and HER-2 receptors. Extracellular matrixreceptors that can promote growth, known as integrins, are also found tobe activated in cancer cells. Perhaps the most important contribution tothe “growth factors independence of cancer cells” comes fromintracellular pathways, particularly the Ras/Raf/MAPK and thePTEN/PI3K/AKT pathways. Altered forms of Ras that can render the cellgrowth independent from extracellular growth signals are found inapproximately a quarter of all cancers and half of colon cancers (FIG.16). The link between Ras and PI3K may further stimulate growth and alsoactivate anti-apoptotic pathways.

Another highly relevant feature of cancer cells is the ability to“disobey” anti-growth orders. These orders are often focused on theblock of the progression through the G1 phase of the cell cycle. Theretinoblastoma protein (Rb) is one of the central negative regulators ofproliferation in normal cells. When bound to transcription factor E2F,Rb prevents the induction of many pro-growth genes. One of the majorregulators of Rb and the anti-proliferation mode is the signalingprotein TGF-beta, which can block the phosphorylation that causes theinactivation of Rb. Cancer cells can become insensitive to anti-growthsignals in many ways including the down-regulation of the TGF-betareceptor or through mutations that cause the inactivation of Rb.

The “self-sufficiency in growth signals and insensitivity to anti-growthsignals” features of cancer cells and the central roles of Ras and Aktin oncogenesis (FIG. 16) are central to the belief that normal but notcancer cells will enter a protective mode in response to starvation orto the inhibition of growth factor signaling and in particular IGF-I.Based on the conserved entry into a “stress resistance” mode in responseto starvation or anti-growth signals in model systems ranging from yeastto mice, it is believed that all normal cells can enter a state in whichthey are protected or partially protected against chemotherapy, althoughit is not yet known how effective this protection will be. By contrast,the “self-sufficient” cancer cells should disobey or partially disobeythe “stress resistance orders” and continue on their pro-growth path.IGF and IGFBP alterations in animal models of cancer Transgenic micethat develop prostate tumors show an IGF axis disturbance very similarin their behavior to the human disease. It has been shown that TRAMPmice have IGF-I and IGF-IR alterations similar to those proposed in thehuman disease. Similar findings have been demonstrated in theMyc-over-expressing mouse model. Additionally, it has been demonstratedthat various interventions that affect the development of cancer in miceact by modulating the IGF axis; including green tea extract, thatincreases IGFBP-3 and lowers IGF-I levels; and the flavanoids quercetinand apigenin. It was observed that IGFBP-3 directly induces apoptosis incancer cells and that it mediates cell death induced by other agents,including p53, which mediates IGFBP-3 actions Several cytokines,including TGFβ and TNFα and anticancer drugs, such as retinoic acid canalso induce IGFBP expression as well as apoptosis. The action of theseagents appear to require the expression of IGFBP-3 for the induction ofapoptosis, as their effects are blocked by reagents that specificallyblock IGFBP-3 (such as siRNA, antisense oligomers, and neutralizingantibodies). IGFBP-3-induced apoptosis has now been detected in multiplemodels, and IGFBP-3 has been identified as a target of the HPVoncoprotein E7, that targets it to degradation, thereby preventing itsapoptotic effects. It was also demonstrated that IGFBP-3 is a downstreamtarget of EWS/FLI-1 and is lost in sarcoma. IGFBP-3 was identified as ap53 target gene that was frequently inactivated by methylation in germcell tumors and bladder carcinoma. IGFBP-3 inhibits IGF-I action ongrowth and survival of cancer and also directly induces apoptosis incancer cells. Another object is to test the role of IGFBP3 in theresistance of mice to chemotherapy but also in the sensitization ofcancer cells to various chemotherapy drugs.

Pharmacological Blockade of the IGF Axis in Cancer

As a result of the overwhelming data dealing with the role of the IGFsystem in the development and progression of various cancers, over adozen pharmaceutical companies have initiated the development of IGFantagonists. Several classes of IGF blockers are now in clinical trials,including IGFBPs, IGF-receptor blocking antibodies, and various smallmolecule inhibitors. The most promising and in the most advanced stageof development are the IGF-I receptor antibodies which are in Phase IItrials in several types of malignancies and have shown promising effectsin early reports. Interestingly, in most published papers, IGF-IRblockade is synergistic with agents that block parallel pathways. Asdiscussed below, there is a clear rationale for combining IGF-IRblockade and chemotherapy, including likely synergistic efficacy as wellthe expected avoidance of host toxicity. Another object is to test therole of IGF-receptor blocking antibodies in the resistance of mice tochemotherapy but also in the sensitization of cancer cells to variouschemotherapy drugs.

Short-Term Starvation Induces Differential Stress Resistance AgainstOxidative Stress in Yeast

To test whether constitutively active oncogenes or oncogene homologs canprevent the switch to a protective maintenance mode in response tostarvation, whether acute starvation would be as effective in increasingstress resistance as it has been shown for long-term calorie restriction(CR) was first determined. Such long-term CR strategy would not beappropriate for chemotherapy treatments since it requires several monthsto be effective. DSR studies were first performed in S. cerevisiae. Ashort-term starvation paradigm, as well as the deletion of the SCH9/AKTand/or RAS2 genes, each of which mimics in part calorie restriction andwas shown to cause high resistance to oxidative stress, was selected. Itwas believed that the combination of these genetic manipulations withstarvation would maximize DSR. The combination of STS (switch fromglucose medium to water at day 1 [OD=9-10] and incubation in water for24-48 hours) with the deletion of SCH9/AKT or both SCH9/AKT and RAS2increased resistance to a 30-60 minute treatment with hydrogen peroxideor menadione a 1,000- to 10,000-fold compared to cells expressing theconstitutively active oncogene homolog RAS2^(val19) or cells lackingSCH9/AKT (sch9/aktΔ) but expressing RAS2^(val19) (sch9/aktΔRAS2^(val19))(FIG. 17A). The rationale for this experiment was to model in a simplesystem the effect of the combination of short-term starvation and agenetic approach on the differential protection of normal and cancercells. The results show that the expression of the oncogene-likeRAS2^(va)19 prevents the 1,000-10,000-fold protection caused by thecombination of STS and inhibition of Sch9/Akt activity.

The effect of another oncogene homolog (SCH9/AKT) on resistance tooxidants was also tested. As with RAS2^(val19), overexpression ofSCH9/AKT sensitized yeast cells to both H₂O₂ and menadione (FIG. 17B).Similarly to the effect of the deletion of RAS2 and SCH9/AKT, thedeletion of the homolog of TOR, another gene implicated in cancer,slightly increased the resistance to oxidants. Whereas the expression ofRAS2^(val19) completely reversed the protective effect of the deletionof SCH9/AKT, it only had a minor effect on the reversal of theprotective effect of the tor1α (FIG. 17B). This is an importantdifference because it suggests that it may be problematic to attempt toachieve DSR by inhibiting intracellular targets instead of inhibitingreceptors extracellularly since inhibition of certain cytosolic pathwaysmay also protect cancer cells in which the target is downstream of theoncogenic mutation. For example the inhibition of Akt may also protectcancer cells with a PTEN mutations that causes the constitutiveactivation of PI3K.

Short-Term Starvation Induces Differential Stress Resistance AgainstAlkylating Agents in Yeast

To test whether DSR would also occur after treatment of yeast with ahigh concentration of chemotherapy drugs, the effect of SCH9/AKTmutations on the toxicity caused by alkylating agents methylmethanesulfonate (MMS) and cyclophosphamide (CP, a widely usedchemotherapy drug) was studied. As a very simple model for the effect ofSTS and/or IGF-I inhibition on metastatic cancer mutants lackingSCH9/AKT were mixed in the same flask with mutants lacking SCH9/AKT butalso expressing RAS2^(val19) at a 25:1 ratio and the mixture was exposedto chronic treatment with CP or MMS. The monitoring of the viability ofthe two mixed populations was possible since each population can bedistinguished by growth on plates containing different selective media.Of the approximately 10 million sch9/aktΔRAS2^(val19) cells mixed with250 million sch9/aktΔ, less than 5% of the sch9/aktΔRAS2^(val19) cellssurvived a 48-hour treatment with 0.01% MMS whereas the great majorityof sch9/aktΔ survived this treatment (FIG. 17C). Similar results wereobtained with mixed sch9/aktΔRAS2^(val19)/sch9/aktΔ cultures treatedwith cyclophosphamide (FIG. 17D). An experiment in which each cell typewas treated with CP separately was also performed and a similardifferential stress resistance between cells expressing RAS2^(val19) andcells lacking SCH9/AKT was observed. These results in a very simplemodel system suggest that DSR has the potential to work effectivelyagainst metastatic cancer by selectively killing cancer cells but notnormal cells. Considering the very limited success of therapies aimed attreating metastasis, it is essential to explore further the potential ofnew strategies like DSR.

Short-Term Starvation Induces Differential Stress Resistance AgainstCyclophosphamide in Mammalian Cells

To test the efficacy of the starvation-based DSR method on mammaliancells, primary rat mixed glial cells (astrocytes+5-10% microglia), threedifferent rat, one human glioma and one human neuroblastoma cell lineswere incubated in medium containing low serum and either normal (1 g/L)or low (0.5 g/L) glucose and then treated with the chemotherapy drug CP(1 g/L glucose is within the normal human blood glucose range whereas a0.5 g/L glucose concentration is reached in mammals during prolongedstarvation). The 1% serum concentration minimizes the contribution ofglucose from serum, which is approximately 1 g/L. To avoid majordifferences in proliferation, glia and glioma cells were allowed toreach a 100% confluency. Whereas 80% of glial cells were resistant to 12mg/ml CP in the presence of 0.5 g/L glucose, only 20% of the cellssurvived this treatment in 1 g/L glucose (FIG. 2A). The increased stressresistance at the lower concentration of glucose (0.5 g/L) was observedstarting at 6 mg/ml CP but became much more pronounced at 12 mg/ml CP(FIG. 2A). By contrast, the lower glucose concentration did not increasethe resistance of cancer cell lines including C6, A10-85, RG2 ratglioma, LN229 human glioma or human SH-SY5Y neuroblastoma cells to 12-14mg/ml CP (FIG. 2A). The lower glucose concentration actually decreasedthe resistance of CP to RG2 glioma cells to 6 and 8 mg/ml doses (FIG.2A). To determine whether the DSR is affected by the high cell densitythis experiment was also repeated with cells that were only 70%confluent and similar results were obtained.

To determine whether the constitutive activation of the Ras/Erk pathwaymay be implicated in the unresponsiveness of the glioma andneuroblastoma cells above to starvation the phosphorylation of Erk,which functions downstream of Ras, in 1% serum or serum-starved cellswas measured. The phosphorylation data indicate that 2 of the 5 linesmaintain a high level of Erk activity even after a 16-hour starvation(FIG. 11B), in agreement with the 30% frequency of Ras mutations inhuman cancers. The reduction of Erk phosphorylation but inability toincrease protection to cyclophosphamide in the other 3 lines (FIG. 2A)is consistent with an anti-resistance role of other common mutations inpro-growth pathways such as the PTEN/PI3K/AKT pathway. Notably, it isbelieved that the constitutive activation of any pro-growth pathway (notonly the Ras and Akt pathway) would make cancer cells unresponsive orless responsive to the starvation or IGF-I reduction-dependentprotection.

The experiments above were performed in medium containing 1.0 g/Lglucose and different concentrations of glucose. The effect of onlyreducing the level of serum from the standard 10% to 1% on the toxicityof high-dose cyclophosphamide was also tested. Treatment with 15 mg/mlCP was toxic to primary glial cells in 10% serum but the switch to 1%serum caused a reduction in toxicity (FIG. 2B). By contrast, the sameconcentration of CP was as toxic to CG glioma cells in 10% serum as itwas in 1% serum (FIG. 2B).

In the S. cerevisiae experiments above it was showed that the deletionof SCH9/AKT protects whereas the constitutive activation of Ras2(RAS2^(val19)) or SCH9/AKT overexpression sensitizes the yeast cells tooxidants and/or alkylating agents. Since mammalian Ras and Akt are majorsignal transduction proteins downstream of the IGF-I receptor, andconsidering the role of the IGF-I pathway in regulating stressresistance, the effect of IGF-I and of an antibody against IGF-IR on DSRwas also tested. It was reasoned that primary cells would respond to theIGF-1-inhibiting treatment by increasing stress resistance whereascancer cells, which often express oncogenes that cause constitutive Rasand Akt activation, would not. Treatment with 100 ng/ml IGF-I (in thelow IGF-I range for human adults) caused a 3-fold increase in thetoxicity of cyclophosphamide to primary mixed glia but did not increasethe toxicity of CP to C6 glioma cells (FIG. 2C). Furthermore,pre-incubation with an anti-IGF-IR antibody (aIR3) protected primaryglia but not three glioma cell lines tested against CP toxicity (FIG.2D). A similar sensitizing role of IGF-I was observed with primary ratcortical neurons but not the rat pheochromocytoma tumor PC12 cell linetreated with oxidants. These results in normal glia and in rat and humanglioma and neuroblastoma cell lines are consistent with those in yeastcells and support the belief that short-term starvation and/or drugsthat down-regulate IGF-IR/Ras/Akt signaling can protect normal cellsmuch more effectively than cancer cells against chemotherapy. Notably,this differential stress resistance should apply to the great majorityof pro-growth oncogenic mutations and not only to cancer cells withmutations in the Ras, Akt or mTor pathways. In fact, it worked with allthe six cancer cell lines tested (FIG. 2), independently of cancerorigin.

Short-Term Starvation Induces Differential Stress Resistance AgainstChemotherapy in Mice

To test DSR in vivo mice were treated with high dose chemotherapy incombination with STS and/or GH/IGF-I lowering strategies. For thispurpose etoposide, a widely used chemotherapy drug which damages DNA bymultiple mechanisms and displays a generalized toxicity profile rangingfrom myelosuppression to liver and neurologic damage, was selected. A/Jmice were administered with a high dose of etoposide (80-110 mg/kg)after a period of starvation, GH/IGF-I lowering treatment or both. Inhumans, a third of this concentration of etoposide (30-45 mg/kg) isconsidered to be a high dose and therefore in the maximum allowablerange.

To reduce GH/IGF-I mice were pre-treated for four days with thesomatostatin analogue octreotide. This pre-treatment was followed byetoposide administration. A sub-group of mice were also starved for 48hours (STS) before treatment with etoposide. The mice pre-treated withoctreotide received this treatment for 4 additional days afterchemotherapy. Whereas 80 mg/kg etoposide killed 43% of control (Eto,n=23, 2 experiments) and 29% of octreotide pre-treated mice (Oct/Eto,n=17), none of the mice treated with octreotide and also pre-starved for48 hours died after 80 mg/kg etoposide treatment (Oct/STS/Eto/Oct, n=35)and only one of the mice that were only starved (STS/Eto, n=16) diedafter etoposide treatment (FIG. 7A). Remarkably, STS-octreotidepre-treated mice, which lost 20% of the weight during the 48 hours ofstarvation, regained all the weight in the four days after chemotherapy(FIG. 7B) whereas in the same period the control mice lost approximately20% of the weight (FIG. 7B). Control mice treated with etoposide showedsigns of toxicity including reduced mobility, ruffled hair and hunchedback posture whereas Oct/STS/Oct pre-treated mice showed no visiblesigns of stress or pain following etoposide treatment.

The effect of STS alone on the protection of mice of another geneticbackground (CD1) was also tested. To determine whether an extended STSstrategy can be effective against a higher concentration of chemotherapydrugs 110 mg/kg etoposide was administered and the starvation period wasalso increased to 60 hours. Based on the experiments with oxidativestress, it was determined that this period is the maximum STS thatprovides protection. Longer starvation periods can weaken the animalsand have the opposite effect. This concentration of etoposide killed allthe control mice (Eto 110) but none of the STS pre-treated mice (STS/Eto110, n=5) (FIG. 7C). As with the A/J mice, pre-starved CD1 mice lost 40%of the weight during the 60 hours of starvation but regained all theweight in the week after the etoposide treatment and showed no visiblesign of toxicity (FIG. 7D).

The effect of the STS-based method was similar in athymic (Nude-nu)mice, widely used in cancer research to allow the study of human tumors.Whereas 100 mg/kg etoposide killed 56% of the nude mice and all the miceco-treated with octreotide, none of the STS/Eto/Oct or STS/Eto treatedmice (48-hour starvation) died (FIG. 7E). As observed with the other twogenetic backgrounds, the pre-starved mice gained weight during theperiod in which the Eto-treated mice lost weight (FIG. 7F).

In summary, out of 70 mice from three genetic backgrounds that werestarved before etoposide treatment, only one mouse in the STS only groupand none of the mice in the STS/Oct group died (FIG. 7I). By contrast,out of the 63 mice treated with etoposide alone or etoposide andoctreotide, 34 died of toxicity. These results are consistent with theyeast and glia/glioma data showing increased resistance to chemotherapytoxicity in response to starvation. In mice, octreotide alone was notsufficient to protect against etoposide toxicity and virtually all theprotection was due instead to STS. The discrepancy between the effect ofIGF-I in vitro and octreotide in vivo may be due to the relativelymodest effect of octreotide on the reduction of circulating IGF-I level.

Transgenic Mice with Low Circulating IGF-1 (LID) Show IncreasedResistance Against Cyclophosphamide

To determine whether a much more severe reduction in IGF-I level thanthat achieved with octreotide can increase resistance to chemotherapy invivo as shown in vitro, the resistance against a high dose ofcyclophosphamide of male and female LID mice, in which the liver IGF-Igene was conditionally deleted, resulting in a 75-90% reduced serumIGF-I concentration, was studied. The LID mice treated with 500 mg/kgcyclophosphamide showed a remarkable improvement in resistance, with 30%mortality vs the 70% mortality for control mice (FIG. 7G, P<0.002).Furthermore, the LID mice lost an average of 10% of weight vs 20% weightloss in control mice (FIG. 7H). The 70% surviving LID mice also did notshow any signs of toxicity. Together with the in vitro results withIGF-I and anti-IGF-IR antibodies and the established role of starvationon the reduction of IGF-I levels, these data suggest that the inhibitionof IGF-IR signaling may mediate part of the effects of STS on resistanceto cyclophosphamide in vivo. Notably, IGF-IR antibodies have been usedsuccessfully in a number of studies to reduce the growth or increase thedeath of cancer cells and are currently being evaluated in clinicaltrials.

Short-Term Starvation in Combination with Octreotide Protects Mice Butnot Cancer Cells Against High Dose Chemotherapy

To determine whether the differential stress resistance observed inyeast and mammalian cells would also occur in mice, the survival of miceinjected with cancer cells was followed. A particularly aggressiveneuroblastoma (NB) tumor line (NXS2) (NB is the most common extracranial solid tumor, and the first cause of lethality in pre-school agechildren) was selected. Advanced NB patients, who representapproximately 50% of the cases, show metastatic dissemination atdiagnosis, and have a long-term survival rate of only 20% in spite ofaggressive chemotherapy with autologous hematopoietic stem cell support.

The NXS2 neuroblastoma line in mice induces consistent and reproduciblemetastases in a pattern which resembles the clinical scenario observedin neuroblastoma patients at advanced stages of disease. Experimentalmetastases in the liver, kidneys, adrenal gland, and ovaries wereobserved after 25-30 days of the inoculation with 200,000 NXS2 cells(Table 2) as previously described. The tumor development and survival ofSTS/Eto treated mice was significantly different from that of controls(Gr. 7 vs. Gr. 1 p<0.0001) (FIG. 8A, Table 2) suggesting that STS aloneprovides strong protection to the mouse but only partial protection ofcancer cells against etoposide. Based on these results, the use of STSalone would require several or many chemotherapy cycles to obtaintoxicity to cancer cells comparable to that caused by high dosechemotherapy alone.

By contrast, none of the Oct/STS/Eto/Oct injected with NXS2 cells dieduntil day 46, at a point when all the controls had died of cancer (FIG.8A, Table 2) (Gr. 4 vs. Gr. 1 p<0.0001). One mouse from this groupsurvived until day 130. The survival of Oct/NXS2/STS/Eto/Oct mice wasnot significantly different from that of NXS2/Eto and Oct/NXS2/Eto/Octgroups (Table 2) but, as described above, 50% of mice not protected withSTS died of etoposide toxicity (FIG. 7A). Even if the initialetoposide-dependent deaths are not considered, the long-term survival ofthe octreotide/STS/NXS2/etoposide group was not significantly differentfrom that of the NXS2/etoposide. These results suggest that incombination with octreotide, STS protects the animal but not or muchless the cancer cells against chemotherapy. Although a single injectionof high dose etoposide cannot be expected to cure the mice injected withNXS2 cancer cells, the high protection provided by STS/Oct against theinitial chemotherapy toxicity to mice but not cancer cells provides asystem that allows multiple or many cycles of etoposide treatment.Although the Eto alone group appears to perform slightly better than theSTS/Oct/Eto group, the initial high toxicity would prevent the use ofhigh dose Eto alone. Attempts to combine weekly injections of etoposidewith STS/Oct were discontinued because of the damage to the tails causedby the many i.v. injections, which prevented additional injections.Thus, the present results show that the differential stress resistancealso works in vivo.

Octreotide does not Sensitize NXS2 Neuroblastoma Cells to Etoposide

Somatostatin analogues have been reported to promote anti-tumor activitythrough two distinct effects: direct actions, mediated by somatostatinreceptors, and indirect actions, independent of the receptors. Thesomatostatin/octreotide receptor-mediated effect includes inhibition ofcell cycle and growth factor effects, and induction of apoptosis. Incontrast, the indirect effects comprise inhibition of the release ofgrowth factors such as growth hormone and IGF-I. To determine whetheroctreotide was acting directly on cancer cells the toxicity of etoposideto NXS2 cells cultured in vitro in the presence or absence of octreotidewas tested. Either 10 or 50 micromolar octreotide did not sensitize NXS2cells to etoposide treatment (FIG. 8B) suggesting that it is notincreasing the survival of the NXS2 injected mice by directlysensitizing the cells to etoposide. Because of the many studies showingan anti-tumor growth and survival effect of lower GH and IGF-I orinhibition of the IGF-I and GH receptors, these results suggest thatoctreotide may be improving long-term survival of STS treated mice byits well established role in decreasing GH and IGF-I levels althoughother effects cannot be ruled out. Notably octreotide and othersomatostatin analogues have been shown to have therapeutic effects in anumber of cancers. In the absence of short-term starvation, octreotidealone did not protect mice against NXS2-dependent death (FIG. 8A),suggesting that it is the synergism between etoposide and octreotidethat is effective in killing tumor cells. These results also suggestthat octreotide pre-treatment before the injection of NXS2 cells doesnot affect the tumor growth.

Targeted Deletion of Hepatic Igf1 in TRAMP Mice Leads to DramaticAlterations in the Circulating IGF Axis But does not Reduce TumorProgression

The role of systemic and local IGF-I in the development of prostatecancer is still controversial. TRAMP mice express the SV40 T-antigenunder the control of the probasin promoter, and spontaneously developprostate cancer. TRAMP mice was crossed with liver IGF-I deficient (LID)mice to produce LID-TRAMP mice, a mouse model of prostate cancer withlow serum IGF-I, to allow the study of the effect of circulatory IGF-Ilevels on the development of prostate cancer. LID mice have a targeteddeletion of the hepatic Igf1 gene but retain normal expression of Igf1in extra-hepatic tissues. Serum IGF-I and IGFBP-3 levels in LID andLID-TRAMP mice were measured using novel assays, which showed that theyare approximately 10% and 60% of control L/L⁻ mice, respectively. SerumGH levels of LID-TRAMP mice were 3.5-fold elevated relative to L/L-TRAMPmice p<0.001). Rates of survival, metastasis, and, the ratio ofgenitourinary tissue weight to body weight were not significantlydifferent between LID-TRAMP and L/L-TRAMP mice (FIG. 18). There was alsono difference in the pathological stage of the prostate cancer betweenthe two groups at 9-19 weeks of age. These results are in strikingcontrast to the published model of the GH-deficient lit/lit-TRAMP, whichhas smaller tumors and improved survival, and indicate that thereduction in systemic IGF-I is not sufficient to inhibit prostate cancertumor progression in the TRAMP model, which may require reduction of GHlevels as well. On the other hand, LID mice were less susceptible tochemotherapy toxicity as shown in FIG. 7G, indicating that in some andpossibly many cancers, the main benefit of IGF blockade, may in fact bein the potential for protection of normal but not tumor cells againstchemotherapy.

Development of Novel Mouse Specific IGF-Related Assays (IGFBP-3, IGF-I,and Other Mouse IGF Axis Analytes)

One object is to study the effects of GH/IGF lowering treatmentstogether with chemotherapeutic agents in mouse models. A key element instudying mice models involving IGF-related effects is the development ofmouse-specific IGF and IGFBP assays. Novel assays for the IGF axis havebeen developed. Highly accurate mouse-specific assays for mIGF-I,mIGF-II, mGH, mALS, mIGFBP-1, mIGFBP-2 and mIGFBP-3 have been developed(FIG. 19). These mouse-specific ELISA assays have been recentlydeveloped using rat-anti-mouse monoclonal antibodies and recombinantmouse IGF-related proteins from R&D Systems. These assays havesensitivities of less than 0.2 ng/mL, have no cross-reactivity withhuman homologues (human serum reads <1 ng/ml) and no interference withother IGFs or IGFBPs. Inter- and intra-assay CVs are <6% and recoveriesare 88-110% in the linear range of the assays. Importantly, a cleardevelopmental pattern for IGF-I, IGFBP-3, and ALS has been demonstrated,and it was showed that levels are low in GH deficient mice and in LID(Liver IGF-deficient) mice as well as being zero in the serum specificKO mice.

Starvation-Dependent Protection Against Chemotherapy

To understand whether STS is effective against a wide range ofchemotherapy drugs, its effect against the widely used drug doxorubicinwas also tested. A 48-hour STS effectively protected all mice (n=5)against 16 mg/Kg doxorubicin (FIG. 20). By contrast, the same dose ofdoxorubicin killed all the mice that were not pre-starved (FIG. 20).

Low IGF-1-Dependent Protection Against Chemotherapy

The role of IGF-I deficiency in the resistance to etoposide anddoxorubicin was tested. Surprisingly, the IGF-I deficient LID mice wereless resistant to etoposide compared to controls, although thedifference in survival was not significant (FIG. 21). By contrast, LIDmice were remarkably more resistant than controls to treatments withdoxorubicin. In this experiment multiple cycles of chemotherapy weremodeled by injecting the mice first with 20 mg/kg and 22 days later witha higher dose (28 mg/kg) of doxorubicin. All LID mice survived themultiple treatments whereas 75% of control mice died (FIG. 22).

Mechanisms of Regulation of Oxidative Stress and Chemotherapy Resistance

In the experiments shown below primary rat neurons were studied to beginto identify effectors of resistance to oxidative stress and chemotherapydownstream of Ras. It was showed that 2 inhibitors of MEK1/ERK,signaling kinases downstream of Ras, increase resistance to bothhydrogen peroxide and menadione (FIG. 23), providing evidence for a roleof ERK in regulating resistance to chemotherapy.

Starvation, Oncogene Homologs and Differential Resistance toChemotherapy Drugs in S. cerevisiae

The belief that the DSR system can protect normal but not cancer cellsagainst chemotherapy is based on the findings that starved yeast cellslacking oncogene homologs RAS2 or SCH9/AKT are resistant to oxidativestress as well as alkylating agents. In previous studies it was showedthat this resistance is reversed by the overexpression or constitutiveactivation of RAS2 or SCH9/AKT, which models oncogenic mutationscommonly found in human cancers. Thus, one object is to understandwhether and how starvation and/or down-regulation of these pathways canprotect normal cells but not cells expressing oncogene homologs againstdifferent classes of chemotherapy drugs. To dissect the mechanism ofprotection the role of various stress resistance transcription factorsinhibited by the Ras and Sch9/Akt pathways and in the resistance tothese chemotherapy drugs will be tested. Resistance to alkylatingagents, a topoisomerase II inhibitor, a thymidylate synthetaseinhibitor, and pro-oxidant drugs will be tested. Previous results pointto the error-prone polymerase Rev1 and recombination proteins in themediation of spontaneous age-dependent mutations. Here, the role ofthese error-prone enzymes and homologous recombination proteins in thesensitivity of cells expressing or overexpressing RAS and SCH9/AKT tochemotherapy agents will also be tested. Finally, a number of strainspreviously generated to characterize the range of DNA damage caused bythe various chemotherapy drugs and the effect of Ras and Sch9/Aktactivity on this damage will be used. Although results in S. cerevisiaedo not always reflect the biology of mammalian cells, the studiessuggest that oncogene homologs play conserved roles in the modulation ofresistance to chemotherapy drugs.

The following studies will be performed:

a) Determine the resistance of starved (48 hours in water) ornon-starved wild type, ras2Δ, sch9/aktΔ, ras2Δsch9Δ expressing eitherRAS2^(val19), SCH9/AKT or an empty vector to cyclophosphamide,etoposide, 5 FU, and menadione (vitamin K3). Both acute and chronictreatments will be performed (see FIG. 17 legend and detailed methods).Mix culture experiments as described in the legend of FIGS. 17C and Dwill also be performed. These chemotherapy drugs were chosen becausethey are commonly used to treat cancer (with the exception of menadione)but also because they represent different categories of toxicity: DNAalkylation (CP), topoisomerase II inhibition (ETO), thymidylatesynthetase inhibition (5FU), and oxidation-dependent single and doublestrand DNA breaks (menadione). RAS2^(val19) or SCH9 overexpression modelthe very common oncogene mutations that cause the activation of Akt orRas in cancer cells (see FIG. 17 legend and detailed methods).

b) Determine the role of the major stress resistance transcriptionfactors Msn2/Msn4, Gis1 and forkhead transcription factors Fhl1, Fkh1,Fkh2, and Hcm1 on the protection of sch9/aktΔ and ras2Δ mutants againstDNA alkylation, topoisomerase II inhibition, thymidylate synthetaseinhibition, and oxidation-dependent single and double strand DNA breaks.These transcription factors have been identified as major mediators ofresistance to multiple stresses in yeast, C. elegans, and mammaliancells. These studies will help identify the mediators of resistance tochemotherapy downstream of Sch9/akt and Ras and may point to humantranscription factors that play similar roles.

c) Study the mechanisms of RAS2- and SCH9/AKT-dependent sensitization ofcells against DNA damage in yeast cells treated with cyclophosphamide,etoposide, 5 FU, and menadione. Examine point mutations, smallinsertions/deletions, and gross chromosomal rearrangements using systemsdescribed below. Determine the role of Rev1 and Rad52 in the DNA damagecaused by the various chemotherapy agents by studying reu1Δ, rad52Δ,ras2Δ, sch9/aktΔ and sch9/aktΔrev1Δ, ras2Δrad52Δ, sch9Δ rad52Δ,ras2Δreu1Δ. Resistance to the chemotherapy agents in sch9/aktΔ and ras2Amutants overexpressing REV1 or RAD52 will also be studied. Theseexperiments will test the role of error-prone polymerases and homologousrecombination in the toxicity caused by chemotherapy drugs.

One object is to confirm that the combination of starvation and the lackof both SCH9/AKT and RAS2 causes an up to 10,000-fold increase in theresistance to menadione and hydrogen peroxide but also caused a majorincrease in the resistance to alkylating agents cyclophosphamide andMMS. It is expected that resistance to these toxins will be reversed bythe overexpression of SCH9/AKT or by the constitutive activation of RAS2(RAS2^(val19)). However, the effect of either STS or ras2-sch9/aktmutations alone on DSR will be investigated further. In previous studiesit was also determined that 5FU and etoposide are toxic to yeast, asshow by others. It is believed that the DSR will also work with thesechemotherapy drugs.

Based on previous studies it is expected that stress resistance zincfinger transcription factors Msn2/Msn4 and Gis1 and to a lesser extendforkhead transcription factors (TF) Fhl1, Fkh1, Fkh2, and Hcm1 willmodulate protection against chemotherapy-dependent DNA damage. Althoughit has been shown that Msn2/Msn4 and Gis1 are effective against avariety of stresses, it cannot be excluded that different TF may provideprotection against different chemotherapy drugs.

It is also believed that the error-prone polymerase Rev1 plays a majorrole in the DNA damage caused by alkylating agents, oxidants andtopoisomerase II inhibitors as it did in the generation of spontaneousmutations which appear to be caused by a variety of insults includingoxidative damage. It will be very important to determine how each drugaffects DNA damage ranging from point mutations to gross chromosomalrearrangements (GCRs) both after acute and chronic treatments.

Another object is to investigate the role of error-prone polymerasessuch as Rev1 in the generation of chemotherapy-induced DNA damage inmammalian cells.

Starvation, IGF-I, Oncogenes and Differential Resistance to ChemotherapyDrugs in Primary Mammalian Cells and Cancer Cell Lines

The results indicate that reduction in the level of glucose or serumprotects primary glial cells more effectively than rodent or humanneuroblastoma and glioma cancer cells against high dosecyclophosphamide. It was also showed that the presence of IGF-Isensitized primary glia but not cancer cell lines againstcyclophosphamide. These results are consistent with the belief firsttested in S. cerevisiae, that Ras and Akt, which function downstream ofIGF-I in mammals, regulate stress resistance and that starvation orIGF-I receptor inhibition would differentially protect normal and cancercells against chemotherapy. Activation of the Ras or Akt pathway andpossibly of other pro-growth pathways by oncogenic mutations is expectedto force the cells into a pro-growth and low stress resistance mode. Oneobject is to perform experiments analogous to those for S. cerevisiae:the cyclophosphamide toxicity studies will be continued and extended todifferent toxic agents to begin to establish whether the STS/lowIGF-1-dependent DSR has the potential to be applied to a wide range ofchemotherapy treatments. Another object is to study the mechanismresponsible for the effect of oncogenes and proto-oncogenes onresistance to chemotherapy. The putative role of Ras and Akt insensitizing the cells to chemotherapy but also protecting againstapoptosis, at least under certain conditions will also be addressed.Finally, the mechanisms of protection with focus on Erk, p38, and FOXO3,which have been implicated as either positive or negative regulators ofstress resistance will be studied.

The following studies will be performed:

a) Investigate the role of low serum (1%) or low glucose (0.5 g/L) onthe resistance of primary glia and 7 lines of glioma and neuroblastomacells to different classes of chemotherapy drugs. Primary rat glialcells, rat glioma cell lines (C6, A10-85, RG2 and 9L), human glioma(LN229), mouse NXS2 neuroblastoma and human neuroblastoma (SH-SY5Y) celllines against cyclophosphamide, etoposide, 5 FU, and menadione will betested (see FIG. 2 legend and detailed methods). The focus on ratgliomas will enable one to determine the DSR between rat glia-derivedcancer cells and primary rat glial cells. In previous studies it wasshowed that the reduction of either serum from 10% to 1% or of glucosefrom 1 g/L to 0.5 g/L protected primary glia but not cancer cell linesagainst cyclophosphamide (FIG. 2). One object is to continue the studiesof the role of low serum or low glucose on the resistance tocyclophosphamide but also extend the studies to the different classes ofchemotherapy drugs listed above (see studies described above anddetailed methods). Both cell death (MTT, LDH assays) and apoptosis(Annexin V, TUNEL) will be measured.

b) Investigate the role of IGF-I in the resistance of primary glia andthe 7 lines of glioma and neuroblastoma to cyclophosphamide, etoposide,5 FU, and menadione. The effect of IGF-I and of IGF-I inhibitoryproteins including IGFBP-3 and IGF-I antibodies on stress resistance ofnormal and cancer cells will be studied (see FIGS. 2C and D and detailedmethods).

c) Investigate the effect of different concentrations of IGF-I, serum,and glucose on the activity of the Ras and Akt pathways in primary glialcells and cancer cell lines (FIG. 11B). The DSR method is based on thebelief that normal but not cancer cells will up-regulate stressresistance systems normally inhibited by the Ras and Akt pathways inresponse to starvation or a reduction in growth factors such as IGF-I.Because Ras and Akt are among the signal transduction proteins mostcommonly found in a constitutively active or up-regulated state incancers, whether either the Ras or Akt pathway or both remain activeafter the switch to low serum, low IGF-I, and low glucose as suggestedin the studies described above (FIG. 11B) will be determined. The 7different cancer lines listed above as well as primary rat glia will betested (see studies described above and detailed methods). For primaryglia the time course for the inactivation of the Ras and Akt pathwaysafter the switch to low serum, IGF-I, or glucose will also bedetermined.

d) Investigate the role of Ras and Akt in the regulation of resistanceagainst cyclophosphamide, etoposide, 5 FU, and menadione in primary gliaand determine whether cells are protected against necrosis or apoptosis(see detailed method). The yeast studies indicate that Sch9/Akt andpossibly Ras regulate oxidative stress-dependent DNA damage bycontrolling a pathway that includes serine/threonine kinases, and stressresistance transcription factors. One object is to test the role ofinhibition of Ras and Akt signaling in the protection against thechemotherapy drugs listed above in both primary glia and glioma cellslines. Whether the cell death is apoptotic or necrotic (see detailedmethod) will be determined. Another object is to study the role of Erk,p38, and FOXO transcription factors in the regulation of stressresistance downstream of Akt and Ras. These kinases and transcriptionfactors have been implicated in the regulation of stress resistance. Thephosphorylation status of Erk, p38, Akt, and FOXO3 in primary cellstreated with IGF-I (see detailed method) will be determined. Stillanother object is to test the effect of the inhibition of Erk, p38,PI3K/AKT activity and overexpression of FOXO3 transcription factors onthe resistance to chemotherapy drugs in primary rat glial cells treatedwith IGF-IR antibodies. Inhibitory drugs and/or siRNA will be used toreduce the activity of the above enzymes/transcription factors inprimary glia treated with IGF-I.

In the results described above (FIG. 2) starvation and/or reduction ofIGF-I was effective in protecting normal cells but not cancer cellsagainst the alkylating agents cyclophosphamide. Based on the results itis believed that the reduction in IGF-I signaling or starvation willalso protect against menadione and etoposide treatment (FIGS. 7 and 8B).As suggested by the studies described above (FIG. 11B) it is expectedthat Ras or Akt and downstream effectors will be constitutively activein the cancer cell lines but not in the primary glia. Thus, the removalor reduction of IGF-I, serum, or glucose should attenuate the activityof these pathways in glia but not glioma or neuroblastoma cells. The“apoptosis” experiments should enable one to discern the pro-damage andanti-apoptotic role of Ras and Akt. One possibility suggested by theexperiments described above is that the inhibition of Ras increasesapoptosis in the first 24 hours after treatment with oxidants, buteventually decreases necrosis. Based on the results described above, itis believed that Erk and to a lesser extent P38 mediate thesensitization to stress. This result is consistent with the opposingeffects of Erk and p38 in the regulation of apoptosis.

Another object is to understand how stress resistance affects otherprimary cells as well as cell lines representing additional types ofcancers including major ones such as breast and colon carcinomas. Yetanother object is to examine the role of additional signal transductionproteins and transcription factors in the resistance to chemotherapydrugs. For example, it would be useful to investigate additionaltranscription factors implicated in stress resistance such as FOXO1.

Starvation and Differential Resistance to Chemotherapy Drugs in Mice

The results in mice suggest that STS can be effective in the protectionagainst a dose of etoposide (topoisomerase II inhibitor) that killsapproximately 50% of the non-starved mice. It was also showed that STSalone only partially protects injected NXS2 neuroblastoma cells. Thisprotection was abolished by pre-treatment with the somatostatin analogoctreotide. One object is to test whether the combination of octreotideand STS is effective in the protection of mice against differentchemotherapy drugs (etoposide, 5 FU, and cyclophosphamide, andmenadione). Another object is to test the effect of STS/octreotideagainst several cancer cell lines using xenograft models (etoposideonly). In previous results only a single round of chemotherapy wasadministered, which was not sufficient to cure the mice from NXS2cancer. Because pre-starved mice did not show any visible sign oftoxicity, one object is to focus on multiple rounds ofSTS/octreotide/chemotherapy to attempt to kill all the injected cancercells or at least obtain a much greater delay of the cancer-dependentdeath in animals injected with cancer cells.

The following studies will be performed: In previous studies it wasshowed that STS protected against high dose etoposide. One object is totest whether STS is effective in the protection of mice against variouschemotherapy drugs. The role of STS on the protection of 4 differentmouse genetic backgrounds to high dose etoposide, 5 FU, andcyclophosphamide, and menadione will be studied. Different mouse strainswill be studied to allow xenografts with different types of cancer celllines and also to confirm that the STS strategy is effective in avariety of specific genetic backgrounds. The chemotherapy drugs abovewere chosen based on previous results and because they are among themost commonly used in the treatment of human cancers. The breast andovarian carcinomas models were added to test the effect of STS on morecommon carcinomas.

a) Test the effect of STS in combination with octreotide pre-treatmenton the resistance of C57BL6 mice against cyclophosphamide, etoposide, 5FU, and menadione.

b) Perform multiple injections of etoposide in combination with STS andoctreotide treatment in A/J mice pre-injected with NXS2 or Neuro2aneuroblastoma cells.

c) Perform multiple injections of etoposide in combination with STS andoctreotide treatment in athymic Nude (nu/nu) mice pre-injected withHT1A-230 or SH-5Y-SY human neuroblastoma cells.

d) Perform multiple injections of etoposide in combination with STS andoctreotide treatment in SCID mice pre-injected with MDA-MB1-231 humanbreast carcinoma.

e) Perform multiple injections of etoposide in combination with STS andoctreotide treatment in athymic Nude (nu/nu) mice pre-injected withOVCAR-3 human ovarian carcinoma.

f) To begin to understand the role of the GH/IGF-I axis in the DSReffect of STS, the effect of starvation on the level of growth hormone,IGF-1, IGFBP1, and IGFBP3 after the 48-hour starvation will be tested(see previous studies described above and detailed methods).

The systems listed above are among the major model systems for thetreatment of neuroblastoma. The ovarian carcinoma and breast carcinomasmodel systems were added to begin to understand whether theSTS/octreotide system is also effective in protecting normal but notother cancer cell types against high dose chemotherapy.

Based on previous results it is believed that STS will be consistentlyeffective against high dose etoposide and to a lesser extent againstcyclophosphamide. Octreotide is not expected to protect againstetoposide but may increase protection against other drugs and especiallymenadione. Because of the very low toxicity of etoposide in combinationwith STS and octreotide, the multiple injection experiments are likelyto be more effective against the injected NXS2, Neuro2A, HTLA-230,SH-5Y-SY, MDA-MB1-231, and OVCAR-3 cells compared to single injections.Based on previous results, octreotide should increase the toxicity toNXS2 cells and may increase the toxicity of etoposide against the cancercell lines listed above. In fact, it was showed that it had no directprotective effect on NXS2 cells (FIG. 8B) suggesting that it does notact through the activation of a specific receptor which may be specificto NXS2 cells. Naturally, octreotide may or may not reverse the smallprotective effect of STS on the other cancer lines as observed with NXS2cells. One problem was the damage to the tail of the mice caused by theinjections of cancer cell, chemotherapy drugs, and octreotide. To beginto address this problem mini-pumps for the slow delivery of octreotide(see detailed methods) has been already successfully used. Since 8injections of octreotide and one of cancer cells plus one forchemotherapy are performed in each cycle, the minipump will reduceinjections by 80%, which should allow many cycles ofSTS/octreotide/etoposide treatment.

Another object is to perform the multiple-injections experiment abovewith cyclophosphamide, menadione and 5-FU but eventually also with otherwidely used chemotherapy drugs such as doxorubicin. To begin tounderstand whether the STS method can be useful for human treatmentsimilar experiments with rats or other model systems will also beperformed.

Genetic and Pharmacologic Manipulations of the GH/IGF Axis in Mice andTheir Effects on Differential Resistance to Chemotherapy

A) One object is to utilize mouse models that have altered GH/IGF axis(including systemic IGF-deficient LID mice, local prostaticIGF-deficient PID mice, and the IGFBP-3 and IGFBP-1 KO mice) to decipherthe effects of local versus systemic IGF-1 and of IGFBPs on the host andcancer cells sensitivity to chemotherapy.

B) Another object is to determine the therapeutic index of chemotherapydrugs in these mice models that have been mated into a cancer (myc orTRAMP) background.

C) The third object is to investigate the role of IGFBP-3 and/orinhibitory antibodies against IGF-I either alone or in combination withSTS on the resistance of mice and of injected NXS2 neuroblastoma cellsto chemotherapy.

It is believed that 1) modulation of systemic (but not local), total orbio-available, IGF-I determines the differential toxicity of variouschemotherapeutic agents to mice and cancer cells; 2) higher doses ofvarious chemotherapeutic agents will be tolerated and will prove moreeffective in mice models of cancer with reduced total or bio-availablesystemic IGF-I.

In previous studies it was demonstrated that manipulations that decreasethe IGF-I signaling in a number of in vitro and in vivo models lead toincreased stress resistance in the host (or non-malignant) cells, butdid not affect and in some cases increased sensitivity to chemotherapyin the cancer or cancer-like cells. As discussed above, the circulatingIGF system is complex and IGF-signaling is controlled by both(endocrine, liver-derived) IGF-I and by locally produced(autocrine/paracrine) IGFs. Furthermore, IGF activity is regulated by anumber of IGFBPs, some of which (such as IGFBP-1) are themselvesup-regulated by factors such as starvation (inversely to IGF-I which isreduced by starvation and caloric restriction), while others, such asIGFBP-3 are regulated primarily by growth hormone and are down regulatedby somatostatin (in the same manner as IGF-I). A series of geneticallyaltered mice with a variety of specific modulations in the GH/IGF systemhave therefore been derived and/or acquired. These mice include: a)GHRKO mice with reduced growth hormone activity that harbor a GHreceptor deletion. These mice are small in size, have low systemic IGF-Iand low IGFBP-3 levels, and high IGFBP-1 levels. These mice havepreviously been shown to have delayed tumor development when mated intothe prostate cancer TRAMP model. b) LID (liver IGF-deficient) mice witha targeted deletion of the IGF-I gene in liver obtained. These mice arenearly normal in size, have very low systemic IGF-I levels, low IGFBP-3,and low IGFBP-1. As shown in previous studies, these mice displayreduced susceptibility to chemotherapy but do not have a reduced growthof prostate tumors when mated into the TRAMP model. c) PID (prostateIGF-deficient) mice with a prostate epithelial-specific deletion ofIGF-I, recently created by mating the prostate-specific probasin-cretransgenic mice with the Igf1-floxed mice. These mice are normal in sizeand have normal systemic IGF-I, IGFBP-3 and IGFBP-1. Their prostateIGF-I levels are currently being characterized. d) IGFBP3KO mice, whichhave been recently developed. These mice are 20% larger than controls,have undetectable IGFBP-3 levels, slightly reduced IGF-I, and normalIGFBP-1 levels in serum. e) IGFBP1KO mice. These mice are normal insize, have no IGFBP-1 and normal IGF-I and IGFBP-3. f) TRAMP mice, whodevelop early and aggressive prostate cancer as a result of prostatespecific expression of the SV40 T-antigen. It was recently showed thatthese mice respond to low fat diets by reducing tumor progression andhave elevated IGF-I levels. g) Myc mice, who develop slower growing andless aggressive prostate cancer as a result of prostate-specific overexpression of myc. It has been recently observed that these mice havehigher levels of IGF-I and also have a more aggressive tumor if fed ahigh fat diet. h) Myc mice have now been mated into the IGFBP-1 andIGFBP-3 knockout strains to create mice with cancer that lack each ofthe specific IGFBPs. It is believed that the IGFBP deletion willaccelerate the progression of the cancer and therefore chose a slowdeveloping tumor. The TRAMP model has been mated into the LID and PIDmodels with the expectation of delaying the progression of the tumors.

To determine the role systemic versus local IGF-I plays in vivo inchemotherapy resistance, LID mice will be compared to L/L− control miceas shown in previous studies. The PID mice will also be used as anadditional control. To determine the role of total versus bio-availableIGF-I IGFBP3KO and IGFBP1KO mice will be compared to control mice andtreated with chemotherapy inducing stress. To determine the role ofIGFBPs as mediators of the DSR effects of starvation and GH-blockadeIGFBP3KO and IGFBP1KO mice will be compared to control mice and treatedwith the 4 chemotherapy drugs as described above.

In each set of experiments there will be four groups of 20 mice pergroup mice: Group 1: WT mice treated with saline injections Group 2: WTmice treated with chemotherapy injections Group 3: Transgenic micetreated with saline injections Group 4: Transgenic mice treated withchemotherapy injections

As described above, one object is to use 4 groups of mice that will betreated with chemotherapy injections and to look at survival, serumIGF-related parameters and other markers of systemic stress and assessif any of the strains listed above are more or less resistant tochemotherapy. See above methods for details of treatments, which will besimilar to those in the immunodeficient mice.

To determine the role combinations and chemotherapy and IGF reduction orblockade in enhancing tumor suppression while improving survival thetreatments described above will be repeated on the genetic modelsdescribed herein. Prostate cancer is the most commonly diagnosed cancerin American men and a major health problem. While localized disease hasan excellent chance for cure, metastatic disease leads toandrogen-independent progression and death within a few years.Chemotherapy has been used clinically in prostate cancer with limitedsuccess (partially due to dose-limiting toxicity). Docetaxel is approvedin the US for hormone-refractory prostate cancer and represents animportant therapeutic milestone and is the current standard of care forthis disease. Cyclophosphamide as well as Etoposide have also beenexplored in human clinical trials, and while they are not universallyrecognized as beneficial in daily patient care, they do have effects athigh doses. Several prostate cancer bearing mice will be used as modelsfor testing the concept of differential stress resistance in response tochemotherapy. Docetaxel, etoposide, and cyclophoshamide will be tested.

There will be multiple sets of experiments conducted:

In each set of experiments there will be four groups of 20 mice pergroup mice: Group 1: Cancer Bearing WT mice treated with salineinjections Group 2: Cancer Bearing WT mice treated with chemotherapyinjections Group 3: Cancer Bearing Transgenic mice treated with salineinjections Group 4: Cancer Bearing Transgenic mice treated withchemotherapy injections

In each of the models of prostate cancer bearing transgenic mice theresponse to chemotherapy (docetaxel, etoposide, and cyclophoshamide)will be compared with the assumption that the combination of geneticablation of one of the components of the IGF system together withchemotherapy will enhance cancer treatment by protecting the host butnot cancer cells. Treatments will be given for 4 weeks at age 12 weeksfor TRAMP and 20 weeks for Myc.

Two primary outcome measures are: (1) prostate weight at sacrifice and(2) pathological grade of tumor. Secondary outcome measures willinclude: (a) TUNEL staining in prostate, (b) Ki67 staining, (c) serumIGF-I and IGFBP-3, (d) quantification of metastasis.

To investigate the role of inhibitory antibodies against IGF-I and/orIGFBP-3 either alone or in combination with STS on the resistance ofmice and of injected Nxs2 neuroblastoma cells to etoposide, menadione, 5FU, and cyclophoshamide (see detailed methods and FIG. 8). Theseexperiments are aimed at testing proteins/drugs with the potential toincrease protection against high dose chemotherapy. This is to establishwhether IGF-I and IGFBP3 are potential STS mimics. Studies with IGF-Iinhibitory antibodies and IGFBP3 have been carried out.

These experiments will be performed essentially as described above(FIGS. 7 and 8, and detailed methods). The IGF-I or IGFBP3 willessentially replace the octreotide/STS treatment.

As shown in previous data it is believed that LID mice and also theGHRKO mice will exhibit increased stress resistance. In addition, it isbelieved that both the IGFBP-1 and IGFBP-3 knock out mice will havereduced stress resistance. Furthermore, it is believed that IGFBP1KOmice will not show as much benefit from starvation, as the increase inIGFBP-1 expected is part of the IGF-limiting effects of the treatment.It is believed that PID mice will not have differential stressresistance, but they will have an increase in the response to chemo interms of tumor suppression. An increase in tumor sensitivity tochemotherapy is expected in the LID-TRAMP mice. In the BPKO-Myc modelsit larger tumors and a poor response to chemo is expected. In general,the treatment with IGF-I antibodies or IGFBP-3 should be consistent withthe results obtained with LID and GHRKO mice. Together the object is toestablish the complex interface between the GH-IGF system and theresistance of normal and cancer cells to chemotherapy using a series ofgenetic cancer models with specific IGF-related deletions.

Detailed Methods

Yeast strains and growth conditions: Experiments are carried out in wildtype (DBY746 MATa, leu2-3, 112, his3D1, trp1-289, ura3-52, GAL⁺), andisogenic strains lacking either Sch9 or both Sch9 and Ras2. Wild type(DBY746) and sch9A strains expressing hyperactive RAS2^(val19) wereconstructed by transformation with a centromeric plasmid containingRAS2^(val19) (pRS406-RAS2^(val19), CEN URA3), and over-expressing REV1or RAD52 were constructed by transforming with multicopy 2μ plasmidcarrying REV1 or RAD52 obtained from Open Biosystems. Yeast strainslacking stress response transcription factors (Msn2, Msn4, or Gis1),forkhead transcription factors (Fhl1, Fkh1, Fkh2, or Hcm1), REV1, andRAD52 were generated by one-step gene replacement. Yeast cultures aregrown in liquid synthetic dextrose complete medium (SDC) with 2%glucose, supplemented with amino acids, adenine, as well as a four-foldexcess of tryptophan, leucine, histidine, uracil. Strains harboring thecentromeric plasmid containing RAS2^(val19) were always grown in theabsence of uracil to maintain selection.

Yeast viability: Overnight cultures are diluted to OD₆₀₀ 0.1 into SDCmedium. After 24 hours (day 1), the appropriate strains will be mixed1:1 based on OD₆₀₀ and incubated for 2 hours. The mixed cultures will bethen treated with either etoposide (300 μM), menadione (200 μM), and5-FU (150 μM) in medium or water (STS). Etoposide, menadione and 5-FUwill be introduced directly into the mixed culture to a finalconcentration of 0.01%. For treatments in water (STS), mixed cultureswill be centrifuged for 5 minutes at 2,500 rpm and the media replacedwith either distilled/sterile water or drug-dissolved water. Viabilitywill be measured by quantifying colony-forming units (CFUs) every 24hours by plating onto appropriate selective media. Viability ofindividual strains will be measured using the same method as for themixed cultures.

DSR assays in yeast: Stress resistance against etoposide, 5-FU, andmenadione will be measured by spotting serial dilutions of control andtreated cells as previously described. Briefly, 24 hours after theinitial inoculation (OD=0.1) in SDC medium, cultures will be washed,resuspended and incubated in water for 48 hours with shaking. At day 3,cells will be treated with etoposide, 5-FU, or menadione for 60 min.Serial dilution (up to 1,000-fold) of the treated cultures were spottedonto YPD plates and incubated for 2-3 days at 30° C.

Mutation studies in yeast: Mutation studies in yeast will be performedas previously described. Point mutations, frame shifts and grosschromosomal rearrangements will be measured.

The Role of STS and IGF-1 lowering treatments in protection againstchemotherapy in vitro: Cells described in previous studies will be used.Glucose and serum restriction will be done as described before. IGF-Itreatment will be performed by incubating cells for 48 hours in DMEM/F12with 1% FBS and rhIGF-I (100 ng/ml, ProSpec-Tany TechnoGene, Rehovot,Israel), which is shown to be within the IGF-I level range for middleage humans. To antagonize IGF-1 receptor activity, cells will beincubated with the neutralizing monoclonal anti-IGF-1R antibody (1μg/ml, Calbiochem) in DMEM/F12 1% FBS for 24 hours. To inhibit IGF-1activity, cells will be treated with IGFBP-3 (200 ng/ml, Abcam) inDMEM/F12, 1% FBS for 24 hours. Following STS/IGF-1 treatments, cellswill be incubated with varying concentrations of cyclophosphamide (6-15mg/ml) for 10 hours, etoposide and 5-fluorouracil (0-120 μM) for 48hours, and menadione (0-150 μM) for 24 hours in DMEM/F12 with 1% FBS.Cytotoxicity will be measured by the ability to reduce (MTT) asdescribed in previous studies. Apoptosis will be measured by Annexin Vbinding using the ApopNexin™ apoptosis kit (Upstate) and DNAfragmentation using the TUNEL apoptosis detection kit (Upstate)following manufacturer's instructions.

The effect of STS on IGF-1R signaling in vitro: Cells described inprevious studies will be STS pre-treated as described above and Ras andAkt activity will be measured. Cells will be lysed at various timepoints of STS treatments and lysates will be tested for Ras and Aktactivity using the Ras activity assay kit (Upstate) and the Akt westernblot assay kit (Calbiochem) following manufacturer's instructions.

The role of IGF-1R signaling in DSR in vitro: Prior to chemotherapeuticdrug treatments, cells will be pretreated to inhibit the activity ofproteins downstream of IGF-1R including RAS, Akt, ERK, p38 and FOXO3a.To inhibit K, H and N-Ras isoforms, cells will be treated with thefarnesyl transferase inhibitor FTI 277 (10 uM) and the geranyltransferase inhibitor GGTI-298 for 48 hours as previously described. Toinhibit Akt signaling, cells will be treated with Wortmannin (100 nM)and LY294002 (20 uM) for 1 hour. Erk will be inhibited using 10 μM ofERK inhibitors U0126 or SL327 and also PD98059 and p38 kinases bySB203580 for 2 hours. siRNA will be used to specifically down-regulatethe FOXO3a transcription factor. In order to determine thephosphorylation status of p38 and FOXO3a, cells will be lysed followingtreatment with IGF-I as described. The lysates will be subjected to aWestern blot analysis. Anti-phospho-p38 specific (Thr180/Tyr182)antibody and anti-p38 antibody will be used to detect p38phosphorylation and total p38 respectively (Cell signaling). Antiphospho FOXSO3a (Thr 32) and anti FOXO3a (Ser 253) will be used todetect FOXO phosphorylation. Anti-FOXO3a will be used to detect totalFOXO3a (Abcam). Anti-phospho-Akt (Ser 253), anti-phospho-Akt (Thr 308)and anti-Akt will be used to detect phosphorylated and total Akt. FOXO3aover expression will be done using the pcDNA3 plasmid containing a 2,000bp FOXO3a insert (Invitrogen). 0.2 ug of the plasmid will be used totransfect 80,000 cells using Fugene (Roche) according to manufacturer'sprotocol. siRNA will be used to specifically silence the FOXO3atranscription factor. Briefly, 80,000 cells will be transfected with 0.2ug of the pSilencer (Ambion) plasmid that express siRNA oligos targetingFOXO3a using Fugene. All drugs will be from Sigma.

Chemotherapy-induced toxicity measurements in mice: For all theexperiments, the animals will be housed in sterile enclosures underspecific virus and antigen-free conditions. Procedures will be reviewedand approved by the Institutional Animal Care and Use Committee (IACUC)of University of Southern California and UCLA, and by the licensing orby the ethics committee of the National Research Center, and by theItalian Ministry of Health. Major toxic side effects of chemotherapysuch as myelosuppression, gastrointestinal damage, DNA damage, celldeath and weight loss will be examined as an indicator oftoxicity/morbidity. Also mice will be monitored twice and weighed oncedaily for any signs of stress or pain and will be euthanized usinginhalant isoflurane (1-4%) followed by cervical dislocation if found so.At 60 hours after chemodrug administration, mice will receive a singlei.p. injection of BrdU (1 mg in 300 μl of PBS). At 72 hourspost-chemotherapy, mice will be deeply anesthetized by a singleintraperitoneal injection of 50 mg/kg Nembutal. Following anesthesia, awhole-body perfusion will be performed and blood will be collected viacardiac puncture through the left ventricle and stored in tubes withK3-EDTA for further analysis. Cervical dislocation will be performed toensure euthanasia and organs will be collected and fixed immediately.

Myelosuppression will be measured by a complete blood cell count with 24parameters using the HEMAVET® 950 FS hematology analyzer. 24 and 48hours after chemodrug injection, 20 μl of blood from the tail vein willbe collected and also from the heart at the time of sacrifice and storedin K3-EDTA containing tubes and immediately analyzed. Histologicalexamination of bone marrow from pelvic bones and spleen (a site ofextra-medullary hematopoiesis in mice) will also be examined forcellularity and content. Gastrointestinal and organ damage will beassessed by looking for areas of ulceration by macroscopic examinationand by histological evaluation of the integrity of the mucosa, areas ofinflammation, and by measuring the villus to glandular height ratio inthe small intestine. Also in pilot experiments, liver, kidney, lung,spleen and heart will be examined for confirmation of organ toxicity byH&E staining focusing on maintenance of architecture, areas of fibrosis.Also organ weight will be recorded. Only one organ most damaged will beselected for each individual drug, and will be examined along with thesmall intestine in full scale experiments. Organs will be collectedafter whole-body perfusion with buffered formalin under deep anesthesiawith Nembutal.Collected organs will be fixed with 10% formalin for 48hours and stored in 70% ethanol to be sent to the Norris Cancer Centerhistology core facility for histological preparations. Specimens will beparaffin embedded and sectioned to 4 μm thickness. DNA damage will bemeasured by BrdU incorporation as previously described with somemodifications. Briefly, 12 hours prior to sacrifice, mice will be i.p.injected with 1 mg BrdU dissolved in 300 μl PBS. 6 mice from each groupwill be randomly selected and BrdU incorporation will be measured fromliver and small intestine tissue samples with antibodies against BrdUfollowing manufacturer's instructions (Abeam). Histological sections ofthe small intestine and liver will be performed as described above bythe Norris Cancer Center histology core facility. Cell death will bedetermined by measuring blood LDH levels using QuantiChrom™ LactateDehydrogenase kit (BioAssay Systems, CA). Procedures will followmanufacturer's protocol.

Short-term starvation-based chemotherapy resistance in mice: Mice from 4different genetic backgrounds will be tested with 4 differentchemodrugs. Mice will be starved (48 hr) as described in previousstudies before prior to chemodrug administration. C57BL/6, A/J, athymicNude, and SCID mice will be tested with cyclophosphamide, etoposide,5-fluorouracil, and menadione. Pilot experiments will first be conductedto determine the optimum dosage of each drug in each mouse strain. 3doses will be tested with 6 mice per dose. Once the optimum dosage isknown, the procedures will follow as described in preliminary studieswith 25 mice per group. The number of mice were determined from previousexperience and statistical calculations expecting, with 95% confidence(α=0.05, β=0.2), a 20% difference between the control and experimentalgroups aided by Statsoft and SigmaStat.

The role of the GH/IGF-1 axis in protection against chemotherapy inmice: Antibodies against the IGF-1 receptor and IGFBP-3 will beemployed. This will be tested in at least two mouse strains with 4 drugsmentioned above. Based on previous experience, a single injection ofantibodies will be given i.p. 2 days prior to chemodrug administrationat 300 μg/kg. As for IGFBP-3, daily i.p. injections with 4 mg/kg/daywill be given for 4 days prior to chemotherapy drug administration. 25mice will be employed per group as calculated above. The groups will betested with one chemotherapy drug at a time and the pre-treatments willbe as follows: Group 1: Control; Group 2: STS; Group 3: IGF-IR antibody;Group 4: IGFBP-3; Group 5: IGF-IR antibody+IGFBP-3; Group 6: STS+IGF-IRantibody+IGFBP-3.

Liver IGF-1 deletion (LID) mice: Due to the limited number of LID mice,2 drugs will be first tested: 5-fluorouracil and menadione. 1)cyclophosphamide: 18 LL⁻ and 19 LID mice will be given 300 mg/kg CP by asingle i.v. injection. 2) Menadione: 11 LL⁻ and 10 LID mice will begiven 100 mg/kg menadione by a single i.v. injection.

TRAMP and Myc and PID (prostate cancer models): 3 drugs will first betested: docetaxal (10 mg/kd per day, single i.p. injection); EtoposideTeva (Teva Pharma B.V., Mijdrecht, Holland) will be injected 80-100mg/kg; cyclophopshamide (Sigma) will be injected at 300 mg/kg. See belowand FIG. 7G for experimental details.

Growth hormone receptor knock-out (GHRKO) mice: 4 heterozygous GHRKObreeding pairs will be received, as homozygous do not breed well. Theaverage litter size is about 6 pups and the average offspring that is ahomozygous GHRKO is 12%. Etoposide, cyclophosphamide, 5-fluorouracil andmenadione will be tested, and in order to obtain statisticallysignificant results at least 20 mice per group is required as calculatedabove. Therefore, 8 groups including corresponding control groups (wildtype GHR) are required, which translates into 80 GHRKO and 80 controlmice. The wild type control group is in the inbred C57BL/6 background.The mating scheme will be as follows. By mating only heterozygotes, itis estimated to take 72 weeks to obtain the desired number of mice. Micewill be genotyped at the age of 6 weeks with DNA obtained by tailbiopsies following Jackson Laboratory protocols. Since GHRKO mice are inthe C57BL/6 background, optimum drug dosages would be derived fromprevious experiments mentioned above.

Starvation-based differential chemotherapy resistance in mice: Thefollowing cancer models will be performed: Murine experimentalmetastatic neuroblastoma model in syngeneic A/J mice: The murine NX3IT28cell line was generated by hybridization of the GD2-negative C1300murine neuroblastoma cell line (A/J background) with murine dorsal rootganglional cells from C57BL/6J mice, as previously described. The NXS2subline was then created by the selection of NX3IT28 cells with high GD2expression. Six-to-seven-week-old female A/J mice, weighing 15-18 g(Harlan Italy, S. Pietro al Natisone, Italy) will be intravenouslyinoculated with 200,000 NXS2 cells. Intravenous injection of NXS2results in experimental metastases to distant organ sites, includingliver, kidneys, ovaries, adrenal gland and bone marrow, as previouslydescribed (Lode N H et al, JNCI 1997). Murine thoracic neuroblastomamodel in syngeneic A/J mice: Six-to-seven-week-old female A/J mice(Harlan Laboratories), weighing 15-18 g, will be injected in themediastinum, through the skin of the precardial area, with 1×10⁶ Neuro2acells, which have the same genetic background than NXS2. Precisely, theneedle will penetrate 3 mm and the syringe made an angle of about 120°with respect to the mediastinum. The pericardial area is located betweenthe second and the third rib. Fifteen days after tumor inoculum,numerous subpleural metastases can be detected in the lung and in thedraining lymphonodes, as previously described. Human experimentalpseudometastatic neuroblastoma model in Nude mice: Six-to-seven-week-oldfemale athymic Nude mice (nu/nu Harlan Laboratories), weighing 18-24 gwill be intravenously injected with 3×10⁶ human neuroblastoma HTLA-230cell line. This experimental model is characterized by the presence ofmacrometastases in different organs such as liver, kidneys, ovaries andadrenal glands, and micrometastases in the bone marrow, as previouslydescribed. Human orthotopic neuroblastoma model in SCID mice:Six-to-seven-week-old female SCID mice (Harlan Laboratories) will beanesthetized with ketamine (Imalgene 1000, Merial Italia s.p.a, Milan,Italy), subjected to laparotomy and injected with 1.5×10⁶ HTLA-230, inthe capsule of the left adrenal gland, as previously described. Humanmetastatic breast carcinoma model in SCID mice: Five-to-six-week-oldfemale SCID mice will be anesthetized with ketamine, and injected with1×10⁶ MDA-MB-321 human breast carcinoma cells in the mammary fad pad.The implantation of this tumor cell line induces the development of lungand lymph nodes metastases. Human intraperitoneal ovarian carcinomamodel in Nude mice: Five-to-six-week-old female athimic Nude mice willbe intraperitoneally injected with 1×10⁶ OVCAR-3 human carcinoma cellline as previously described. In all the models above described, thetherapeutic effect of different chemotherapeutic agents includingetoposide, cyclophosphamide, 5-fluorouracil (5-FU), and menadione willbe tested. All injections will be performed intravenously. Specifically,etoposide Teva (Teva Pharma B.V., Mijdrecht, Holland) will be injected80-100 mg/kg; cyclophopshamide (Sigma) will be injected at 300 mg/kg;5-FU will be injected at 150 mg/kg; Menadione will be injected at 50-100mg/kg. These agents, administered as a single dose or as multiple doses,will be used in combination with short term starvation (STS) andoctreotide (OCT). According to the protocol used for previousexperiments, the animals will be inoculated with tumor cells, starvedfor 48 hours and then intravenously treated with the chemotherapeuticagents. Additional daily doses of OCT will be administered for 4 daysafter chemotherapy. In some experiments, the cycle ofSTS-chemotherapy-OCT will be repeated after 1 week. Control groups ofmice without diet starvation and OCT treatment will be alsoinvestigated. For each cancer model, we will perform an experiment thatincludes 8 groups of animals (10 mice/group), as follows: 1) Controlgroup: 10 mice inoculated with tumor cells on day 1. 2) OCT: 10 miceinoculated with tumor cells on day 1 followed by OCT (1 mg/Kg: dailydose) administration for 4 days from day 4 to day 7. 3) STS: 10 miceinoculated with tumor cells followed by 48 hours-STS from days 1 to day3. 4) STS/OCT: 10 mice inoculated with tumor cells followed by 48hours-STS+OCT administration for 4 days. 5) Chemotherapy: 10 miceinoculated with tumor cells, followed by chemotherapy treatment on day3. 6) Chemotherapy/OCT: 10 mice inoculated with tumor cells followed bychemotherapy treatment/OCT administration for 4 days. 7)STS/Chemotherapy: 10 mice inoculated with tumor cells followed bySTS/chemotherapy treatment. 8) STS/Chemotherapy/OCT: 10 mice inoculatedwith tumor cells followed by STS/chemotherapy treatment/OCTadministration for 4 days. In additional experiments, the chemotherapyand OCT injections will be repeated every 2 weeks.

Octreotide delivery using osmotic pumps: Mini-osmotic pumps (Alzet,Model 2004) will be implanted subcutaneously to instill octreotide overa 3 month period. Octreotide will be delivered at 0.25 microl/hr at aconcentration of 50 microg/kg/hour. Each mini-pump will deliver for 4weeks and therefore will be replaced every 4 weeks. Procedures will beperformed as described by the manufacturer.

In vivo bioluminescence labeling of cancer cells: In order to studydifferential resistance to chemotherapy in vivo, A/J mice will beintravenously injected with 2×10⁵ mouse neuroblastoma NXS2 cell linestably expressing the firefly luciferase gene. Plasmids expressing thefirefly luciferase gene were obtained as a SalI/BglII fragment formpGL3-control vector (Promega), and cloned into the XhoI/BamHI sites ofthe retroviral pLXIN bicistronic vector. Monitoring the growth and deathof cancer cells in the animal will be possible by detectingbioluminescence. This is a non-invasive method to monitor the growth anddeath of cancer cells at multiple stages of the experiment. 25 mice willbe employed in each group and 5 mice will be randomly selected forbioluminescence imaging. Toxicity will also be measured as previouslydescribed. Bioluminescence will be monitored as previously described.Briefly, mice will be given a single i.p. injection of ketamine (50mg/kg) and xylazine (10 mg/kg) followed by an i.v. injection ofluciferin (50 mg/kg). 4.5 minutes later, when the luciferin is welldistributed, mice will be examined with an IVIS 200 optical imagingsystem (Xenogen Corp.). Signal intensity will be quantified as photoncount rate per unit body area per unit solid angle subtended by thedetector (units of photon/s/cm²/steridian). 3-dimentional images ofbioluminescence will be generated by the single-view diffuse tomographycapability of the IVIS 200 and LIVING IMAGE 3D v 2.50. Once injectedcancer cells have metastasized, mice will be starved for 48 hours incombination with IGF-1R antibodies or IGFBP-3 as described above priorto chemotherapy. Each drug (cyclophosphamide, etoposide, 5-fluorouraciland menadione) will be tested with 6 pretreatment schedules describedabove in the role of GH/IGF-1 axis in resistance to chemotherapyexperiment. Toxicity will be measured daily as described above for thefirst 3 days after chemotherapy, followed by monthly tests for 6 months.

IGF-related hormone levels in mouse serum: Novel mouse assays for theIGF axis have been developed or recently published. ELISA for mouseIGF-I, BP-1, 2, 3 and ALS and GH: Blood will be collected at the time ofsacrifice from an intra-cardiac source or the retro-orbital sinus of themice. Novel IGF-related mouse assays have been recently pioneered.mIGF-I, mIGFBP-3, IGFBP-1, IGFBP-2, and mGH and mALS levels will be runwhen appropriate. Prostate cancer mice mating: Colonies of Myc and TRAMPmice are currently in-house in UCLA breeding facility. At 4 wk of age,pups will be weaned and sexed and tail snips from all healthy offspringused for genotyping as required. PCR-based genotyping for mIGFBP3,mIGFBP1, mIGF1, Alb-cre and probasin-cre transgenics, and the T-antigenare routinely employed.

Clinical examination: Animals will be observed for mortality/moribunditytwice daily during the week and once daily on weekends and holidays.Body weights and clinical observations all animals will be recordedweekly. Clinical observations will be made at 7 wk of age, 1 wk prior totreatment, prior to treatment on d 1, and weekly thereafter.

Preparation and Analysis of Prostate Tissues: At the time of sacrifice,the lower GU tract, including the bladder, testes, seminal vesicles, andprostate, will be removed en bloc. The GU wet weight will be recorded tothe nearest 0.01 g. Tissues collected at necropsy will be fixed in 10%(Vol:Vol) phosphate-buffered formalin for 12 h and then transferred to70% ethanol before standard tissue processing (except for a sample thatwill be used for RNA). Sections of the prostate (4 mm) will be cut fromparaffin-embedded tissues and mounted on ProbeOn-Plus slides (FisherScientific). Distant site metastases will be examined at the time ofnecropsy and dissected if identified.

Assessment of prostate histology and immunohistochemistry: Prostate andmetastatic tumor histopathology will be determined by H&E staining, andprostate immunohistochemical analysis of phospho-IGF-IR, phospho-Akt,COX-2, TUNEL will be quantified as described. The techniques forimmunostaining and analyzing the stained tissue (percent of cellsstaining positive, intensity of staining, location of staining) will beused as described.

Image Analysis: Sections will be visualized on a Zeiss-Axiophot DM HTmicroscope. Images will be captured with an attached camera linked to acomputer. Images and figures will be composed by using ADOBE PHOTOSHOP5.5 (Adobe Systems, Mountain View, Calif.). The initial section will behematoxylin-and-eosin (H&E)-stained; 10 unstained sections will follow.Subsequently, at 200 μm deeper into the block, another H&E will befollowed by 10 unstained sections. Histopathological evaluation usinglight microscopy will be performed on all H&E-stained slides preparedfrom the prostate of each animal.

Immunofluorescence analysis and apoptosis detection: Fourmicrometer-thick sections will be cut from paraffin-embedded tissues.Immunofluorescence will be performed by using M30 CytoDEATH antibody(Boehringer Mannheim) with a fluorescence microscope (Axiophot, Zeiss).Scoring of apoptotic cells in these sections will be done by using theOPTIMAS 6 software program (Optimas, Bothell, Wash.). Apoptotic index(%) will be calculated by dividing the number of apoptotic cells(fluorescence positive) by the total number of cells counted percross-section of a sample of the prostate. Prostate pathological slideswill also be processed by using antibodies for PCNA, and β-actinobtained from Santa Cruz Biotechnology for immunohistochemistryassessment of tumor proliferation.

TUNEL assay: The ApopTag in situ apoptosis detection kit will bepurchased from Intergen (New York). In brief, paraffin-embedded tissuesections of tumors will be made from prostates harvested at sacrifice.After de-paraffinization of tissue section, apoptotic DNA fragments willbe labeled by terminal deoxynueleotidyl transferase, and detected byanti-digoxigenin antibody that is conjugated to a fluorescein. Thesamples will be analyzed using a fluorescent microscope, equipped bydigital camera and the degree of apoptosis quantitated with AdobePhotoshop 5.5.

Statistical design: The study was designed in conjunction with thebiostatistical core of the GCRC at UCLA and SPORE in prostate cancer.The following is an example for most complex studies will be carried outwith 4 groups in a 2*2 design: (variable 1:) TRAMP vs LID TRAMP,(variable 2:) Saline vs. IGF-I antibodies infusion. Animals will berandomized: led into the four treatment groups by randomized permutatedblock design with variable block length. There are two primaryendpoints: prostate weight at sacrifice (including tumor) and pathologygrade of tumor. At sacrifice secondary endpoints will include serumIGF-1, K-167, TUNEL. Sample size calculation assumptions: (1) Thefactorial analysis of variance has these effects: genotype and treatmentand the interaction between the two. (2) No adjustment for theassessment of effects for a given primary endpoint. (3) The responses ofthe tumors to the different treatments will be similar in magnitude. (4)The power analysis for each expected or plausible effect size will be0.85 and the sample size n is estimated using this power for each effectsize. (5) From previous data there is evidence of a 30% effect on tumorweight during treatment. (6) Two-way ANOVA, a=0.05, 0.05, 0.15 LID andIGF-I AB effects, and their interaction, respectively. Powers fordetecting the treatment effects listed above.

This assumes that the tumor reduction for single treatment is 30%; twotreatments is 40%; then the power for detecting each effect is >0.95(a=0.05), for detecting the interaction of two treatments is 0.86(a=0.05) if N/group=10. The calculation therefore indicates thatN=10/group, 40 total will be the sufficient sample size for each study.

Statistical analysis of data: The primary analysis for each of the twoprimary endpoints will be analysis of variance for a 2*2-factorialdesign by estimation of each of the three effects in addition to F orT-tests. Also, correlated analyses between the primary endpoints will bestudied in several ways including ANOVA. For longitudinal data, assecondary analysis, mixed-effects models, using the SAS procedure PROCMIXED, and a generalized estimating equations (GEE) approach, using theSAS procedure PROC GENMOD, will be explored to study changes aftertreatments. In cases where model assumptions such as normality orlinearity are violated, non-parametric approaches such asWilcoxon-Mann-Whitney test, classification and regression tree will beexplored to assess the association between outcome variables andtreatment exposure and other potential risk factors for the outcomes.

REFERENCES

-   1. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even P C,    Cervera P, Le Bouc Y. IGF-I receptor regulates lifespan and    resistance to oxidative stress in mice. Nature. 2003; 421:182-7.-   2. Lithgow G J, White T M, Melov S, Johnson T E. Thermotolerance and    extended life-span conferred by single-gene mutations and induced by    thermal stress. Proc. Natl. Acad. Sci. USA. 1995; 92:7540-4.-   3. Longo V D, Finch C E. Evolutionary Medicine: from Dwarf Model    Systems to Healthy Centenarians. Science. 2003; 299:1342-6.-   4. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi P    P, Lanfrancone L, Pelicci P G. The p66shc adaptor protein controls    oxidative stress response and life span in mammals. Nature. 1999;    402:309-13.-   5. Fabrizio P, Pozza F, Pletcher S D, Gendron C M, Longo V T.    Regulation of longevity and stress resistance by Sch9 in yeast.    Science. 2001; 292:288-90.-   6. Fabrizio P, Liou L L, Moy V N, Diaspro A, SelverstoneValentine J,    Gralla E B, Longo V D. SOD2 Functions Downstream of Sch9 to Extend    Longevity in Yeast. Genetics. 2003; 163:35-46.-   7. Pollak M N, Schernhammer E S, Hankinson S E. Insulin-like growth    factors and neoplasia. Nat Rev Cancer. 2004; 4:505-18.-   8. Harper J M, Salmon A B, Chang Y, Bonkowski M, Bartke A, Miller    R A. Stress resistance and aging: influence of genes and nutrition.    Mech Ageing Dev. 2006; 127:687-94.-   9. Longo V D. Mutations in signal transduction proteins increase    stress resistance and longevity in yeast, nematodes, fruit flies,    and mammalian neuronal cells. Neurobiol. Aging. 1999; 20:479-86.-   10. Finkel T, Holbrook N J. Oxidants, oxidative stress and the    biology of ageing. Nature. 2000; 408:239-47.-   11. Paradis S, Ailion M, Toker A, Thomas J H, Ruvkun G. A PDK1    homolog is necessary and sufficient to transduce AGE-1 PI3 kinase    signals that regulate diapause in Caenorhabditis elegans. Genes Dev.    1999; 13:1438-52.-   12. Johnson T E. Increased life-span of age-1 mutants in    Caenorhabditis elegans and lower Gompertz rate of aging. Science.    1990; 249:908-12.-   13. Fabrizio P, Longo V D. The chronological life span of    Saccharomyces cerevisiae. Aging Cell. 2003; 2:73-81.-   14. Thevelein J M, de Winde J H. Novel sensing mechanisms and    targets for the cAMP-protein kinase A pathway in the yeast    Saccharomyces cerevisiae. Mol. Microbiol. 1999; 33:904-18.-   15. Flattery-O'Brien J A, Grant C M, Dawes I W. Stationary-phase    regulation of the Saccharomyces cerevisiae SOD2 gene is dependent on    additive effects of HAP2/3/4/5- and STRE-binding elements. Mol.    Microbiol. 1997; 23:303-12.-   16. Wolff S, Ma H, Burch D, Maciel G A, Hunter T, Dillin A. SMK-1,    an essential regulator of DAF-16-mediated longevity. Cell. 2006;    124:1039-53.-   17. Clancy D J, Gems D, Harshman L G, Oldham S, Stocker H, Hafen E,    Leevers S J, Partridge L. Extension of life-span by loss of CHICO, a    Drosophila insulin receptor substrate protein. Science. 2001;    292:104-6.-   18. Tatar M, Kopelman A, Epstein D, Tu M P, Yin C M, Garofalo R S. A    mutant Drosophila insulin receptor homolog that extends life-span    and impairs neuroendocrine function. Science. 2001; 292:107-10.-   19. Lin Y J, Seroude L, Benzer S. Extended life-span and stress    resistance in the Drosophila mutant Methuselah. Science. 1998;    282:943-6.-   20. Rogina B, Reenan R A, Nilsen S P, Helfand S L. Extended    life-span conferred by cotransporter gene mutations in Drosophila.    Science. 2000; 290:2137-40.-   21. Brown-Borg H M, Borg K E, Meliska C J, Bartke A. Dwarf mice and    the ageing process. Nature. 1996; 384:33.-   22. Coschigano K T, Clemmons D, Bellush L L, Kopchick J J.    Assessment of growth parameters and life span of GHR/BP    gene-disrupted mice. Endocrinology. 2000; 141:2608-13.-   23. Brown-Borg H M, Rakoczy S G. Catalase expression in delayed and    premature aging mouse models. Exp Gerontol. 2000; 35:199-212.-   24. Brown-Borg H M, Rakoczy S G, Romanick M A, Kennedy M A. Effects    of growth hormone and insulin-like growth factor-I on hepatocyte    antioxidative enzymes. Exp Biol Med. 2002; 227:94-104.-   25. Sharma H S, Nyberg F, Gordh T, Alm P, Westman J. Neurotrophic    factors influence upregulation of constitutive isoform of heme    oxygenase and cellular stress response in the spinal cord following    trauma. An experimental study using immunohistochemistry in the rat.    Amino Acids. 2000; 19:351-61.-   26. Yakar S, Liu J L, Stannard B, Butler A, Accili D, Sauer B,    LeRoith D. Normal growth and development in the absence of hepatic    insulin-like growth factor I. Proc Natl Acad Sci USA. 1999;    96:7324-9.-   27. Jones J I, Clemmons D R. Insulin-like growth factors and their    binding proteins: biological actions. Endocr Rev. 1995; 16:3-34.-   28. Flurkey K, Papaconstantinou J, Miller R A, Harrison D E.    Lifespan extension and delayed immune and collagen aging in mutant    mice with defects in growth hormone production. Proc Natl Acad Sci    USA. 2001; 98:6736-41.-   29. Longo V D. The Pro-Senescence Role of Ras2 in the Chronological    Life Span of Yeast. Thesis, University of California Los Angeles;    1997:112-153.-   30. Yan L, Vatner D E, O'Connor J P, Ivessa A, Ge H, Chen W,    Hirotani S, Ishikawa Y, Sadoshima J, Vatner S F. Type 5 adenylyl    cyclase disruption increases longevity and protects against stress.    Cell. 2007; 130:247-58.-   31. Kandel E S, Hay N. The regulation and activities of the    multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res. 1999;    253:210-29.-   32. Sohal R S, Weindruch R. Oxidative stress, caloric restriction,    and aging. Science. 1996; 273:59-63.-   33. Sell D R, Lane M A, Johnson W A, Masoro E J, Mock O B, Reiser K    M, Fogarty J F, Cutler R G, Ingram D K, Roth G S, Monnier V M.    Longevity and the genetic determination of collagen glycoxidation    kinetics in mammalian senescence. Proc. Natl. Acad. Sci. U.S.A.    1996; 93:485-90.-   34. Roth G S, Ingram D K, Joseph J A. Delayed loss of striatal    dopamine receptors during aging of dietarily restricted rats. Brain    Res. 1984; 300:27-32.-   35. Finch C E MT. Food restriction and brain aging. Adv Cell Aging    Gerontol. 1997; 2:279-298.-   36. Breese C R, D'Costa A, Rollins Y D, Adams C, Booze R M, Sonntag    W E, Leonard S. Expression of insulin-like growth factor-I (IGF-I)    and IGF-binding protein 2 (IGF-BP2) in the hippocampus following    cytotoxic lesion of the dentate gyrus. J Comp Neurol. 1996;    369:388-404.-   37. Boden G, Baile C A, McLaughlin C L, Matschinsky F M. Effects of    starvation and obesity on somatostatin, insulin, and glucagon    release from an isolated perfused organ system. Am J Physiol. 1981;    241:E215-20.-   38. Tannenbaum G S, Rorstad O, Brazeau P. Effects of prolonged food    deprivation on the ultradian growth hormone rhythm and    immunoreactive somatostatin tissue levels in the rat. Endocrinology.    1979; 104:1733-8.-   39. Hartman M L, Veldhuis J D, Johnson M L, Lee M M, Alberti K G,    Samojlik E, Thorner M O. Augmented growth hormone (GH) secretory    burst frequency and amplitude mediate enhanced GH secretion during a    two-day fast in normal men. J Clin Endocrinol Metab. 1992;    74:757-65.-   40. Zapf J. Physiological role of the insulin-like growth factor    binding proteins. Eur J Endocrinol. 1995; 132:645-54.-   41. Muller E E, Locatelli V, Cocchi D. Neuroendocrine control of    growth hormone secretion. Physiol Rev. 1999; 79:511-607.-   42. Clemmons D R, Van Wyk J J. Factors controlling blood    concentration of somatomedin C. Clin Endocrinol Metab. 1984;    13:113-43.-   43. Hanahan D, Weinberg R A. The hallmarks of cancer. Cell. 2000;    100:57-70.-   44. Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire    W L. Human breast cancer: correlation of relapse and survival with    amplification of the HER-2/neu oncogene. Science. 1987; 235:177-82.-   45. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases.    Annu Rev Biochem. 1988; 57:443-78.-   46. Lukashev M E, Werb Z. ECM signalling: orchestrating cell    behaviour and misbehaviour. Trends Cell Biol. 1998; 8:437-41.-   47. Medema R H, Bos J L. The role of p21ras in receptor tyrosine    kinase signaling. Crit. Rev Oncog. 1993; 4:615-61.-   48. Kinzler K W, Vogelstein B. Life (and death) in a malignant    tumour. Nature. 1996; 379:19-20.-   49. Downward J. Mechanisms and consequences of activation of protein    kinase B/Akt. Curr Opin Cell Biol. 1998; 10:262-7.-   50. Weinberg R A. The retinoblastoma protein and cell cycle control.    Cell. 1995; 81:323-30.-   51. Cohen P. Clinical implications of the IGF-cancer connection.    Growth Horm IGF Res. 2001; 11:336-8.-   52. Kaplan P J, Mohan S, Cohen P, Foster B A, Greenberg N M. The    insulin-like growth factor axis and prostate cancer: lessons from    the transgenic adenocarcinoma of mouse prostate (TRAMP) model.    Cancer Res. 1999; 59:2203-9.-   53. Adhami V M, Siddiqui I A, Ahmad N, Gupta S, Mukhtar H. Oral    consumption of green tea polyphenols inhibits insulin-like growth    factor-1-induced signaling in an autochthonous mouse model of    prostate cancer. Cancer Res. 2004; 64:8715-22.-   54. Vijayababu M R, Arunkumar A, Kanagaraj P, Arunakaran J. Effects    of quercetin on insulin-like growth factors (IGFs) and their binding    protein-3 (IGFBP-3) secretion and induction of apoptosis in human    prostate cancer cells. J Carcinog. 2006; 5:10.-   55. Shukla S, Mishra A, Fu P, MacLennan G T, Resnick M I, Gupta S.    Up-regulation of insulin-like growth factor binding protein-3 by    apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft    in athymic nude mice. Faseb J. 2005; 19:2042-4.-   56. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor    (IGF)-binding protein-3 induces apoptosis and mediates the effects    of transforming growth factor-beta1 on programmed cell death through    a p53- and IGF-independent mechanism. J Biol. Chem. 1997;    272:12181-8.-   57. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B,    Seizinger B R, Eley N. Induction of the growth inhibitor IGF-binding    protein 3 by p53. Nature. 1995; 377:646-9.-   58. Grimberg A, Liu B, Bannerman P, El-Deiry W S, Cohen P. IGFBP-3    mediates p53-induced apoptosis during serum starvation. Int J Oncol.    2002; 21:327-35.-   59. Rajah R, Lee K W, Cohen P. Insulin-like growth factor binding    protein-3 mediates tumor necrosis factor-alpha-induced apoptosis:    role of Bcl-2 phosphorylation. Cell Growth Differ. 2002; 13:163-71.-   60. Rajah R, Khare A, Lee P D, Cohen P. Insulin-like growth    factor-binding protein-3 is partially responsible for    high-serum-induced apoptosis in PC-3 prostate cancer cells. J    Endocrinol. 1999; 163:487-94.-   61. Mannhardt B, Weinzimer S A, Wagner M, Fiedler M, Cohen P,    Jansen-Durr P, Zwerschke W. Human papillomavirus type 16 E7    oncoprotein binds and inactivates growth-inhibitory insulin-like    growth factor binding protein 3. Mol Cell Biol. 2000; 20:6483-95.-   62. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and    gene profiling of Ewing cells reveal downstream oncogenic pathways    and a crucial role for repression of insulin-like growth factor    binding protein 3. Mol Cell Biol. 2004; 24:7275-83.-   63. Christoph F, Kempkensteffen C, Weikert S, Krause H, Schostak M,    Miller K, Schrader M. Frequent epigenetic inactivation of p53 target    genes in seminomatous and nonseminomatous germ cell tumors. Cancer    Lett. 2007; 247:137-42.-   64. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M,    Miller K, Schrader M. Regularly methylated novel pro-apoptotic genes    associated with recurrence in transitional cell carcinoma of the    bladder. Int J Cancer. 2006; 119:1396-402.-   65. Cohen P. Overview of the IGF-I system. Horm Res. 2006; 65 Suppl    1:3-8.-   66. Liu B, Lee K W, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M,    Lin S, Cohen P. Insulin-like growth factor-binding protein-3    inhibition of prostate cancer growth involves suppression of    angiogenesis. Oncogene. 2007; 26:1811-9.-   67. Wu J D, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P,    Montgomery R B, Ludwig D L, Plymate S R. Combined in vivo effect of    A12, a type 1 insulin-like growth factor receptor antibody, and    docetaxel against prostate cancer tumors. Clin Cancer Res. 2006;    12:6153-60.-   68. Bruce-Keller A J, Umberger G, McFall R, Mattson M P. Food    restriction reduces brain damage and improves behavioral outcome    following excitotoxic and metabolic insults. Ann Neurol. 1999;    45:8-15.-   69. Fabrizio P, Gattazzo, C., Battistella, L., Wei M, Chen, C., and    Longo, V D. Sir2 Blocks Extreme Life Span Extension. Cell. 2005;    123:1-13.-   70. Kaeberlein M, Powers R W, 3rd, Steffen K K, Westman E A, Hu D,    Dang N, Kerr E O, Kirkland K T, Fields S, Kennedy B K. Regulation of    yeast replicative life span by TOR and Sch9 in response to nutrients    [see comment]. Science. 2005; 310:1193-6.-   71. Lin S J, Defossez P A, Guarente L. Requirement of NAD and SIR2    for life-span extension by calorie restriction in Saccharomyces    cerevisiae. Science. 2000; 289:2126-8.-   72. Poole C J, Earl H M, Hiller L, Dunn J A, Bathers S, Grieve R J,    Spooner D A, Agrawal R K, Fernando I N, Brunt A M, O'Reilly S M,    Crawford S M, Rea D W, Simmonds P, Mansi J L, Stanley A, Harvey P,    McAdam K, Foster L, Leonard R C, Twelves C J. Epirubicin and    cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy    for early breast cancer. N Engl J. Med. 2006; 355:1851-62.-   73. Manetta J, Brun J F, Maimoun L, Callis A, Prefaut C, Mercier J.    Effect of training on the GH/IGF-I axis during exercise in    middle-aged men: relationship to glucose homeostasis. Am J Physiol    Endocrinol Metab. 2002; 283:E929-36.-   74. Grunberg S M. Cyclophosphamide and etoposide for non-small cell    and small cell lung cancer. Drugs. 1999; 58 Suppl 3:11-5.-   75. Mistry A R, Felix C A, Whitmarsh R J, Mason A, Reiter A,    Cassinat B, Parry A, Walz C, Wiemels J L, Segal M R, Ades L, Blair I    A, Osheroff N, Peniket A J, Lafage-Pochitaloff M, Cross N C,    Chomienne C, Solomon E, Fenaux P, Grimwade D. DNA topoisomerase II    in therapy-related acute promyelocytic leukemia. N Engl J. Med.    2005; 352:1529-38.-   76. Vinolas N, Graus F, Mellado B, Caralt L, Estape J. Phase II    trial of cisplatinum and etoposide in brain metastases of solid    tumors. J Neurooncol. 1997; 35:145-8.-   77. Kroger N, Hoffknecht M, Hanel M, Kruger W, Zeller W,    Stockschlader M, de Wit M, Weh H J, Kabisch H, Erttmann R, Zander    A R. Busulfan, cyclophosphamide and etoposide as high-dose    conditioning therapy in patients with malignant lymphoma and prior    dose-limiting radiation therapy. Bone Marrow Transplant. 1998;    21:1171-5.-   78. Gronbaek H, Nielsen B, Schrijvers B, Vogel I, Rasch R,    Flyvbjerg A. Inhibitory effects of octreotide on renal and    glomerular growth in early experimental diabetes in mice. J    Endocrinol. 2002; 172:637-43.-   79. Hunter S J, Shaw J A, Lee K O, Wood P J, Atkinson A B, Bevan    J S. Comparison of monthly intramuscular injections of Sandostatin    LAR with multiple subcutaneous injections of octreotide in the    treatment of acromegaly; effects on growth hormone and other markers    of growth hormone secretion. Clin Endocrinol (Oxf). 1999; 50:245-51.-   80. Maccario M, Aimaretti G, Grottoli S, Gauna C, Tassone F, Corneli    G, Rossetto R, Wu Z, Strasburger C J, Ghigo E. Effects of 36-hour    fasting on GH/IGF-I axis and metabolic parameters in patients with    simple obesity. Comparison with normal subjects and hypopituitary    patients with severe GH deficiency. Int J Obes Relat Metab Disord.    2001; 25:1233-9.-   81. Ngo T H, Barnard R J, Tymchuk C N, Cohen P, Aronson W J. Effect    of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and    growth of LNCaP cells in vitro (United States). Cancer Causes    Control. 2002; 13:929-35.-   82. De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di    Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di Cataldo A,    Rizzo A, Tonini G P, Dallorso S, Conte M, Gambini C, Garaventa A,    Bonetti F, Zanazzo A, D'Angelo P, Bruzzi P. Disseminated    neuroblastoma in children older than one year at diagnosis:    comparable results with three consecutive high-dose protocols    adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin    Oncol. 2003; 21:1592-601.-   83. Matthay K K, Villablanca J G, Seeger R C, Stram D O, Harris R E,    Ramsay N K, Swift P, Shimada H, Black C T, Brodeur G M, Gerbing R B,    Reynolds C P. Treatment of high-risk neuroblastoma with intensive    chemotherapy, radiotherapy, autologous bone marrow transplantation,    and 13-cis-retinoic acid. Children's Cancer Group. N Engl J. Med.    1999; 341:1165-73.-   84. Lode H N, Xiang R, Varki N M, Dolman C S, Gillies S D, Reisfeld    R A. Targeted interleukin-2 therapy for spontaneous neuroblastoma    metastases to bone marrow. J Natl Cancer Inst. 1997; 89:1586-94.-   85. Susini C, Buscail L. Rationale for the use of somatostatin    analogs as antitumor agents. Ann Oncol. 2006; 17:1733-42.-   86. Zalatnai A, Schally A V. Treatment of    N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian    golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160    microcapsules. Cancer Res. 1989; 49:1810-5.-   87. Hejna M, Schmidinger M, Raderer M. The clinical role of    somatostatin analogues as antineoplastic agents: much ado about    nothing? Ann Oncol. 2002; 13:653-68.-   88. Lin K, Dorman J B, Rodan A, Kenyon C. daf-16: An HNF-3/forkhead    family member that can function to double the life-span of    Caenorhabditis elegans. Science. 1997; 278:1319-22.-   89. Kops G J, Dansen T B, Polderman P E, Saarloos I, Wirtz K W,    Coffer P J, Huang T T, Bos J L, Medema R H, Burgering B M. Forkhead    transcription factor FOXO3a protects quiescent cells from oxidative    stress. Nature. 2002; 419:316-21.-   90. Schindler D, Davies J. Inhibitors of macromolecular synthesis in    yeast. Methods Cell Biol. 1975; 12:17-38.-   91. Brunet A, Sweeney L B, Sturgill J F, Chua K F, Greer P L, Lin Y,    Tran H, Ross S E, Mostoslavsky R, Cohen H Y, Hu L S, Cheng H L,    Jedrychowski M P, Gygi S P, Sinclair D A, Alt F W, Greenberg M E.    Stress-dependent regulation of FOXO transcription factors by the    SIRT1 deacetylase. Science. 2004; 303:2011-5.-   92. Xia Z, Dickens M, Raingeaud J, Davis R J, Greenberg M E.    Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.    Science. 1995; 270:1326-31.-   93. Wang Z, Prins G S, Coschigano K T, Kopchick J J, Green J E, Ray    V H, Hedayat S, Christov K T, Unterman T G, Swanson S M. Disruption    of growth hormone signaling retards early stages of prostate    carcinogenesis in the C3(1)/T antigen mouse. Endocrinology. 2005;    146:5188-96.-   94. Ellwood-Yen K, Graeber T O, Wongvipat J, Iruela-Arispe M L,    Zhang J, Matusik R, Thomas G V, Sawyers C L. Myc-driven murine    prostate cancer shares molecular features with human prostate    tumors. Cancer Cell. 2003; 4:223-38.-   95. Hadaschik B A, Gleave M E. Therapeutic options for    hormone-refractory prostate cancer in 2007. Urol Oncol. 2007;    25:413-9.-   96. Al-Chalabi T, Figg W D. Benefits of the combination of    thalidomide plus cyclophosphamide in hormone refractory prostate    cancer patients. Cancer Biol Ther. 2007; 6:318-9.-   97. Mackler N J, Pienta K J, Dunn R L, Cooney K A, Redman B G, Olson    K B, Fardig J E, Smith D C. Phase II evaluation of oral    estramustine, oral etoposide, and intravenous paclitaxel in patients    with hormone-sensitive prostate adenocarcinoma. Clin Genitourin    Cancer. 2007; 5:318-22.-   98. Madia F, Gattazzo C, Fabrizio P, Longo V D. A simple model    system for age-dependent DNA damage and cancer. Mech Ageing Dev.    2007; 128:45-9.-   99. Lerner E C, Zhang T T, Knowles D B, Qian Y, Hamilton A D, Sebti    S M. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is    highly resistant to CAAX peptidomimetics and requires both a    farnesyltransferase and a geranylgeranyltransferase I inhibitor in    human tumor cell lines. Oncogene. 1997; 15:1283-8.-   100. Alessi D R, Cuenda A, Cohen P, Dudley D T, Saltiel A R. PD    098059 is a specific inhibitor of the activation of    mitogen-activated protein kinase kinase in vitro and in vivo. J    Biol. Chem. 1995; 270:27489-94.-   101. Cuenda A, Rouse J, Doza Y N, Meier R, Cohen P, Gallagher T F,    Young P R, Lee J C. SB 203580 is a specific inhibitor of a MAP    kinase homologue which is stimulated by cellular stresses and    interleukin-1. FEBS Lett. 1995; 364:229-33.-   102. Gallagher E, Enzler T, Matsuzawa A, Anzelon-Mills A, Otero D,    Holzer R, Janssen E, Gao M, Karin M. Kinase MEKK1 is required for    CD40-dependent activation of the kinases Jnk and p38, germinal    center formation, B cell proliferation and antibody production. Nat.    Immunol. 2007; 8:57-63.-   103. Greene L A, Shain W, Chalazonitis A, Breakfield X, Minna J,    Coon H G, Nirenberg M. Neuronal properties of hybrid neuroblastoma X    sympathetic ganglion cells. Proc Natl Acad Sci USA. 1975; 72:4923-7.-   104. Corrias M V, Bocca P, Anelli E, Cilli M, Occhino M, Pistoia V,    Gambini C. A novel syngeneic murine model for thoracic neuroblastoma    obtained by intramediastinal injection of tumor cells. Cancer Detect    Prev. 2002; 26:468-75.-   105. Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C,    Marimpietri D, Montaldo P G, Gambini C, Allen T M, Bogenmann E,    Ponzoni M. In vitro and in vivo antitumor activity of liposomal    Fenretinide targeted to human neuroblastoma. Int J Cancer. 2003;    104:559-67.-   106. Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase E H,    Allen T M, Ponzoni M. Doxorubicin-loaded Fab′ fragments of    anti-disialoganglioside immunoliposomes selectively inhibit the    growth and dissemination of human neuroblastoma in nude mice. Cancer    Res. 2003; 63:86-92.-   107. Burbridge M F, Kraus-Berthier L, Naze M, Pierre A, Atassi G,    Guilbaud N. Biological and pharmacological characterisation of three    models of human ovarian carcinoma established in nude mice: use of    the CA125 tumour marker to predict antitumour activity. Int J Oncol.    1999; 15:1155-62.-   108. Liao C P, Zhong C, Saribekyan G, Bading J, Park R, Conti P S,    Moats R, Berns A, Shi W, Zhou Z, Nikitin A Y, Roy-Burman P. Mouse    models of prostate adenocarcinoma with the capacity to monitor    spontaneous carcinogenesis by bioluminescence or fluorescence.    Cancer Res. 2007; 67:7525-33.

The contents of all references cited herein are incorporated byreference in their entirety.

1. A method of inducing differential stress resistance in a subject,comprising: starving a subject with cancer for 24-60 hours; andadministering to the subject a chemotherapy agent.
 2. The method ofclaim 1, wherein the subject is starved for 48 hours.
 3. The method ofclaim 1, wherein the chemotherapy agent is a DNA alkylating agent,oxidant, or topoisomerase inhibitor.
 4. The method of claim 1, whereinthe chemotherapy agent is methyl methanesulfonate, cyclophosphamide,etoposide, doxorubicin, or menadione.
 5. The method of claim 1, whereinthe cancer is glioma, neuroblastoma, pheochromocytoma, or prostatecancer.
 6. The method of claim 1, further comprising administering tothe subject a cell growth inhibitor.
 7. The method of claim 6, whereinthe cell growth inhibitor inhibits IGF-I, IGF-IR, GH, Akt, Ras, Tor, orErk in the subject.
 8. The method of claim 7, wherein the cell growthinhibitor is an IGFBP, IGF-R blocking antibody, or small moleculeinhibitor.
 9. The method of claim 7, wherein the cell growth inhibitoris octreotide.
 10. A method of inducing differential stress resistancein a subject, comprising: administering a cell growth inhibitor to asubject with cancer; and administering to the subject a chemotherapyagent.
 11. The method of claim 10, wherein the cell growth inhibitorinhibits IGF-I, IGF-IR, GH, Akt, Ras, Tor, or Erk in the subject. 12.The method of claim 11, wherein the cell growth inhibitor is an IGFBP,IGF-R blocking antibody, or small molecule inhibitor.
 13. The method ofclaim 11, wherein the cell growth inhibitor is octreotide.
 14. Themethod of claim 11, wherein the serum concentration of IGF-I in thesubject is reduced by 75-90%.
 15. A method of inducing differentialstress resistance in a subject, comprising: reducing the caloric intakeby a subject with cancer; and administering to the subject achemotherapy agent.
 16. The method of claim 15, wherein the caloricintake by the subject is reduced by 10-100%.
 17. A method of inducingdifferential stress resistance in a subject, comprising: reducing theglucose intake by a subject with cancer; and administering to thesubject a chemotherapy agent.
 18. The method of claim 17, wherein theblood glucose concentration in the subject is reduced by 20-50%.
 19. Amethod of contacting a cancer cell with a chemotherapy agent,comprising: starving a cancer cell for 24-60 hours; and contacting thecancer cell with a chemotherapy agent.
 20. The method of claim 19,further comprising contacting the cancer cell with a cell growthinhibitor.
 21. A method of contacting a cancer cell with a chemotherapyagent, comprising: contacting a cancer cell with a cell growthinhibitor; and contacting the cancer cell with a chemotherapy agent. 22.A method of contacting a cancer cell with a chemotherapy agent,comprising: cultivating a cancer cell in a medium with reduced serum,IGF-I, or glucose concentration; and contacting the cancer cell with achemotherapy agent.
 23. The method of claim 22, wherein the serumconcentration in the medium is reduced by 10-90%.
 24. The method ofclaim 22, wherein the IGF-I concentration in the medium is reduced by10-100%.
 25. The method of claim 22, wherein the glucose concentrationin the medium is reduced by 20-50%.
 26. A method of increasingresistance of a non-cancer cell to a chemotherapy agent, comprising:starving a non-cancer cell for 24-60 hours; and contacting thenon-cancer cell with a chemotherapy agent.
 27. The method of claim 26,further comprising contacting the non-cancer cell with a cell growthinhibitor.
 28. A method of increasing resistance of a non-cancer cell toa chemotherapy agent, comprising: contacting a non-cancer cell with acell growth inhibitor; and contacting the non-cancer cell with achemotherapy agent.
 29. A method of increasing resistance of anon-cancer cell to a chemotherapy agent, comprising: cultivating anon-cancer cell in a medium with reduced serum, IGF-I, or glucoseconcentration; and contacting the non-cancer cell with a chemotherapyagent.
 30. The method of claim 29, wherein the serum concentration inthe medium is reduced by 10-90%.
 31. The method of claim 29, wherein theIGF-I concentration in the medium is reduced by 10-100%.
 32. The methodof claim 29, wherein the glucose concentration in the medium is reducedby 20-50%.